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Anti-Inflammatory Therapy for Neuroinflammation – Mechanisms of Action in
Murine and Human Microglia Models Provide Valuable Insights into Their
Therapeutic Potential
Abstract
Introduction: Recently, research has revealed the presence of cannabinoid receptor 2 (CB2R) in the central
nervous system (CNS); since then, the receptor has emerged as a promising therapeutic target for
treating multiple neurodegenerative diseases (NDD) such as Alzheimer’s (AD), Parkinson’s (PD), Human
Immunodeficiency Virus (HIV) and Multiple Sclerosis (MS). The restricted and upregulated expression of
CB2R in activated microglia and lack of psychotropic activity make this receptor an attractive target for
discovering novel therapy to treat neuroinflammatory diseases for which there is currently no curative
treatment. Methodology: A library of compounds were synthesized and evaluated in ACTOne and TANGObla functional assays for CB1 and CB2 activity in combination with affinity measurements for the CB1/2
receptors. Moreover, the compounds that demonstrated no activity at functional assays with high binding
affinities to CB2R were further assessed in antagonist (competition) studies against the non-selective
cannabinoid agonist CP 55,940. Compound 45 demonstrated CB2R inverse agonism at G-protein
signaling with high potency, efficacy, and affinity in the binding and functional assays and was selected
for further evaluation in murine and human microglia inflammatory models. On cell polarization assays
were done to measure microglia M1 and M2 surface markers expression. Scratch assay and ROS
measurements were performed to assess the effects of drug treatment on microglia migration and ROS
production. Extensive signaling pathway studies were conducted to identify the downstream signaling
mechanism for compound 45 and cytoskeleton staining was performed to evaluate the microglia
morphological changes upon 45 treatment. A molecular docking study was utilized to explore ligand
protein molecular interaction between 45 and CB2R. Additionally, the similarities and differences in the
activity of compound 45, relative to standard CB2R agonist and inverse agonist, were examined in the
aforementioned assays. Results: Compound 45 demonstrated the highest affinity and selectivity towards
CB2R that translated to higher potency in CB2R ACTOne functional assay, whereas no functional activity
was detected at CB1R. Moreover, testing compound 45 in the TANGO-bla assay revealed neutral
antagonism at β-arrestins signaling, confirming the G-protein functional selectivity of this class of
compounds. Treatment with compound 45 triggered a shift in murine and human microglia polarization
from a pro-inflammatory (M1) to an anti-inflammatory (M2) phenotype after 24 hours of treatment. The
M1 markers were significantly decreased and M2 markers significantly increased relative to LPS stimulus.
These results were further confirmed using microscopic examination wherein compound 45 induced a
remarkable transformation of microglia into ramified morphology with a small cell body and several
elongated cell projections, indicating microglia adopted an anti-inflammatory M2 phenotype. Moreover,
compound 45 significantly reduced cell migration, suppressed the M1 associated ROS production which
causes neurotoxicity and cell damage. Additionally, the application of compound 45 significantly
increased JNK, c-JUN, CREB, and p38 phosphorylation levels and decreased ERK1/2 and NF-κB
representing a unique anti-inflammatory mechanism of CB2R inverse agonists in activated microglia. The
molecular docking study of compound 45 revealed that the thiophene C ring constrained the toggle
switch residue Trp 258 via multiple π-π stacking interactions that stabilized CB2R in the inactive state and
led to 45 inverse agonism activity at CB2R. These results were distinctly different when compared to
standard CB2R agonists and inverse agonists, suggesting further research is needed to explore more
precisely the utility of CB2R based therapeutics in human CNS disorders. Conclusion: The results of these
studies provided valuable information that aids in the development of new analogs of the biaryl-aryl
scaffold for treating neuroinflammation in human neurodegenerative diseases.
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ABSTRACT
Introduction: Recently, research has revealed the presence of cannabinoid receptor 2
(CB2R) in the central nervous system (CNS); since then, the receptor has emerged as a
promising therapeutic target for treating multiple neurodegenerative diseases (NDD) such
as Alzheimer’s (AD), Parkinson’s (PD), Human Immunodeficiency Virus (HIV) and
Multiple Sclerosis (MS). The restricted and upregulated expression of CB2R in activated
microglia and lack of psychotropic activity make this receptor an attractive target for
discovering novel therapy to treat neuroinflammatory diseases for which there is
currently no curative treatment.
Methodology: A library of compounds were synthesized and evaluated in ACTOne and
TANGO-bla functional assays for CB1 and CB2 activity in combination with affinity
measurements for the CB1/2 receptors. Moreover, the compounds that demonstrated no
activity at functional assays with high binding affinities to CB2R were further assessed in
antagonist (competition) studies against the non-selective cannabinoid agonist CP 55,940.
Compound 45 demonstrated CB2R inverse agonism at G-protein signaling with high
potency, efficacy, and affinity in the binding and functional assays and was selected for
further evaluation in murine and human microglia inflammatory models. On cell
polarization assays were done to measure microglia M1 and M2 surface markers
expression. Scratch assay and ROS measurements were performed to assess the effects of
drug treatment on microglia migration and ROS production. Extensive signaling pathway
studies were conducted to identify the downstream signaling mechanism for compound
45 and cytoskeleton staining was performed to evaluate the microglia morphological
changes upon 45 treatment. A molecular docking study was utilized to explore
ligand-protein molecular interaction between 45 and CB2R. Additionally, the similarities
and differences in the activity of compound 45, relative to standard CB2R agonist and
inverse agonist, were examined in the aforementioned assays.
Results: Compound 45 demonstrated the highest affinity and selectivity towards CB2R
that translated to higher potency in CB2R ACTOne functional assay, whereas no
functional activity was detected at CB1R. Moreover, testing compound 45 in the
TANGO-bla assay revealed neutral antagonism at β-arrestins signaling, confirming the
G-protein functional selectivity of this class of compounds. Treatment with compound 45
triggered a shift in murine and human microglia polarization from a pro-inflammatory
(M1) to an anti-inflammatory (M2) phenotype after 24 hours of treatment. The M1
markers were significantly decreased and M2 markers significantly increased relative to
LPS stimulus. These results were further confirmed using microscopic examination
wherein compound 45 induced a remarkable transformation of microglia into ramified
morphology with a small cell body and several elongated cell projections, indicating
microglia adopted an anti-inflammatory M2 phenotype. Moreover, compound 45
significantly reduced cell migration, suppressed the M1 associated ROS production
which causes neurotoxicity and cell damage. Additionally, the application of compound
45 significantly increased JNK, c-JUN, CREB, and p38 phosphorylation levels and
decreased ERK1/2 and NF-κB representing a unique anti-inflammatory mechanism of
v

CB2R inverse agonists in activated microglia. The molecular docking study of compound
45 revealed that the thiophene C ring constrained the toggle switch residue Trp 258 via
multiple π-π stacking interactions that stabilized CB2R in the inactive state and led to 45
inverse agonism activity at CB2R. These results were distinctly different when compared
to standard CB2R agonists and inverse agonists, suggesting further research is needed to
explore more precisely the utility of CB2R based therapeutics in human CNS disorders.
Conclusion: The results of these studies provided valuable information that aids in the
development of new analogs of the biaryl-aryl scaffold for treating neuroinflammation in
human neurodegenerative diseases.
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CHAPTER 1.

INTRODUCTION

Historical Perspective of Cannabis Use
Cannabis is one of the oldest plants that was widely utilized by several cultures
for its health benefits and healing properties. The Chinese culture utilized cannabis to
gain balance and harmony between Yin and Yang that prevent disease. The plant seeds
were utilized as a laxative for treating constipation with the advantage that cannabis seeds
lack the main active constituent '9-tetrahydrocannabinol ('9-THC) but are rich in fatty
acids. These fatty acids such as γ-linoleic acid were applied topically to treat several skin
conditions such as eczema and psoriasis. The oral use of cannabis fatty acids was
beneficial for the treatment of atherosclerosis, osteoporosis, and inflammatory based
conditions. Additionally, Chinese culture had several other applications of cannabis such
as manufacture papers, strings, fibers, and also they used cannabis seeds in cooking
preparation and as a source of food. In India, the psychoactive effect of cannabis was
popular which supported its broad use with religious and meditation rituals. The
preparation of cannabis in Indian culture was quite different in that they had three main
types of cannabis preparation and each one differs in its active cannabis content and in
the parts of the cannabis plant used. Bhang is considered to be the weakest cannabis
preparation and Charas is the strongest one. Moreover, Indian culture utilized cannabis as
an analgesic, anti-inflammatory, antispasmodic, diuretic, anesthetic, and anticonvulsant.
The wide use of cannabis in India resulted in the spreading of the plant to Arabia
for medicinal purposes. In fact, some Arab texts reported that the son of caliph’s
Chamberlain, who suffered from frequent seizure episodes, was treated successfully with
cannabis resin. However, Ibn al-Badri documented that the son of the caliph’s became
addicted to it. In Africa, cannabis was introduced by Indian and Arab traders; its use
shared a high degree of similarity to Indian culture. Additionally, cannabis was utilized in
Africa to treat malaria, snakebite, asthma, blood poisoning, and an analgesic during labor.
In the West, O’Shaughnessy (an Irish physician) and Moreau’s (a French psychiatric)
introduced cannabis in the second half of the 19th century and significantly contributed to
the advances of cannabis in western medicine. The application of cannabis in multiple
infectious diseases such as cholera and tetanus, and as anti-vomiting agent, greatly
enhanced the spreading of cannabis as medicine from England to North America
(cannabis history reviewed by (Aldrich, 1997; Raphael Mechoulam, 1986)).
The first scientific conference that discussed cannabis therapeutics was held in
Ohio, United States in 1860 (McMeens, 1860) and the first characterization of cannabinol
was done in 1932 (Cahn, 1932) followed by chemical synthesis of cannabinol and
cannabidiol in 1940 (Adams, Baker, & Wearn, 1940; Jacob & Todd, 1940). In 1964, the
psychoactive constituent of cannabis plant '9-THC was isolated and partially synthesized
(Gaoni & Mechoulam, 1964). At that time, it was widely believed that '9-THC worked
by disrupting the lipid membrane, although the sterospecificity of THC analogs suggested
differently; the discovery and characterization of the two cannabinoid receptors finally
dispelled this theory. In the early 20th century, over thousands of publications studied the
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medicinal properties and therapeutic applications of cannabis in multiple disease
conditions. Currently, cannabis-based medicine has expanded rapidly in several
pathological conditions wherein natural derivatives, i.e. phytocannabinoids, and
chemically synthesized cannabinoid ligands can serve as novel therapeutic agents for
treating wide variety of diseases conditions (Raphael Mechoulam, 1986).
The Discovery of the Endocannabinoid System
The first cannabinoid receptor-1 (CB1R) was initially identified in 1988 in rat
brain tissue using tritiated non-selective agonist [3H]-CP-55,940 (Devane, Dysarz,
Johnson, Melvin, & Howlett, 1988) followed by cloning cDNA of CB1R from rat
cerebral cortex in 1990 (Matsuda, Lolait, Brownstein, Young, & Bonner, 1990). The
following year, human CB1R was isolated from a human brain stem, identified to share
97.3% homology with rat CB1R (Gerard, Mollereau, Vassart, & Parmentier, 1991). The
distribution of CB1R was identified using [3H] CP 55,940 and showed that CB1R is
mainly condensed in the brain regions such as basal ganglia, substantia nigra,
hippocampus and cerebellum (Herkenham et al., 1990). Moreover, it was reported by
several studies that CB1R distribution is conserved between species such as rat, monkey,
dog, and pig with only minor differences (Herkenham et al., 1990; Mailleux &
Vanderhaeghen, 1992; Roger G Pertwee, 1997). CB1R can be also expressed in some
peripheral tissues at a lower level such as ileum longitudinal smooth muscles (Croci et
al., 1998) and cardiovascular tissues (Szabo, Nordheim, & Niederhoffer, 2001; Wagner,
Járai, Bátkai, & Kunos, 2001). This receptor plays a crucial regulatory role in glucose
metabolism (Nogueiras et al., 2009), food intake (Trillou, Delgorge, Menet, Arnone, &
Soubrie, 2004), neurotransmitter release modulation (through M-type potassium
channels) (Kim & Thayer, 2000; Schweitzer, 2000), cancer (Pisanti, Picardi,
D’Alessandro, Laezza, & Bifulco, 2013) and, importantly, pain (Roger G Pertwee, 2001).
In 1993, the second cannabinoid receptor-2 (CB2R) was discovered and
characterized using human promyelocytic leukemic cell line HL60. Initially, CB2R was
named as a peripheral cannabinoid receptor because of the high expression of CB2R in
peripheral immune cells such as macrophages, spleen (S. Munro, K. L. Thomas, & M. J.
N. Abu-Shaar, 1993b), B‐cells, natural killer cells, monocytes, neutrophil and T cells
(Galiègue et al., 1995). However, recent advances in research tools and techniques led to
the identification of CB2R in the brain microglia during inflammatory conditions (Kearn
& Hillard, 1999). The structure of CB2R consists of 360 amino acid residues with more
diversity in the C-terminus region among different species (human, rat, mouse) (Brown,
Wager-Miller, & Mackie, 2002; Griffin, Tao, & Abood, 2000). The homology between
the CB1/2 is approximately 44% in the amino acid sequence and 68% in the
ligand-binding site (S. Munro, K. L. Thomas, & M. Abu-Shaar, 1993a). Both CBRs
belonged to a class A G-protein coupled receptor (GPCR) and contain seven
transmembrane helices (Figure 1-1) that are embedded in a lipid bilayer with
extracellular N-terminus and intracellular C-terminus (Bramblett, Panu, Ballesteros, &
Reggio, 1995; Pándy-Szekeres et al., 2017). CB2R plays an important regulatory role in
inflammation and serve as a novel therapeutic target for multiple neuroinflammatory
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Figure 1-1. The Protein Structure of CB2R.
The CB2R structure is represented as A) snake, B) helix box diagram. Residues colored
in red highlight important interactions between ligand and CB2R crystal structure. The
CB2R PDB is 5ZTY. Image created from GPCRdb database (http://www.gpcrdb.org/).
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disease conditions such as Alzheimer's disease, Parkinson's disease, multiple sclerosis
(Miriam Mecha, Carrillo-Salinas, Feliú, Mestre, & Guaza, 2016).Two years after the
discovery of CB1R, the first endogenous ligand arachidonoyl ethanolamide (anandamide,
AEA) was identified from the porcine brain. AEA demonstrated high binding affinity
toward CB1R and exhibit similar psychoactive properties of '9-THC when tested in
rodents (Devane et al., 1992). In 1995, the second endogenous cannabinoid ligand
2-arachidonoylglycerol (2-AG) was discovered and isolated from the canine gut (Raphael
Mechoulam et al., 1995). Both ligands are lipids analogs and synthesized on-demand
after (path)physiological stimuli.
AEA is classified as a fatty acid amide that behaves as a partial non-selective
agonist at CBRs (Devane et al., 1992; Felder et al., 1996). This ligand binds with greater
affinity to CB1R (Ki = 71.7 nM) and behaves as a partial and full agonist depend on
tissues and functional assays used. At CB2R, AEA binds with lower affinity (Ki = 279
nM) and behaves as a partial agonist or antagonist depending on the experimental method
that was applied (Gonsiorek et al., 2000). In neurons, AEA is synthesized on demand (in
response to stimuli or infection) via phospholipid dependent pathway that utilizes
N-arachidonyl phosphatidylethanolamine (N-arachidonyl PE) as a starting precursor. The
cleavage of N-arachidonyl PE into AEA is catalyzed by the enzyme phospholipase D
(PLD) which produces two main products, AEA and phosphatidic acid (intermediate
metabolite). There are several PLD enzymes in the body and the PLD enzyme that is
responsible for AEA biosynthesis is not as yet characterized. Following AEA release into
the extracellular space, it binds and activates cannabinoid receptors to produce a variety
of biological responses. To prevent depletion of the main precursor N-arachidonyl PE, an
enzyme named N-acyl transferase enzyme (NAT) is responsible for removing
arachidonic acid moiety from phosphatidylcholine (PC) and reattach it to the primary
amino group in phosphatidylethanolamine (PE). The hydrolysis of AEA is mediated by
fatty acid amide hydrolase (FAAH) or AEA amidohydrolase (AAH) which is highly
expressed in the brain and liver. Two main products resulting from AEA hydrolysis are
arachidonic acid and ethanolamine. Arachidonic acid is further utilized and incorporated
into phospholipids to generate PC that can be subsequently used in PE formation
(reviewed by (Pacher, Bátkai, & Kunos, 2006)).
2-Arachidonoylglycerol (2-AG) was the second endocannabinoid identified that
demonstrated full agonist activity at CB1/2 receptors, with a lower affinity toward CB1R
(Ki = 472 nM) but full efficacy compared to AEA. The affinity of 2-AG for CB2R was
lower with a Ki value of 1.4 μM in transfected cells and comparable values were reported
in brain tissues (Sugiura et al., 1995). Unlike AEA, 2AG has two main biosynthetic
pathways. The first pathway involves hydrolysis of phosphatidylinositol 4, 5
bisphosphate (PIP2) into diacylglycerol (DAG) and inositol 1, 4, 5 triphosphates (I3P).
This rapid hydrolysis is mediated by phospholipase C (PLC β or γ) which uses Ca+2 as a
cofactor. DAG is further hydrolyzed to yield 2-AG which is carried out by DAG lipase (α
or β) enzyme. The second biosynthetic pathway is through the conversion of
phosphatidylinositol 4, 5 bisphosphate (PIP2) into 2-arachidonoylglycerol
lysophosphatidic acid (2AG-LPI) which is mediated by phospholipase A1 enzyme
(PLA1). The resulting 2-AG-LPI intermediate is further hydrolyzed by specific PLC
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(lyso-PLC) to give 2-AG. The degradation of 2-AG is mediated by an uncharacterized
monoacylglycerol lipase (MAGL) that is highly expressed in brain neurons. The
intracellular hydrolysis of 2-AG produces two main products, arachidonic acid, and
glycerol that can be further recycled and utilized (reviewed by (Piomelli, Giuffrida,
Calignano, & de Fonseca, 2000; Rodriguez de Fonseca et al., 2004).
Non CB1/CB2 Receptors
Other GPCRs have been classified as non CB1/CB2 receptors, or orphan
cannabinoid receptors, the most extensively studied being GPR55 and GPR119 which
can be activated by cannabinoid ligands. GPR55 receptor was discovered from expressed
sequence tags (EST) database and partially cloned from IMAGE Consortium in 1999
(Sawzdargo et al., 1999b). This receptor consists of 316 amino acid residues; the
physiological role and endogenous ligands of this orphan receptor have not been fully
elucidated. However, GPR55 is activated by several endogenous and synthetic
cannabinoid ligands such as '9-THC, CP 55,940, HU-210, AM251, and SR141716A
suggesting that GPR55 can be considered as a novel cannabinoid receptor (atypical
cannabinoid receptor or CB3) (Ryberg et al., 2007). GPR55 activation increases the
intracellular calcium level through coupling to Gq and G12/13 protein (Lauckner et al.,
2008). Interestingly, GPR55 only shares 13.5% and 14.4% similarity with CB1 and CB2,
respectively, and it is highly expressed in human CNS and in certain rat brain regions
(Sawzdargo et al., 1999a). In mouse, GPR55 is localized in the adrenals, gastrointestinal
tract, and some of the brain regions such as the hypothalamus, brainstem. It is also
present in some peripheral tissues such as the lung, liver, and kidney (Ryberg et al.,
2007). Additionally, several reports indicated the presence of GPR55 in microglia (Pietr
et al., 2009), osteoclasts and osteoblasts (Whyte et al., 2009) and in neuronal cells
(Lauckner et al., 2008) which supports its critical function in regulating neuropathic pain,
inflammation and bone disorders (reviewed by (Sharir & Abood, 2010)).
In 2003, GPR119 was discovered using the human genome database and was
expressed in various mammalian species and in the gastrointestinal tract, pancreatic and
intestinal tissues (Chu et al., 2007; Soga et al., 2005). The structure of GRP119 consists
of 335 amino acids residues and couples to Gs protein, thus receptor activation leads to an
increases in the intracellular level of cyclic adenosine monophosphate (cAMP) and
protein kinase A (PKA) activity (Chu et al., 2007; Fredriksson, Höglund, Gloriam,
Lagerström, & Schiöth, 2003). Additionally, several reports indicated the involvement of
ATP-sensitive K+ and voltage-dependent Ca2+ channels in mediating GPR119 signaling
(Ning et al., 2008). Numerous fatty acid ligands have been identified as an agonist of
GPR119 transfected cells; however, oleoylethanolamide (OEA) demonstrated the highest
potency and efficacy towards this receptor. Thus, it has been proposed that OEA is the
endogenous ligand for GPR119 (Lauffer, Iakoubov, & Brubaker, 2009; Overton et al.,
2006). Other GPR119 agonists were chemically synthesized such as PSN632408
(Overton et al., 2006), AR231453 (Semple et al., 2008) and several animal studies
supported the beneficial effects of GPR119 receptor activation in decreasing the food
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intake (Overton et al., 2006) and lowering glucose levels in diabetic mice (Fyfe et al.,
2006).
The Constitutive Activity of Cannabinoid Receptors
Cannabinoid receptors type 1 and 2 are GPCRs that exhibit constitutive activity
(basal G-protein signaling) in the absence of a ligand. The existence of basal activity
allows for three classes of ligands to interact with the receptors represented by agonists,
inverse agonists (or antagonists) and neutral antagonists. Each class of ligands has a
distinct pharmacological profile and unique molecular interaction with the receptor
resulting in specific modulation in the downstream signaling activity. The unique
interactions arise from discrete energetically favorable conformations of the receptors
which transition between active and inactive conformations that ligands select to produce
a specific ligand-receptor response (Figure 1-2). For example, agonists shift the
equilibrium toward receptor active states which lead to downstream signaling activation
(positive efficacy). The agonist selects one specific active conformation (in the presence
of other active states) that is linked to specific signaling effectors. Conversely, inverse
agonists favor receptor inactive states and shift the equilibrium toward the inactive
receptor conformations which in turn deplete the available active conformations and
decrease the constitutive activity (negative efficacy). Inverse agonists decrease the basal
level and block the orthosteric agonist from binding to the receptor-binding site. The
neutral antagonists don’t distinguish between the active and inactive states and have
specific molecular interaction that allows the ligand to bind to the receptor regardless
whether it’s in an active or inactive conformation. This specific receptor interaction
explains why neutral antagonists are rare. Neutral antagonists have an affinity to the
receptor with no efficacy and also prevent the agonist from binding to the orthosteric
binding site (reviewed by (Greasley & Clapham, 2006; A. C. Howlett et al., 2011;
Kenakin, 2001)).
Cannabinoid Receptors Downstream Signaling Activity
Canonical Pathway
The canonical cannabinoid pathway regulates multiple downstream effectors
including cAMP, ion channels and mitogen-activated protein kinase (MAPKs, Figure
1-3). CB1/2 receptors couple to the heterotrimeric G-protein complex via Gαi which is
pertussis toxin (PTX) sensitive in most cell types ranging from neuronal to immune cells
(Felder, Veluz, Williams, Briley, & Matsuda, 1992; A. Howlett, Qualy, & Khachatrian,
1986). In addition, CB1R has been shown to couple to Gαs in primary cell culture of
striatal neurons under certain conditions such as PTX treatment and the presence of
specific isoforms of adenylyl cyclase (AC) (Michelle Glass & Felder, 1997). Depending
on the adenylyl cyclase isoforms that exist in CB1/CB2 expressing cells, inhibition (AC
isoform 1,3,5,6 and 8) or activation (AC isoform 2, 4, 7) of cAMP can occur
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Figure 1-2. Functional Selectivity of Cannabinoid Ligands.
(A) Agonists shift the receptor equilibrium toward the active states and each agonist
selectively binds to a specific active receptor conformation producing a ligand-specific
response. Conversely, (B) Inverse agonists favor the inactive states that are linked to
multiple downstream effectors depend on the inverse agonist used.
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Figure 1-3. Proposed Canonical Signaling Pathway for CB2R.
CB2R is coupled to Gαi that inhibits the AC activity, negatively affects the cAMP level
and protein kinase A (PKA) activity. Protein kinase A regulates the biological function of
several MAPKs and ion channels that are important in cell gene expression. Moreover,
the dissociation of βγ dimer regulates the function of potassium and calcium channels in
addition to protein kinase C (PKC), phospholipase C (PLC), and
phosphatidylinositol-3-kinase (PI3K) downstream activity that regulates the expression of
several genes.
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(A. Howlett et al., 2002b; Rhee, Bayewitch, Avidor‐Reiss, Levy, & Vogel, 1998).
Activation of cannabinoid receptors results in inhibition of the AC which in turn
suppresses the intracellular cAMP level, thus affecting protein kinase A activity (PKA).
Moreover, the dissociation of Gαi from Gβγ subunits can initiate an independent
downstream signaling cascade that is associated with the free Gβγ dimer (Atwood, WagerMiller, Haskins, Straiker, & Mackie, 2012). The Gβγ signaling cascades include activation
of several MAPKs, inhibition of voltage-dependent calcium channels, regulate potassium
(K+) ion influx through G protein-coupled inwardly-rectifying potassium (GIRK)
channels (Soethoudt et al., 2017), and activation of phosphatidylinositide-3-kinase
(PI3K), (reviewed by Khan et al. (Khan, Sung, & Hebert, 2016)).
Ion channels modulation can result from Gαi/o activation and Gβγ subunits. At
presynaptic terminals, CB1R (Gβγ) activates A-type potassium (K+) channels which
increases K+ influx and inhibits L, N, P, Q type Ca+2 channels that decrease the calcium
concentration inside the cell which plays a crucial role in neurotransmitters release
(Caulfield & Brown, 1992; K Mackie, Devane, & Hille, 1993; K Mackie, Lai,
Westenbroek, & Mitchell, 1995). The inhibition of N-type Ca+2 channels by the CB1R
was reported to be mediated by Gαi (K Mackie et al., 1993). Additionally, CB1R is
positively coupled to the GIRK channel and this coupling is directly associated with Gαi
dependent pathway (Henry & Chavkin, 1995). CB2R has been reported to modulate the
calcium channels based on the functional selectivity of the ligand (Atwood et al., 2012).
Moreover, several reports demonstrated that cannabinoid ligands can modulate sodium
(Na+) channels, e.g, WIN55212 modulated Na+ channels in rat trigeminal ganglion
neurons (Fu, Xiao, Cao, Ming, & Liu, 2008), and CP 55,940 modulated Na+ channels in
mouse brain (Duan, Liao, Jain, & Nicholson, 2008) and several other examples are
reviewed by Pertwee et al. (Roger Guy Pertwee et al., 2010).
The CB1/2 receptors are upstream regulators of MAPK activation, which regulate
a wide variety of cell functions such as cell growth, differentiation, and apoptosis
(reviewed by (Seger & Krebs, 1995)). CB1R positively regulates the extracellular
signal-regulated kinase 1 or 2 (ERK1/2) via Gαi/o protein (Daigle, Kearn, & Mackie, 2008)
and β-arrestin pathways (Ahn, Mahmoud, Shim, & Kendall, 2013; Graham et al., 2006).
Moreover, several cannabinoid ligands activated ERK1/2 via CB2R, suggesting the ability
of CB2R to mediate MAPKs activation (Atwood et al., 2012).
Noncanonical Pathway
In mammalian cells, there are four types of β-arrestins including two visual
β-arrestins that are expressed only in the retina and β-arrestin 1 and 2 that are widely
distributed in various types of tissues (reviewed by (Miller & Lefkowitz, 2001)). The
β-arrestins were initially characterized as proteins that desensitize and internalize GPCRs
(Ferguson et al., 1996) via interaction with clathrin and activator protein 2 (AP-2) which
induce desensitization and internalization, respectively. Recently, several reports have
demonstrated a new regulatory role of β-arrestins as a scaffolding protein that has the
ability to modulates multiple downstream effectors (Miller & Lefkowitz, 2001).
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Β-arrestins activation starts when the C-terminus of a GPCR is phosphorylated by a
specific G protein receptor kinases (GRKs) to facilitate β-arrestin binding to the receptor
tail. Depend on C-terminus phosphorylation barcode, specific GRKs are recruited and
each phosphorylation pattern on the C-terminus will activate a specific β-arrestin
function. For example, GRK type 2 and 3 (GRK2/3) will recruit β-arrestins to interact
with the receptor tail and terminate G-protein signaling (desensitization). Alternatively,
GRK 5 and 6 (GRK5/6) can facilitate β-arrestins binding to the third intracellular loop
(ICL3) and initiate β-arrestins downstream signaling cascade (reviewed by (Lefkowitz,
1998; Liggett, 2011; Moore, Milano, & Benovic, 2007; Shenoy & Lefkowitz, 2011)).
Additionally, β-arrestins have the ability to activate several MAPKs (p35 and JNK) and
cause late activation of ERK1/2 (Figure 1-4), however, the detailed β-arrestin signaling
mechanisms have not been fully elucidated (reviewed by Ibsen et al. (Ibsen, Connor, &
Glass, 2017)).
Cannabinoid-Based Therapeutics
Neuroinflammatory Cycle
Microglia are the resident brain immune cells that serve as a primary defensive
mechanism to maintain brain homeostasis and protection from injury. In a healthy brain,
microglia are deactivated and function as surveying cells that detect minor changes in the
brain microenvironment. Once insult to the brain occurs, microglia switch to an activated
state that triggers the immune responses in order to restore homeostasis and clearance of
the activating molecules. Acute inflammation is usually protective and characterized by a
short duration of inflammation that normally self-resolves. However, chronic
inflammatory signals can trigger other immune cells to produce pro-inflammatory
mediators that worsen the disease state over a long period of time. The presence of
elevated pro-inflammatory cytokine/chemokines can damage the blood-brain barrier
integrity, neurons and alter the brain homeostasis that collectively affects the brain
immune system causing neuroinflammation (reviewed by (C. K. Glass, Saijo, Winner,
Marchetto, & Gage, 2010)).
Microglia recognize damage-associated molecular patterns (DAMPs) and
pathogen-associated molecular patterns (PAMPs) via specific cell surface receptors.
Normally microglia progress through a spectrum of activation states beginning with a
pro-inflammatory phenotype and terminating in a pro-wound healing phenotype.
However, chronic neuroinflammation can be triggered by persistent production of
pro-inflammatory cytokine/chemokines such as tumor necrosis factor-alpha (TNF-α),
interferon-gamma (IFN-γ), interleukin 1 beta (IL-1β) and monocyte chemoattractant
protein-1 (MCP-1) in response to persistent stimulation. The prolonged-release of these
pro-inflammatory markers activate other immune cells that damage normal brain tissues
such as parenchymal cells and affect the blood-brain barrier integrity (Figure 1-5). In
addition, the release of reactive oxygen species (ROS) and induction of nitric oxide (NO)
synthase both work to amplify to the inflammatory signal that exacerbates the disease
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Figure 1-4. Proposed Noncanonical Signaling Pathway for CB2R.
The activation of β arrestins starts when the C-terminus of a GPCR is phosphorylated by
a specific G protein receptor kinases (GRKs) to facilitate β-arrestin binding to the
receptor. Depend on C-terminus phosphorylation barcode, specific GRKs are recruited
and each phosphorylation pattern on the C-terminus will activate a specific β-arrestin
function. For instance, GRK2/3 recruits β-arrestins to interact with the receptor tail to
desensitize the G-protein signaling. Conversely, GRK5/6 facilitates the binding of
β-arrestins to the third intracellular loop (ICL3) that initiates β-arrestins downstream
signaling activity including activation of several MAPKs and stabilization of NF-κB
complex, thus regulating several gene expressions that are important in cellular
responses.

11

Figure 1-5. Neuroinflammatory Process Mediated by Microglia.
(1) The brain resting microglia (M0) are stimulated by injury, bacteria, and protein
aggregates, e.g. beta-amyloid, that polarize microglia from M0 into an M1 activated
phenotype (2) which upregulates CB2R expression. The release of pro-inflammatory
cytokines (3) such as TNF-α, IL-1β, and IL-6 are responsible for activating other immune
cells (4) including macrophages, T cells, lymphocytes, and natural killer cells. These
immune cells produce more inflammatory cytokine/chemokines (proinflammatory storm)
which disrupt the blood-brain barrier (BBB) integrity (5) and allows immune cells
infiltration into the brain, which causes neuronal toxicity and persistent microglial
activation leading to chronic neuroinflammation (6).
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condition (reviewed by (C. K. Glass et al., 2010)).
Alzheimer’s Disease
AD is a chronic cognitive disorder that affects 40 % of the people older than 80
years; this disease is characterized by irreversible, progressive, neurodegeneration with
permanent mental and functional loss affecting short-term memory, progressive mobility
deterioration, and behavioral disturbance (disease pathology reviewed by (Selkoe, 2001)).
The currently available AD treatment such as cholinesterase inhibitors are only used to
slow down disease progression and there is no curative treatment available till today.
Non-steroidal anti-inflammatory (NSAID) drugs didn’t demonstrate any beneficial
effects in AD patients (Jaturapatporn, Isaac, McCleery, & Tabet, 2012), vaccine clinical
trials have failed with some causing encephalitis in 6% of patients (Orgogozo et al.,
2003), and anti-tau agents have yet to demonstrate clinical efficacy (Cummings, Lee,
Ritter, & Zhong, 2018). The accumulation of insoluble aggregates of extracellular
amyloid-β (Aβ) plaques and intracellular neurofibrillary tangles (NFT) are harmful to the
brain neurons, trigger microglial cell activation and initiation of chronic
neuroinflammation (reviewed by (Tuppo & Arias, 2005)). Therefore, the discovery of
novel therapeutic candidates to regulate chronic neuroinflammation is a current unmet
clinical need.
In postmortem AD patients' brains, CB1R expression was unchanged, or in some
studies decreased in the hippocampus and basal ganglia. However, CB2R was
upregulated in microglia that were associated with aggregates or plaques in the
hippocampus, entorhinal and frontal cortex. Elevation of the AEA degrading enzyme
FAAH was reported in astrocytes which were associated with upregulation of several
pro-inflammatory cytokine/chemokines including IL-1β, TNF-α, interleukin 6 (IL-6) and
MCP-1 in AD patient’s brain (Cristina Benito et al., 2003; Ramírez, Blázquez, del Pulgar,
Guzmán, & de Ceballos, 2005). The potential of targeting the ECS in AD has been
demonstrated in studies using the cannabinoid ligands WIN 55,212-2 (CB1/2 agonist)
and JWH-133 (CB2R agonist) wherein drugs treatment reduced microglial activation,
attenuated pro-inflammatory cytokines/chemokines release, and reduced β-amyloid
accumulation in vitro and in vivo. Therefore, CB2R modulation could provide a new
alternative for therapeutic intervention in AD (Martín-Moreno et al., 2012; Tolón et al.,
2009). It is also been proposed that changes in the ECS could be utilized as an early AD
biomarker in the elderly (C Benito et al., 2008).
Parkinson’s Disease
PD is a chronic disorder that affects the central nervous system causing permanent
damage and loss to the dopaminergic neurons in 2% of people over 60 years of age. PD is
characterized by a gradual loss of movement, tremor, and bradykinesia that worsen with
disease progression; furthermore, behavioral changes such as depression, mental
deterioration, and insomnia can occur. The major pathological hallmarks of PD are the
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progressive loss of dopaminergic neurons in the substantia nigra, accumulation of
α-synuclein (Lewy bodies) aggregates and microglial cell activation. Activated microglia
play a crucial role in PD disease etiology as evidenced by elevated pro-inflammatory
mediators in the PD human brain tissues (reviewed by (C. K. Glass et al., 2010)).
Currently, available treatments are only palliative (Lang & Lozano, 1998), and there are
no curative treatments available for PD.
The upregulation of the ECS in certain brain tissues in PD patients, as well as
animal models of PD, strongly indicate the involvement of CB receptors in PD (Di
Marzo, Hill, Bisogno, Crossman, & Brotchie, 2000; Lastres‐Becker et al., 2001; Pisani et
al., 2005). Moreover, neuroinflammation is reported to be the main contributor in PD
pathology with a concomitant upregulation of CB2R in activated microglia surrounding
aggregates, thus suggesting a strong correlation between chronic microglial activation
and PD (Concannon, Okine, Finn, & Dowd, 2015; McGeer, McGeer, & disorders, 1998).
In PD mouse model, CB1/2 nonselective agonist WIN55,212‐2 demonstrated beneficial
anti-inflammatory effects by decreasing microglial activation and impeding the
neurodegenerative process (Price et al., 2009b). Numerous studies have examined CB2R
ligands in modulating PD disease further demonstrating a protective role of CB2R,
supporting it as a novel target for treating PD (Garcia et al., 2011b; Gómez-Gálvez,
Palomo-Garo, Fernández-Ruiz, García, & Psychiatry, 2016).
Human Immunodeficiency Virus and Human Immunodeficiency Virus Encephalitis
HIV-1 is a lifelong disease that attacks the immune system and infects important
immune cells such as monocytes, and macrophages that protect the human body against
infection. HIV-1 patients can experience a variety of cognitive and motor dysfunction as
the disease progresses. Brain immune cells can be affected by HIV-1 which leads to
disease progression with neurocognitive impairment resulting in loss of memory,
concentration, speech, and other behavioral changes that lead to encephalitis (Sacktor,
2002). Antiretroviral therapy can protect the brain from HIV-1 associated damage and
development of encephalitis if it is initiated in the early stages of HIV-1. However, when
a patient reaches the HIVE stage, it is difficult to treat and manage the
neuroinflammation using traditional antiretroviral therapy (Sacktor, 2002; Spencer &
Price, 1992).
Microglia and T lymphocytes play a prominent role in the neuroinflammatory
process in HIVE and the upregulation of ECS components has been reported. In HIVE
patients, the expression of CB2R was highly elevated in microglia and T lymphocytes
along with significant increases in FAAH expression in astrocytes. This is in contrast to
non-infected controls wherein no upregulation was reported suggesting a critical role of
ECS in modulating HIVE (Cristina Benito et al., 2005; Cabral, Griffin-Thomas, &
Targets, 2008; Ghosh, Preet, Groopman, & Ganju, 2006). This assertion is further
supported by the fact that selective CB2R ligands such as JWH-133 (Ramirez et al.,
2013) and JWH-015 (Rock et al., 2007) showed promising therapeutic benefits in HIV-1
disease. Specifically, JWH-133 and JWH-015 decreased viral replication which could
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prevent the exacerbation of HIV-1 into encephalitis, thus indicating CB2R is a promising
unique target in HIV-1 and related encephalitis (Ramirez et al., 2013; Rock et al., 2007).
Multiple Sclerosis
MS is an autoimmune disease that damages the central nervous system including
the brain, spinal cord, and eye nerves by demyelination of the protective layers of
neurons affecting nerve impulses. This can manifest as blurred vision, pain, cognitive,
and motor dysfunction. Environmental, infectious, and genetic factors play a critical role
in disease susceptibility; however, the etiology of the disease is still unknown (Frohman,
Racke, & Raine, 2006). MS affects females more than males and causes cognitive
deterioration as the disease progresses (C. K. Glass et al., 2010). The demyelination
process is also accompanied by elevated levels of pro-inflammatory mediators such as
IL-1β, TNF-α and IL-6 and microglial activation as observed in MS patients (Kempuraj
et al., 2016).
In 2002, a large randomized blinded clinical trial called cannabinoid in multiple
sclerosis (CAMS) was done using Cannador (plant extract that contains '9-THC and
cannabidiol (CBD)) and Marinol (approved drug that contains synthetic '9-THC for
treating spasticity in MS patients). Both '9-THC and plant extract didn’t improve the
patient condition and treatment side effects were more pronounced using plant extract
compared to '9-THC alone (Killestein et al., 2002). However, a follow-up study
conducted in 2005 reported beneficial effects of '9-THC long term treatment on
spasticity, pain relief, and mobility when patients continued to take Marinol for 12
months compared to placebo and Cannador (Zajicek et al., 2005). The use of THC: CBD
oromucosal spray was also evaluated in MS patients to treat pain and sleep disturbance in
another randomized controlled trial in 2005. Cannabinoids adjunctive treatment
demonstrated significant improvement in the pain and sleep disturbance in MS patients
compared to the control group (Rog, Nurmikko, Friede, & Young, 2005). Moreover,
several studies reported beneficial effects of cannabinoids in MS animal models which
decreased the excitotoxic effect that induces axonal damage and reduced neuronal deficit
in MS models (Arévalo-Martı́n, Vela, Molina-Holgado, Borrell, & Guaza, 2003;
Docagne et al., 2007; Lyman, Sonett, Brosnan, Elkin, & Bornstein, 1989). In humans,
expression of CB2R was elevated in postmortem specimens that were taken from the
spinal cord and active plaques of MS patients (Cristina Benito et al., 2007; Yiangou et al.,
2006), suggesting that targeting CB2R could be a promising therapeutic approach for
treating MS as well as other autoimmune disease conditions.
Huntington’s Disease
HD is an inherited neurodegenerative disorder that damages brain neurons and
causes motor, cognitive, and psychiatric dysfunction. Disease symptoms can vary
depending on the patient but it usually involves imbalanced movement, muscle rigidity,

15

dementia, depression, and suicidal thoughts (Cattaneo et al., 2001; Cattaneo, Zuccato, &
Tartari, 2005).
Brain tissues were taken from postmortem HD patients, as well as animal models,
have shown downregulation of CB1R in basal ganglia (M Glass, Dragunow, & Faull,
2000; M Glass, Faull, & Dragunow, 1993). However, the expression of the CB2R in
activated microglia was upregulated and considered to be a protective mechanism against
damage and neuroinflammation. Additionally, several studies reported the involvement
of CB2R in HD pathology and the selective CB2R agonist HU-308 had neuroprotective
effects in an HD rat model (Palazuelos et al., 2009b; Sagredo et al., 2009). In 2016, a
phase I clinical trial with Sativex (plant extract that contains THC and CBD), in the form
of an oral spray administered twelve sprays per day, was conducted with 26 HD patients
for 12 weeks. The primary endpoint was the safety of Sativex in HD patients and none of
the patients experienced severe adverse effects. The second endpoint was to evaluate the
effectiveness of Sativex in HD disease; however, none of the patients demonstrated any
motor or behavioral improvement compared to control. These data suggested the need for
evaluating different cannabinoid compounds with longer duration and higher doses, or
potential receptor-specific ligands with unique functional activity, in the HD clinical trial
(Moreno et al., 2016).
Traumatic Brain Injury
TBI is a brain injury that is largely associated with the young population resulting
from sports injury, falls, violence, vehicle accidents, combat, or repeated CNS insult
which occur over a long period of time, e.g. chronic traumatic encephalopathy (CTE) in
football players. Currently, the available treatments for TBI such as barbiturates,
hyperventilation, cerebrospinal fluid drainage, and corticosteroids are used to alleviate
symptoms only (Roberts, Schierhout, Alderson, & Psychiatry, 1998). These symptoms
range from moderate, normally associated with no loss of consciousness or only a few
seconds, which include headache, nausea, and vomiting, to severe cases that involve
convulsions, seizures, loss of coordination depending on the extent of physical damage to
the brain (Langlois, Rutland-Brown, & Wald, 2006).
As with all the neurodegenerative disorders described thus far, the ECS has been
implicated as a key regulator of neuroinflammation and disease progression in TBI (R
Mechoulam & Shohami, 2007). The endogenous ligand 2AG demonstrated a
neuroprotective effect in the mouse TBI model (Panikashvili et al., 2001), and the
synthetic cannabinoid agonist GP1a alleviated neuroinflammation and reduced brain
injury by polarizing macrophages to M2 alternative phenotype (Braun et al., 2018).
Recently, CB2R inverse agonists served as a unique class of ligand that can treat TBI.
For example, SMM-189 is a selective CB2R inverse agonist (C. Presley, A. Abidi, S.
Suryawanshi, S. Mustafa, B. Meibohm, B. M. J. P. r. Moore, et al., 2015) that was
reported to be efficacious in mild TBI mouse models by polarizing microglia from M1
proinflammatory to M2 anti-inflammatory state. The in vivo treatment with SMM-189
has reversed the neuronal deficit and improved the overall neuronal outcomes in TBI
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mouse models (Bu et al., 2016b; Guley et al., 2019; Liu et al., 2017; Reiner et al., 2015b).
Therefore, there is an urgent need for discovering curative therapies for TBI in which
CB2R serves as a unique target for TBI and other neuroinflammatory conditions.
Hypothesis
It was not until the beginning of the 21st century that research revealed the
presence of the CB2R in the central nervous system. There remains a paucity of data on
the total distribution in various brain regions; however, it is now accepted that CB2R is
highly expressed in microglia under certain neuroinflammatory conditions. The restricted
expression of CB2R in CNS, lack of psychotropic activity, and upregulation of CB2R by
microglia in various pathologies make this receptor an attractive target for discovering
novel approaches to treat diseases for which there are currently no efficacious therapies.
The current cannabinoids literature is mainly focused on developing and evaluating
CB2R agonists as anti-inflammatory agents; however, none of the agonists that have
progressed to clinical trials have met the specified endpoints in terms of efficacy
(Aghazadeh Tabrizi, Baraldi, Borea, & Varani, 2016). It is not clear what factor(s) are
limiting the clinical progression of CB2R agonists and this has raised questions regarding
the therapeutic potential of targeting CB2R using inverse agonists.
My hypothesis on the current challenges of targeting CB2R with agonist arises, in
part, to differences in downstream effector activation due to ligand bias, which is a
function of the ligand structure. I hypothesize that the complexity of agonist signaling
pathways can be circumvented by developing selective CB2R inverse agonists which
interact with the inactive conformation of the receptor, reducing constitutive activity, and
potentially unmasking signaling cascades from other constitutively active GPCRs which
may be beneficial in regulating microglial function. Although the latter is theoretical in
nature, we have previously demonstrated our selective CB2R inverse agonist, SMM-189,
is effective in biasing of microglia away from pro-inflammatory M1 phenotype while
enhancing the pro-wound healing M2 phenotype. Furthermore, the inhibition of
pro-inflammatory cytokine release by microglia in vitro, bias of microglia to an M2 state
in vivo, and the efficacy of the drug in preventing adverse effects of model traumatic
brain injury in the mouse model strongly support my hypothesis. Other factors may have
limited clinical efficacy of CB2R agonists − such as translating the results from animal
models to the human disease state – but my focus in this dissertation was to determine if
CB2R inverse agonists could provide an alternate or better approach to treating
neuroinflammation in human diseases.
My first objective was to evaluate the effects on functional activity of modifying
the C1` functional groups in our lead compound SMM-189. To this end, six compounds
were synthesized to determine optimum functional group substitution. I evaluated these
compounds in ACTOne and TANGO-bla functional assays for hCB1, hCB2, and parental
cell lines, in addition to determining compounds affinities toward hCB1/2 receptors.
Moreover, the compounds that demonstrated no activity at functional assays with high
binding affinities to CB2R were further assessed in antagonist (competition) study
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against the non-selective cannabinoid agonist CP 55,940. Docking and simulation studies
were performed on the six compounds to understand the specific molecular interaction
with CB2R. The results of these studies provided valuable information to aid in the
development of new analogs of SMM-189.
Based on our promising results with SMM-189, we started a new drug
development program that focuses on identifying the structure-activity relationship
(SAR) of the tri-aryl scaffold. The objective was to improve potency, efficacy, and
affinity of our lead SMM-189 as determined using in vitro pharmacological evaluation of
the newly synthesized series. Twenty compounds were synthesized with modifications to
the A and C rings in the SMM-189 scaffold. I evaluated the pharmacological activity of
the compounds against hCB1 and hCB2 using ACTOne cAMP reporter assay and the
TANGO-bla β-arrestin assays, as well as receptor binding assays. Compound 45
demonstrated the highest potency, efficacy, and affinity in the binding and functional
assay and was selected for further evaluation in murine and human microglia
inflammatory models. On cell polarization assays were done to evaluate microglia M1
and M2 surface markers expression, in addition to scratch assays to assess microglia
migration ability after compound 45 treatment. Moreover, a ROS detection assay was
performed to evaluate ROS generation and an extensive signaling pathway study was
done at six-time points to understand the downstream signaling mechanism for
compound 45. Lastly, cytoskeleton staining was performed for compound 45 treated cells
and morphological changes were determined and compared to LPS stimuli.
Lastly, to better understand the differences between CB2R agonist and inverse
agonist activity, I performed a pharmacological evaluation of two selective CB2R
agonists HU-308, JWH-133 and two selective CB2R inverse agonists SR144528 and
SMM-189 in ACTOne and TANGO-bla assays. The anti-inflammatory properties of the
four compounds were investigated in LPS stimulated human microglia model to examine
if the drugs will produce distinct biological responses under the same experimental
paradigm. Several studies were done to achieve this, on cell polarization assays were
done to assess M1 and M2 surface markers. In addition to ROS and scratch assays to
evaluate ROS generation and migration ability of drugs treated cells. A molecular
pathway study was performed for three selected time points to assess the downstream
signaling activity. Last, morphological cytoskeleton staining was done to assess
cytoskeleton changes upon drugs treatment.
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CHAPTER 2. FUNCTIONAL GROUP MODIFICATION OF THE C1`
POSITION IN THE BIARYL-ARYL-MENTHONE SCAFFOLD – EFFECTS ON
AFFINITY, POTENCY, AND EFFICACY AT THE CB1 AND CB2 RECEPTORS
Introduction
The CB1 and CB2 receptors have emerged as important regulators in the initiation
and progression of a variety of disease conditions. Their distinct functions and
localizations make them attractive targets for the development of novel therapeutic
interventions to treat a spectrum of human diseases. The widespread distribution of
CB1R in CNS provides a great opportunity to target this receptor for pain management,
improvement of cognition and memory, regulation of food intake, and behavior
modification as reviewed by Howlett and colleagues (A. Howlett et al., 2002a). However,
the high expression of CB1R in the brain can pose a significant challenge owing to the
psychotropic effects of CB1R agonists. Notwithstanding, the receptor has been targeted
for obesity as evidenced by the development of CB1R antagonist/inverse agonist. The
first CB1R antagonist/inverse agonist SR141716, or Rimonabant, (Rinaldi-Carmona et
al., 1994) was effective in promoting weight reduction in obese patients (Van Gaal et al.,
2005) which led to the European approval of Rimonabant in 2006 but failed to be
approved in the United States. Two years later, Rimonabant was withdrawn from the
market due to a drug-induced increase in the rates of suicide in patients receiving the
medication (reviewed by (Leite, Mocelin, Petersen, Leal, & Thiesen, 2009)). The
potential of targeting CB1R with antagonist/inverse agonist remains attractive and
considerable research is ongoing to develop peripherally restricted analogs to treat
obesity and other diseases (Roger G Pertwee, 2005).
The limitations on CB1R ligand functional activity and/or ability to penetrate the
CNS have not yet been observed for ligands that target the CB2R. The CB2R is mainly
localized in immune cells, with limited CNS distribution, thus yielding a novel target for
immunomodulation and regulation of inflammatory responses without complicating
psychotic side effects. Furthermore, the upregulation of CB2R expression in many
disease states provides vast opportunities for discovering novel anti-inflammatory and
immune regulation therapies with improved safety profiles relative to existing drugs. To
this objective, a novel biaryl-aryl scaffold was discovered in our lab in 2009 that
demonstrated moderate affinities to cannabinoid receptors (Bhattacharjee, Gurley, &
Moore II, 2009). Further scaffold development and optimization revealed that SMM-189
(Figure 2-1) increased cAMP production in ACTOne functional assay, thus
demonstrating this class of compounds was inverse agonists. The promising
anti-inflammatory responses of SMM-189 with the favorable pharmaceutical properties
prompted us to further investigate the 2,6-dihydroxy-biphenyl-aryl-methanone scaffold
(C. Presley, A. Abidi, S. Suryawanshi, S. Mustafa, B. Meibohm, & B. M. Moore, 2015).
Consequently, a series of compounds were synthesized and evaluated with modifications
in the C ring (Figure 2-2) which revealed that substitution at position 4 provided the
highest inverse agonist activity in ACTOne functional assay (C. S. Presley, Mustafa,
Abidi, & Moore, 2015). To further develop the structure-activity relationship of this class
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Figure 2-1.

Chemical Structure of SMM-189.

Figure 2-2.
Scaffold.

Ring C Modification in 2,6-Dihydroxy-Biphenyl-Aryl-Methanone
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of CB2R inverse agonist, the substituent at the C1`position of the biaryl-aryl-menthone
scaffold (Figure 2-3) was modified. For this purpose, six compounds were synthesized
and pharmacologically examined for the effects on activity in the G-protein (canonical)
and β-arrestins (noncanonical) pathways.
The G-proteins signaling of CB2R involves activation of Gαi subunit that
negatively regulates AC activity. The process of Gαi activation involves the exchange of
guanosine diphosphate (GDP) for guanosine triphosphate (GTP) with subsequent
dissociation of the Gαi from βγ dimer. In terms of Gαi modulation, cannabinoids can
either activate or sequester Gαi depend on the pharmacological profile of the ligand, i.e.
agonist or inverse agonist, respectively. Agonists activate Gαi and decrease cAMP
production, inverse agonists sequester Gαi and increase the cAMP level while neutral
antagonists have no effect on cAMP production. To assess the compounds functional
activity at the G-protein pathway, the ACTOne assay system was utilized which provides
a real-time measurement of the intracellular cAMP level upon ligand binding. In this
system, cells were transfected with hCB1 or hCB2 receptors and cyclic nucleotide-gated
(CNG) ion channels that respond to changes in cAMP levels. The channels open when
the cAMP level increases, allowing the influx of ions inside the cells which in turn alters
the membrane potential. A membrane potential specific dye is used to measures the
potential change which corresponds to cAMP levels. This system is activated by
forskolin to induce AC and phosphodiesterase (PDE) inhibitor (Ro 20-1724) to prevent
the endogenous hydrolysis of cAMP allowing for an accurate cAMP measurement.
The β-arrestins are now recognized as scaffolding proteins that, in addition to
their role in receptor desensitization, have the ability to activate G-protein independent
signaling cascades such as MAPKs and NF-κB. Because of the importance of the
β-arrestin component in cannabinoid signaling, we utilized the TANGO-bla functional
assay to evaluate the ability of our compounds to recruit β-arrestin following receptor
ligation. In this assay, cells are transfected with hCB1 or hCB2 receptors with a
C-terminus modification containing a TEV protease site that is linked to a Gal4-VP16
transcription factor (TF). When the TEV protease tagged β-arrestin is recruited to CB1/2
receptors, it cleaves TF from the C-terminus then translocates to the nucleus and initiates
beta-lactamase expression as a function of total cleaved TF. The detection of b-lactamase
activity (bla), and by extension β-arrestin recruitment, is accomplished by fluorescence
resonance energy transfer (FRET). The substrate has a cephalosporin ring system that
tethers the donor and acceptor molecules to allow efficient energy transfer and green
fluorescence is emitted. Cleavage of the lactam ring results in the release of the acceptor
revealing the blue fluorescent of the donor molecule. Thus, using the appropriate filters,
the intensities of the blue and green fluorescence can be measured and the degree of
β-arrestin activation can be determined. In terms of functional activity at β-arrestins,
cannabinoids can either activate or block β-arrestins based on the pharmacological
activity of the ligands, i.e. agonist or neutral antagonist, respectively. Agonist recruits
β-arrestins, cleave the bla substrate and blue fluorescent is detected, while, neutral
antagonist doesn’t recruit β-arrestins, leaves BLA substrate intact and green fluorescent is
observed. TANGO-bla assay is a high throughput screening (HTS) method that provides
an indirect sensitive endpoint measurement of β-arrestins activity for cannabinoid ligand.
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Figure 2-3.

C1`Position of the Biaryl-Aryl-Menthone Scaffold.
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The main objective of this project was to determine the structural requirement at
C1` position of the biaryl-aryl-menthone scaffold. The three specific aims were set forth
to achieve this goal. 1) Examine the binding affinity of the six synthesized compounds
for hCB1/2 receptors using [3H]-CP 55,940 competition binding assays; 2) evaluate
CB1/2 pharmacological efficacy of the six compounds for activation of G-protein and
β-arrestin pathways using ACTOne and TANGO-bla assays, respectively; 3) perform
docking and simulation studies of the six compounds using modified CB2R inactive
crystal structure to correlate the pharmacological activity with ligand-protein molecular
interactions.
Materials and Methods
Reagents
The HEK-CNG, HEK-CNG + CB1, and HEK-CNG + CB2 cell lines were
purchased from Codex BioSolutions, Inc (Gaithersburg, MD). Tango™ CNR2-bla and
CNR1-bla U2OS cell lines were purchased from Invitrogen (Carlsbad, CA). Puromycin,
DMEM, penicillin/streptomycin, gentamicin, PBS, 0.25% Trypsin/EDTA, Hank’s Buffer,
HEPES, EDTA, Tris base, sucrose, MgCl2, Millipore filter plates and punch kits, EcoLite
scintillation cocktail, and Poly-d-lysine coated 96-well plates catalog # 356461 were
purchased from Fisher Scientific (Waltham, MA). G418 was purchased from KSE
Scientific (Durham, NC). FBS was purchased from Atlanta Biologicals (Flowery Branch,
GA). Ro 20-1724, acetonitrile, DMSO, polyethylene amine, and fatty acid-free BSA were
purchased from Sigma Aldrich (St. Louis, MO). ACTOne Membrane Potential Dye was
purchased from Codex BioSolutions (Gaithersburg, MD). Forskolin and CP-55,940 were
purchased from Tocris (Bristol, UK). LiveBLAzer™-FRET B/G Loading Kit, Solution
D, Recovery™ Cell Culture Freezing Medium, FreeStyle™ Expression Medium,
McCoy's 5A Medium (modified) (1X), fetal bovine serum (FBS) dialyzed, non-essential
amino acids (NEAA), sodium pyruvate, HEPES (1 M, pH 7.3), 0.05% Trypsin/EDTA,
Zeocin ™, Hygromycin, Geneticin were purchased from Invitrogen (Carlsbad, CA).
Black-wall, clear-bottom, 96-well assay plates #3603 were purchased from Corning
(Corning, NY). Tritiated [3 H]-CP-55,940 was purchased from PerkinElmer (Waltham,
MA). The 96-well filter plates and punch tips were purchased from Millipore (Billerica,
MA). Pierce BCA protein assay kit and Fisherbrand™ 7mL Borosilicate Glass
Scintillation Vial were purchased from Thermofisher (Waltham, MA). Ecolite(+) LC
Fluid, MP Biomedicals was purchased from Tocris. Schrödinger Release 2019-3:
Desmond Molecular Dynamics System, Glide, LigPrep, Maestro, Schrödinger, LLC,
New York, NY, 2019.
Cell Culture
CNR2-bla and CNR1-bla U2OS cell lines were cultured in McCoy's 5A medium
with 10% dialyzed FBS, 1%P/S, 0.1 mM NEAA, 25 mM HEPES, 1 mM sodium
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pyruvate, 200 μg/ml Zeocin ™, 50 μg/ml Hygromycin, 100 μg/ml Geneticin. CNR2-bla
and CNR1-bla U2OS cells were passaged every 2 to 3 days or when confluence reach
80%. HEK-CNG + CB1 and HEK-CNG + CB2 cells were cultured in DMEM with 10%
FBS, 1% P/S, 25 μg/mL G418, and 5 μg/mL puromycin. HEK-CNG cells were cultured
in DMEM with 10% FBS, 1% P/S, and 25 μg/mL G418. HEK-CNG+CB1 and
HEK-CNG+CB2 cells were passaged every 2–3 days or when confluence reached 80%.
For all functional cell lines, culture flasks were changed every five passages or after two
weeks of use.
ACTOne (G-Protein) Functional Assay
The ACTOne functional assay is used to measure the G-protein signaling as a
function of cAMP production following ligand binding to CB1/2 receptors. In this assay,
forskolin is used to activate adenylyl cyclase and phosphodiesterase (PDE) inhibitor (Ro
20-1724) is added to prevent the endogenous hydrolysis of cAMP by PDE enzymes. The
HEK-CNG (parental cell line), HEK-CNG + CB1, and HEK-CNG + CB2 cells were
plated in clear poly-D-lysine coated 96-well plates in plating media (DMEM, 10% FBS,
1% P/S) at 50,000 cells/100 μL medium and plates were incubated for 16-18 hours at
37°C / 5% CO2. The next day, 100 μL of ACTOne membrane potential dye was added to
each well and the plates were maintained at room temperature for 1 h in the dark. 5X of
tested compounds were prepared from 1 × 10−6 to 1 × 10−9 with 25 μmol/L Ro 20-1724,
and 800 nmol/L forskolin in PBS with 2.5% (v/v) DMSO. Once test compounds were
added, plates were read using a BioTek (Winooski, VT) plate reader (Ex 540 nm, Em 590
nm) for one hour. The data at 50 mins were combined and analyzed to determine
compounds pharmacological activity. Six to nine biological replicates were used for data
analysis. The gold standard CP 55,940 was used as a positive control in each
experimental run and plate read is considered acceptable if CP 55,940 has EC50 from 1 to
10 nM and % of cAMP suppression from 70 to 95 for both cell lines.
Antagonist studies were performed by adding 100 μl of ACTOne membrane
potential dye for 30 mins, followed by 20 μL addition of antagonist (concentration were
chosen to be one log above and below the previously determined EC50). Plates were
incubated for an additional 30 mins in the dark at room temperature prior to the addition
of CP-55,940. One hour after dye addition, 30 μL of CP-55,940 in PBS with 2.5%
DMSO buffer, 25 μmol/L Ro 20-1724 and 800 nmol/L forskolin was added to each well.
Plates were read using a BioTek (Winooski, VT) plate reader (Ex 540 nm, Em 590 nm)
for one hour. The data at 50 mins were combined and six to nine biological replicates
were used for data analysis.
Tango™ -BLA (β-Arrestins) Functional Assay
CNR2-bla and CNR1-bla U2OS cells were plated in black-wall, clear-bottom,
96-well assay plates in FreeStyle™ Expression Medium at 50,000 cells/100 μL well and
incubated for 16-18 hours at 37°C / 5% CO2. The next day, 10X stock of test compounds
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were prepared in FreeStyle™ Expression Medium with 0.5% DMSO. The final
concentrations of tested compounds were 1 x 10-6 to 1 x 10-9. Test compounds were
added to each well, full agonist control CP 55,940 (at 5 μM) was added to the stimulated
wells and assay medium with 0.5% DMSO was added in the cell-free and unstimulated
wells. The plates were incubated in humidified 37°C/5% CO2 for 5 hours. After that, a
6X loading solution was prepared as described in the manufactures assay protocol. Assay
plates were removed from the humidified incubator and 20 μL of loading solution was
added to each well. The plates were incubated at room temperature for an additional 2
hours and maintained in the dark to protect plates from light and evaporation. Plates were
read using Synergy 2 BioTek (Winooski, VT) plate reader (Ex 409/20 nm, Em 460/40
nm, Em 530/30 nm) with fluorescence reading set to a bottom-read mode with optimal
gain and 5 reads. CP 55,940 served as a positive control for all runs and the acceptable
run was defined by CP 55,940 EC50 between 30-40 nM for CB2 and 1-10 nM for CB1,
with % activation range between 80-100% for both cell lines. Three to nine biological
replicates were used for data analysis.
In order to determine antagonist activity, cells were plated at 50,000 cells/100 μL
well and incubated for 16-18 hours at 37°C / 5% CO2. Following day,10X stock of
antagonist compounds were prepared in assay medium with 0.5% DMSO and 10 μL of
antagonists were added to each well and incubated for 30 minutes in humidified 37°C/5%
CO2. 10X stock of EC80 concentration of CP-55,940 was prepared in an expression assay
medium with 0.5% DMSO. After 30 minutes of incubation with the antagonist, 10 μL of
CP 55,940 (final concentration EC80) was added to each well and incubated in humidified
37°C/5% CO2 for 5 hours. After that, 6X loading solution was added to each well and the
plates were incubated at room temperature for an additional 2 hours and were covered to
protect plates from light and evaporation. Plates were read using Synergy 2 BioTek plate
reader (Ex 409/20 nm, Em 460/40 nm, Em 530/30 nm) as described above. At least four
biological replicates were used for data analysis.
Membrane Preparation
The membrane preparations used in the binding experiments were prepared from
the functional cell lines HEK-CNG + CB1 or HEK-CNG + CB2 to allow for a direct
correlation between EC50 and Ki. Briefly, HEK-CNG + CB1 or HEK-CNG + CB2 cells
were plated in 500 cm2 culture dishes and incubated for two days or when it reached
80-90 % confluence. Media was removed and cells were washed with 10 mL of ice-cold
PBS. Then, cells were scrapped after the addition of 10 mL of ice-cold PBS with 10
mmol/L EDTA and the cell suspension was centrifuged at 4°C, 500g for 5 min. The
supernatant was discarded, and the pellet homogenized in 10 mL of solution A (50 mM
Tris HCL, 320 mM sucrose, 2 mM EDTA and 5 mM MgCl2) and the cell suspension was
centrifuged at 4°C, 1600g for 10 min. The supernatant was saved, and the cell pellet
washed three times in 8 mL of solution A. All supernatants were combined and
centrifuged at 4°C, 50,228g for 3 h. The supernatant was discarded and the pellet
suspended in 3 mL of solution B (50 mM Tris HCL, 10% sucrose, 2.5 mM EDTA and 5
mM MgCl2). Protein concentration was determined using a Pierce BCA protein assay kit
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and membrane aliquots were stored at −80°C. Scatchard experiments were done using
CB1 and CB2 membrane preparations wherein the CB1 membrane preparation Kd was
3.1 nmol/L and Bmax was 2.4 pmol/mg. The CB2 membrane preparation Kd was 1.72
nmol/L with Bmax 1.51 pmol/mg.
Receptor Radioligand Binding Assay
Millipore filter plates were filled with 210 μL/well of 0.05% (w/v) polyethylene
amine in deionized water and incubated for 1 hour at room temperature. Plates were then
washed five times with 250 μL/well of deionized water then filtered using vacuum
manifold before starting the experiment. After plate coating, 125 μL binding buffer was
added to each well, followed by addition of 5 μL of [3H]-CP 55,940, 10 μg of membrane
protein in binding buffer, and 50 μL of test compound in binding buffer (final
concentration ranging from 1 nmol/L to 10 μmol/L). Plates were incubated at 30°C for
1.5 hours, then solutions were removed via vacuum and washed nine times with binding
buffer. The plates were vacuum dried and punch tips were used to punch out filters into 5
mL of Eco-lite scintillation cocktail in 7ml scintillation vials. Counts per minute (CPM)
were measured the next day using PerkinElmer Liquid Scintillation Analyzer Tri-Carb
2810TR, 3-min dwell time. At least six biological replicates were used for data analysis.
Data Analysis
For the binding assays, Ki values were determined using Cheng and Prusoff
equation (Cheng & Prusoff). For the ACTOne data, the analysis was done using
nonlinear regression analysis and fluorescent measurements at 50 mins. The data were
normalized using a scaling equation:
ܺᇱ ൌ  ܣ
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For the agonist study, A= Blank well-containing dye and cells only, B = Forskolin
stimulation, X` = Normalized value, X max = 100 %, X = min 0 %. For the antagonist
study, A = Maximal inhibitory of the effect of the tested agonist, B = Minimal inhibitory
effect, X` = Normalized value, X max = 100 %, X min = 0 %.
For the Tango-BLA assay, the analysis was done using fluorescent measurements.
The background (cell-free wells) was subtracted from both emission channels (460 nm
and 530 nm). Blue/Green Emission Ratio was calculated for each well by dividing the
background-subtracted blue emission values by the background-subtracted green
emission values.
Background-Subtracted Fluorescence (Fl) = Fl Sample – Fl Cell-free control
େ୭୳୫ୟ୰୧୬୫୧ୱୱ୧୭୬ሺସ୬୫ሻ

Emission Ratio = ୪୳୰୭ୣୱୡ୧୬୫୧ୱୱ୧୭୬ሺହଷ୬୫ሻ
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Molecular Docking and Simulation of BMM-V-Compounds
The CB2R crystal structure PDB 5ZTY, (Li et al., 2019) was modified at the third
intracellular loop (ICL3) to remove the T4-lysozyme protein, then the protein structure
was processed and modified using Protein Preparation Wizard. The structures of
compounds were converted into 3D using LigPrep and several conformations were
generated and minimized. The docking was performed using Glide XP for molecular
docking (Friesner et al., 2006). For the simulation, the protein-ligand complex was
embedded into the POPC lipid membrane with SPC water molecules. The potassium ions
were set to 0.15 M and nine chloride ions were added to neutralize the system. The
simulation runs were performed in the NPT ensemble and the temperature was set to 300
and pressure of 1 atm. The system was relaxed before simulation followed by a
simulation run that lasts for 400 ns. The simulation trajectories were taken every 20 ps
and these trajectory files were used for further simulation analysis.
Results and Discussion
Measurement of Receptor Affinity and Pharmacology of BMM-V-19 in ACTOne
Functional Assay
This chapter was set to investigate the structural requirement at C1` position of
our lead compound SMM-189. For this project, six compounds were synthesized,
measured for affinity at the CB1 and CB2 receptors, and pharmacologically evaluated for
G-protein activation using ACTOne assay and β-arrestin using TANGO-bla reporter
assay. SMM-189 scaffold consists of three aromatic rings designated A, B, and C,
wherein, the B and C rings are linked by a carbon designated C1` (Figure 2-4). In the
SMM-189 structure, C1` contains ketone suggesting sp2 carbon with an
electron-withdrawing group is favored. Substitution of this group by an sp3 carbon while
retaining the electronegative oxygen, i.e. menthol group (BMM-V-19, Figure 2-5)
reduced CB2R affinity (121.3 nM versus 227 nM) and increased CB1R affinity from 4.78
μM to 2.70 μM, thus reducing the CB1R/CB2R selectivity ratio (SR) to 12 relative to
39.4 for SMM-189 (Table 2-1).
The pharmacological activity of BMM-V-19 at activating the G-protein pathway
downstream of CB1R and CB2R was investigated using ACTOne functional assay and
parental HEK-CNG cell line to determine the specificity of the responses (Table 2-1). In
HEK-CNG + CB2 cells, BMM-V-19 did not affect the cAMP level which is surprising,
since it demonstrated a moderate binding affinity (Ki = 227 nM) towards CB2R (Figure
2-6A, black squares). The inactive functional profile with moderate binding affinity
suggests that BMM-V-19 is a neutral antagonist at CB2R and to confirm that, an
antagonist study was performed using a range of BMM-V-19 concentrations (from 27.7
nM to 500 nM) against the non-selective CB agonist CP 55,940. The antagonist
competition results showed an upward increase in cAMP accumulation (% max = 42)
with no change in CP 55,940 EC50 suggesting that BMM-V-19 is a non-competitive
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Figure 2-4.

C1`Position in SMM-189 Structure.

Figure 2-5.

Chemical Structure of BMM-V-19.
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Table 2-1.
BMM-V-19

ACTOne
assay
(G-protein
signaling)
TANGO-bla
assay
(β-arrestins
recruitment)

Pharmacological Values for BMM-V-19.
Affinity
Potency
at
and
CB1R
Efficacy at
Ki (nM)
CB1R
2703
Inactive.

ND

Inactive.

Affinity Potency and
at
Efficacy at
CB2R
CB2R
Ki (nM)
227
Inactive in the
agonist study
and neutral
antagonist in
competition
study.
ND
Inactive in the
agonist study
and neutral
antagonist in
competition
study pEC50 =
5.7 (ER =
0.93).

ER = emission ratio, ND = not determined.
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Pharmacological
Activity
Non-competitive
neutral antagonist
in CB2R
G-protein
signaling.
Neutral
antagonist in
CB2R β-arrestin
signaling.

Figure 2-6. The Functional Activity of BMM-V-19 in ACTOne Assay.
A) Functional activity of BMM-V-19 in HEK-CNG + CB2 cells (black squares) and in
parental cell line HEK-CNG (black rhombus) and CP 55,940 is used as a positive control
(black circles). B) Antagonism of CP 55,940 G-protein activation in HEK-CNG+CB2
cells due to increasing concentrations of BMM-V-19. C) Functional activity of
BMM-V-19 in HEK-CNG + CB1 cells (black squares) and in parental cell line
HEK-CNG (black rhombus) and functional activity of positive control CP 55,940 (black
circles). N = 6-9, error is SEM.
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antagonist at CB2R (Figure 2-6B). Treatment of the HEK-CNG + CB1 cells with
BMM-V-19 did not alter the cAMP level (Figure 2-6C, black squares) which is
consistent with the weak binding affinity at CB1R. Further testing of BMM-V-19 in the
parental cell line (HEK-CNG) revealed no effect on cAMP levels confirming BMM-V-19
functional activity is mainly through CB2R (Figure 2-6A, black rhombus).
Pharmacological Evaluation of BMM-V-19 in TANGO-bla Assay
To determine the pharmacological activity of BMM-V-19 at the β-arrestin
pathway, the TANGO-bla functional assay was used to measure ligand-mediated
recruitment of β-arrestins to the CB1 and CB2 receptors (Table 2-1). Using U2OS + CB2
cells, BMM-V-19 did not affect emission ratio, and by extension β-arrestins recruitment,
indicating that BMM-V-19 does not activate CB2R (Figure 2-7A, black squares). To
further confirm the functional activity of BMM-V-19 at CB2R β-arrestins pathway, a
dose-response experiment using BMM-V-19 against EC80 of CP 55,940 was performed.
The antagonist competition results showed that higher BMM-V-19 concentration resulted
in a four folds reduction in CP 55,940 emission ratio (pEC50 = 5.7 and ER = 0.93)
confirming BMM-V-19 is also a neutral antagonist at β-arrestins signaling (Figure
2-7B). Application of BMM-V-19 in U2OS + CB1 cells had no effect on the emission
ratio (Figure 2-7C, black squares) which was consistent with the G-protein activation
assay and weak binding affinity at CB1R. Overall, substitution ketone with menthol
group switches the functional activity from an inverse agonist to a neutral antagonist at
G-protein and β-arrestins signaling. Thus, it is proposed that BMM-V-19 binds to both
the active/inactive CB2R conformations that led to neutral antagonism.
Molecular Docking and Simulation of BMM-V-19 in the CB2R Inactive Crystal
Structure
Recently, it was reported by Li et al. (Li et al., 2019) the critical role of
tryptophan (Trp 258) residue in the CB2R activation mechanism and how agonists and
antagonists differ in their molecular interaction with Trp 258. Moreover, Li et al.
suggested that selective CB2R inverse agonist SR144528 exhibits binding pose that
interacts and constrains the toggle switch (Phe 117 and Trp 258) residues, thus stabilizing
CB2R in the inactive conformation. Conversely, the non-selective CB1/2 agonist CP
55,940 had no stabilizing interactions deep in the binding pocket thereby allowing for
interactions with an active conformation wherein Trp 285 active rotamer is preferred
yielding CB2R activation (Li et al., 2019).
In the functional assays, the racemic mixture of BMM-V-19 demonstrated neutral
antagonism at G-proteins and β-arrestins pathways. Therefore, the aim of this docking
study is to understand ligand-protein molecular interactions that resulted in specific
ligand pharmacological profile. The 2D structures of the two enantiomers were converted
into 3D and prepared using LigPre tool. Several conformations were generated,
minimized, and flexibly docked into a modified CB2R crystal structure using Glide XP
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Figure 2-7. The Functional Activity of BMM-V-19 in TANGO-bla β-Arrestin
Recruitment Assay.
A) Functional activity of BMM-V-19 in U2OS + CB2 cells (black squares), CP 55,940 is
used as a positive control in each run (black circles). B) Antagonist study of BMM-V-19
in U2OS + CB2 cells in the presence of the EC80 of CP55, 940. C) Functional activity of
BMM-V-19 in U2OS + CB1 cells (black squares), functional activity of positive control
CP 55,940 (black circles). N = 2-8, error is SD.
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tool. The docking results for (R) BMM-V-19 configuration showed that (Figure 2-8) the
phenyl A ring established aromatic π-π stacking interaction with Phe 87 residue in
transmembrane 2 (TM 2). Additionally, one of the hydroxy groups in B ring established
direct hydrogen bond (H-bond) interaction with Thr 114 located in TM 3 and the
aromatic C ring interacted with Phe 183 (ECL2) through aromatic stacking interaction. In
(S)-BMM-V-19 configuration, one of the chlorine atoms formed halogen bond interaction
with Ser 90 in TM 2 (Figure 2-9). Additionally, the hydroxy group in ring B established
H-bond with Ser 285 (TM 7) and multiple π-π stacking interactions were formed between
B aromatic ring and Phe 87 (TM 2), Phe 183 (ECL2) residues. Moreover, the hydroxy
group at C1` interacted with Cys 288 residue in TM 7 via hydrogen bond interaction. It’s
worth mentioning that none of the BMM-V-19 enantiomers constrained the toggle switch
residue Trp 258, indicating a possibility of unique ligand-CB2R molecular interaction
that allows for an equal affinity of the ligands towards active and inactive CB2R states.
To further validate docking results, the two enantiomers were embedded in POPC
lipid bilayer, solvated with SPC water molecules in the presence of potassium ions, and
400 ns simulation was performed and analyzed using Desmond molecular dynamics
system. The simulation results suggest (Figure 2-10) that the B ring in (R)-BMM-V-19
established two π-π stacking interactions with Phe 87 (TM 2) and Phe 183 (ECL2).
Additionally, the two hydroxy groups in B ring formed H-bond interactions with Ser 285
(TM 7) and Ile 110 (TM 3) residues. As presented in Figure 2-11, one of the hydroxy
groups in (S)-BMM-V-19 configuration established single H-bond interaction with Phe
281 in TM 7. It should be noted that none of the enantiomers blocked the Trp 258 residue
that is important in CB2R activation mechanism, indicating the (R, S)-BMM-V-19
configurations might interact equally with active and inactive conformations of CB2R,
thus rendering BMM-V-19 a neutral antagonist in CB2R signaling pathways.
The docking and simulation results revealed distinct molecular interactions
between (R, S)-BMM-V-19 configurations and CB2R, suggesting we might see
differences in their functional activity at CB2R. Therefore, future work is needed to
separate the two enantiomers, evaluate their affinity and functional activity at CB1/2
receptors.
Measurement of Receptor Affinity and Pharmacology of BMM-V-21 in ACTOne
Functional Assay
We have previously reported that substitution of the C1` position in the classical
cannabinoid series with a thiophenyl group yielded a compound with a high affinity for
both the CB1R and CB2R (Krishnamurthy, Gurley, & Moore II, 2008). Therefore, in
BMM-V-21, the ketone functional group at C1` of SMM-189 scaffold (Figure 2-4) was
replaced with gem-dimethyl and the ring C phenyl was substituted with thiophenyl
(Figure 2-12). The functional groups transformations significantly increased CB2R
affinity (121 nM versus 8.1 nM) and also increased CB1R affinity (4.77 μM to 10.8 nM)
with a significant drop in SR to 1.3 (Table 2-2). The affinity results suggest that sp2
carbon is required for maintaining selectivity for CB2R and hydrophobic groups are
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Figure 2-8. The Docked Pose for (R)-BMM-V-19 Configuration in the CB2R
Crystal Structure-Based Model.
The structure of (R)-BMM-V-19 is depicted in dark green, the toggle switch residues are
colored green, other amino acid residues are shown in red, pi-pi stacking interactions are
shown in blue, H-bonds are shown in yellow, and CB2R crystal structure PDB 5ZTY was
used to generate the model.

Figure 2-9. The Docked Pose for (S)-BMM-V-19 Configuration in the CB2R
Crystal Structure-Based Model.
The structure of (S)-BMM-V-19 is depicted in faded green, the toggle switch residues are
colored green, other amino acid residues are shown in red, pi-pi stacking interactions are
shown in blue, H-bonds are shown in yellow, halogen bond is shown in purple and CB2R
crystal structure PDB 5ZTY was used to generate the model.
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Figure 2-10. The (R)-BMM-V-19-CB2R Complex at 391 ns.
The structure of (R)-BMM-V-19 is depicted in dark green, the toggle switch residues are
colored green, other amino acid residues are shown in red, pi-pi stacking interactions are
shown in blue, H-bonds are shown in yellow, and CB2R crystal structure PDB 5ZTY was
used to generate the model.

Figure 2-11. The (S)-BMM-V-19 -CB2R Complex at 391 ns.
The structure of (S)-BMM-V-19 is depicted in faded green, the toggle switch residues are
colored green, other amino acid residues are shown in red, H-bonds are shown in yellow,
and CB2R crystal structure PDB 5ZTY was used to generate the model.
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Figure 2-12. Chemical Structure of BMM-V-21.

Table 2-2.
BMM-V-21

Pharmacological Values for BMM-V-21.
Affinity
at CB1R
Ki (nM)

ACTOne
assay
(G-protein
signaling)

10.8

TANGO-bla
assay
(β-arrestins
recruitment)

ND

Potency
and
Efficacy
at CB1R
Agonist
with pEC50
= 6.4 (%
max
= -82).
Agonist
(ER = 1.4).

Affinity
at CB2R
Ki (nM)
8.1

ND

Potency
and
Efficacy
at CB2R
Agonist
with pEC50
= 7.9 (%
max
= -20).
Agonist
with pEC50
= 7.0 (ER
= 2.8).

Pharmacological
Activity
Agonist at CB1/2
G-protein
signaling.
Agonist at CB1/2
β-arrestins
signaling.

ER = emission ratio, ND = not determined, negative values indicate cAMP suppression.
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preferred by both receptors as evidenced by a reduction in SR towards CB2R.
Functional evaluation of BMM-V-21 was performed at CB1, CB2, and
HEK-CNG for G-protein signaling using ACTOne assay. The results revealed an agonist
pharmacological profile with high potency at CB1/2 receptors (Table 2-2). Using
HEK-CNG + CB2 cells, BMM-V-21 behaved as an agonist with high potency pEC50 of
7.9 and low efficacy (% max = -20, a negative value indicates cAMP suppression, Figure
2-13A, black squares). The ligand potency at CB2R correlated well with the high binding
affinity; however, the compound efficacy was low as we predicted. Additionally,
BMM-V-21 demonstrated an agonist functional activity in HEK-CNG + CB1 cells
(pEC50 = 6.4, % max = -82, Figure 2-13B, black squares), confirming activation of both
receptors. Of note, the binding affinities of BMM-V-21 at CB1/2 were comparable;
however, the functional evaluation of the ligand in ACTOne assay demonstrated different
potency and efficacy values between CB1/2 receptors. In other words, BMM-V-21 was
more potent and less efficacious at CB2R, whereas it demonstrated less potency and
greater efficacy at CB1R. Moreover, BMM-V-21 failed to cause any change in cAMP
levels in the HEK-CNG (Figure 2-13A, black rhombus) cells indicating the
pharmacological activity of BMM-V-21 is through cannabinoid receptors.
Pharmacological Evaluation of BMM-V-21 in TANGO-bla Assay
The β-arrestins recruitment initiation by BMM-V-21 was determined for CB1/2
receptors using TANGO-bla assay (Table 2-2). In U2OS + CB2 cells, BMM-V-21
demonstrated agonist activity with high potency (pEC50 = 7.0) and moderate efficacy (ER
= 2.8, Figure 2-14A, black squares) at CB2R comparable to that of CP 55,940.
Surprisingly, the application of BMM-V-21 in U2OS + CB1 cells resulted in weak
agonist activity with a 1.4 increase in emission ratio (Figure 2-14B, black squares),
yielding an opposite functional activity to CB1R G-protein pathway. In sum, the
substitution of ketone with gem dimethyl group switches pharmacological profile from
inverse agonist to an agonist at CB1/2 G-protein and β-arrestin pathways; therefore, it is
proposed that BMM-V-21 interacts with active CB2R conformations for both signaling
pathways. One of the most striking outcomes regards the efficacy differences between the
G-protein and β-arrestin assays. Specifically, BMM-V-21 exhibits high efficacy with
respect to inhibition of cAMP production for CB1R but poor β-arrestin recruitment
efficacy. Conversely, the data from CB2R experiments reveals low efficacy in G-protein
activation but high efficacy in β-arrestin recruitment.
Molecular Docking and Simulation of BMM-V-21 in the CB2R Inactive Crystal
Structure
In this study, BMM-V-21 and CB2R complex interactions were investigated
using molecular docking and simulation tools. The 2D structure of BMM-V-21 was
converted into 3D with the generation of several ligand conformations using the LigPrep
tool in Schrodinger software. The generated conformations were then minimized and
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Figure 2-13. The Functional Activity of BMM-V-21 in ACTOne Assay.
A) Functional activity of BMM-V-21 in HEK-CNG + CB2 cells (black squares) and in
parental cell line HEK-CNG (black rhombus), CP 55,940 is used as a positive control in
each run (black circles). B) Functional activity of BMM-V-21 in HEK-CNG + CB1 cells
(black squares) and in parental cell line HEK-CNG (black rhombus), functional activity
of positive control CP 55,940 (black circles). N = 6-9, error is SEM.
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Figure 2-14. The Functional Activity of BMM-V-21 in Tango-bla Assay.
A) Functional activity of BMM-V-21 in U2OS + CB2 cells (black squares), CP 55,940 is
used as a positive control in each run (black circles). B) Functional activity of
BMM-V-21 in U2OS + CB1 cells (black squares), functional activity of positive control
CP 55,940 (black circles). N = 4, error is SD.
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flexibly docked into the modified CB2R crystal structure using Glide XP and several
binding poses were evaluated.
The molecular docking results (Figure 2-15) revealed that BMM-V-21 forms π-π
stacking interactions with Phe 183 (ECL2) and Phe 87 residue in TM 2 via aromatic B
ring. Moreover, the thiophenyl C ring oriented in the ligand-binding pocket such that it
did not block Trp 258 in TM 6, thus allowing outward movement of helix VI which is
necessary for an active conformation of CB2R (Figure 2-16).
To validate docking results, the BMM-V-21 selected pose was embedded in
POPC lipid bilayer, solvated with SPC water molecules in the presence of potassium
ions, and 400 ns simulation was performed for the ligand-protein complex. Simulation
results (Figure 2-17) demonstrated that several aromatic interactions were formed with
protein residues in TM 2, the aromatic A ring established π-π stacking with Phe 94 (TM
2) and additional aromatic stacking was formed with Phe 183 (ECL2) via benzene in B
ring. One of the hydroxy groups formed hydrogen bond (H-bond) with Ser 285 (TM 7)
and the other hydroxy participated in H-bond network formed by water molecule with
isoleucine Ile 110 and threonine Thr 114 in TM 3. At 391 ns, BMM-V-21 is positioned in
an agonist binding pose that does not constrain Trp 258 residue (Figure 2-18), allowing
orientation change of Trp 258, thus rendering 21 an agonist at CB2R signaling pathways.
Measurement of Receptor Affinity and Pharmacology of BMM-V-23 in ACTOne
Functional Assay
To evaluate the effects of C ring size on the gem-dimethyl C1` analogs, the
thiophene group in BMM-V-21 was replaced by a phenyl ring (Figure 2-19). The
substituent change resulted in a modest increase in affinity for CB2R compared to the
thiophene ring (8.1 nM versus 4.9 nM). Interestingly, the larger phenyl negatively
impacted CB1R affinity (Ki = 55.8 nM), compared to the thiophene ring (Ki = 10.8 nM),
but increased the SR to 11.4 compared to 1.3 for BMM-V-21 (Table 2-3). Based on these
results, I hypothesize that increasing the steric bulk around the phenyl C ring may allow
for the preparation of selective CB2R agonists based on the biaryl-aryl scaffold.
The functional evaluation of the C ring phenyl analog BMM-V-23 in ACTOne
cell-based assay revealed an agonist activity profile at both CB1 and CB2 receptors
(Table 2-3). As shown in Figure 2-20A (black squares), BMM-V-23 is a full agonist at
CB2R with high potency (pEC50 = 7.7) and modest efficacy (% max = -25) comparable
to that of BMM-V-21. Although the introduction of the phenyl ring in BMM-V-23
decreased affinity for CB1R, the potency (pEC50 = 6.3) and efficacy (% max = -70,
Figure 2-20B, black squares) were largely unaffected by the switch from thiophene to a
phenyl ring. In the parental cell line, BMM-V-23 had no effect on cAMP levels indicated
no off-target GPCR effects (Figure 2-20A, black rhombus).
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Figure 2-15. The 2D Ligand Interaction Map for BMM-V-21 Docked Pose.

Figure 2-16. The Docked Pose for BMM-V-21 in the CB2R Crystal
Structure-Based Model.
The structure of BMM-V-21 is depicted in purple, the toggle switch residues are colored
green, other amino acid residues are shown in red, pi-pi stacking interactions are shown
in blue, and CB2R crystal structure PDB 5ZTY was used to generate the model.
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Figure 2-17. The 2D Ligand Interaction Map for BMM-V-21 at 391 ns.

Figure 2-18. BMM-V-21 and CB2R Protein Complex at 391 ns.
The structure of BMM-V-21 is depicted in purple, the toggle switch residues are colored
green, other amino acid residues are shown in red, pi-pi stacking interactions are shown
in blue, hydrogen bonds are colored yellow and halogen bonds colored purple. CB2R
crystal structure PDB 5ZTY was used to generate the model.
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Figure 2-19. Chemical Structure of BMM-V-23.

Table 2-3.
BMM-V-23

ACTOne
assay
(G-protein
signaling)
TANGO-bla
assay
(β-arrestins
recruitment)

Pharmacological Values for BMM-V-23.
Affinity
at CB1R
Ki (nM)
55.8

ND

Potency
and
Efficacy at
CB1R
Agonist
with pEC50
= 6.3 (%
max = -70).
Agonist
with pEC50
= 7.3 (ER =
1.9).

Affinity Potency and
at
Efficacy at
CB2R
CB2R
Ki (nM)
4.9
Agonist with
pEC50 = 7.7
(% max = 25).
ND
Agonist with
pEC50 = 7.2
(ER = 2).

Pharmacological
Activity
Agonist at CB1/2
G-protein
signaling.
Agonist at CB1/2
β-arrestins
signaling.

ER = emission ratio, ND = not determined, negative values indicate cAMP suppression.
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Figure 2-20. The Functional Activity of BMM-V-23 in ACTOne Assay.
A) Functional activity of BMM-V-23 in HEK-CNG + CB2 cells (black squares) and in
parental cell line HEK-CNG (black rhombus), CP 55,940 used as a positive control in
each run (black circles). B) Functional activity of BMM-V-23 in HEK-CNG + CB1 cells
(black squares) and in parental cell line HEK-CNG (black rhombus), functional activity
of positive control CP 55,940 (black circles). N = 6-9, error is SEM.
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Pharmacological Evaluation of BMM-V-23 in TANGO-bla Assay
The recruitment of β-arrestin triggered by BMM-V-23 binding to CB1R and
CB2R was similar in effect to that of BMM-V-21 (Table 2-3). In this assay, BMM-V-23
behaved as an agonist activity with comparable potency to BMM-V-21 but reduced
efficacy compared to BMM-V-21 and CP 55,940 (pEC50 = 7.2 and ER = 2, Figure
2-21A, black squares). As observed with BMM-V-21 in the β-arrestin assay, BMM-V-23
was a weak agonist with pEC50 of 7.3 and ER = 1.9 at CB1R (Figure 2-21B, black
squares). The combined results for the 2 gem-dimethyl analogs raise an intriguing
question – can this scaffold be used as a platform for tailoring signaling bias to affect
different cellular cascade activation pathways targeted to specific disease states?
Molecular Docking and Simulation of BMM-V-23 in the CB2R Inactive Crystal
Structure
The protein-ligand molecular interactions responsible for the agonist
pharmacological activity of BMM-V-23, and for comparative evaluation with
BMM-V-21, were determined via molecular modeling. The 2D ligand structure was
converted into 3D and multiple ligand conformations were generated using LigPre tool.
Then, minimized conformations were flexibly docked into a modified CB2R crystal
structure using Glide XP. The resulted docking poses were analyzed and one selected
pose was used for further interaction analysis.
As presented in Figure 2-22, the docking results showed that aromatic A ring
established π-π stacking with Phe 94 (TM 2) and an additional aromatic interaction was
formed with Phe 183 (ECL2) via resorcinol in B ring. The phenyl C ring in BMM-V-23
structure did not block the toggle switch residues (Phe 117, TM 3 and Trp 258, TM 6)
indicating that Trp 258 reoriented with an outward movement of helix VI that led to
CB2R activation (Figure 2-23).
The docking results were further confirmed using a 400 ns simulation with the
selected pose and a similar simulation method described for BMM-V-21. The molecular
dynamics revealed several π-π stacking interactions were formed between A, B aromatic
rings and residues in TM2, Phe 94, Phe 87, and Phe 183 (ECL2) (Figure 2-24). Also, one
of the chlorine atoms in ring A engaged in halogen bond interaction with Ser 90 in TM2.
Moreover, one of the hydroxy groups in the resorcinol established H-bond with Ser 285
in TM7 and the other formed an indirect H-bond interaction with Thr 114 in TM3 via
bridging water molecule. At 391 ns, BMM-V-23 adopts an agonist binding pose with no
interaction with Trp 258 providing insights into the agonist functional activity at CB2R
(Figure 2-25).
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Figure 2-21. The Pharmacological Activity of BMM-V-23 in Tango-bla Assay.
A) Functional evaluation of BMM-V-23 in U2OS + CB2 cells (black squares), CP 55,940
is used as a positive control in each run (black circles). B) Functional activity of
BMM-V-23 in U2OS + CB1 cells (black squares), functional activity of positive control
CP 55,940 (black circles). N = 3, error is SD.
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Figure 2-22. The 2D Ligand Interaction Map for BMM-V-23 Docked Pose.

Figure 2-23. The Docked Pose of BMM-V-23 with Modified CB2R Crystal
Structure.
The structure of BMM-V-23 is depicted in blue, the toggle switch residues are colored
green, other amino acid residues are shown in red, pi-pi stacking interactions are shown
in blue, and CB2R crystal structure PDB 5ZTY was used to generate the model.
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Figure 2-24. The 2D Ligand Interaction Map for BMM-V-23 with CB2R at 391 ns.

Figure 2-25. BMM-V-23 with CB2R Protein at 391 ns.
The structure of BMM-V-23 is depicted in blue, the toggle switch residues are colored
green, other amino acid residues are shown in red, pi-pi stacking interactions are shown
in blue, hydrogen bonds are shown in yellow, and halogen bond is shown in purple.
CB2R crystal structure PDB 5ZTY was used to generate the model.
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Measurement of Receptor Affinity and Pharmacology of BMM-V-27 in ACTOne
Functional Assay
To further determine the functional group requirements of the biaryl-aryl scaffold,
the ketone group in SMM-189 was replaced with methylene (Figure 2-26). The
substitution increased affinity for CB2R (Ki = 52 nM) relative to SMM-189; however,
there was a significant decrease relative to the gem-dimethyl analogs BMM-V-21 and
BMM-V-23. Thus, the results for the CB2R affinity indicate that a critical hydrophobic
interaction occurs with the methyl groups that are absent in BMM-V-27. A more extreme
effect on activity was measured in the CB1R assay wherein removal of the two methyl
groups in BMM-V-21 and BMM-V-23 decreased affinity for the receptor by almost 2
orders of magnitude (Ki = 2.65 μM, Table 2-4). The substitution did increase the SR to
51 which, based on the functional activity (discussed below), could provide a novel class
of cannabinoid ligands.
Treatment of HEK-CNG + CB2 cells with BMM-V-27 did not affect the
intracellular concentration of cAMP using ACTOne assay (Figure 2-27A, black squares,
Table 2-4). The high affinity of BMM-V-27 at CB2R, but no functional activity,
prompted the evaluation of the ligand in an antagonist study. A dose-response experiment
using BMM-V-27 (from 5.3 nM to 2000 nM) at constant CP 55,940 (Figure 2-27B)
uncovered a rise in cAMP accumulation (% max = 41) with a dextral shift of CP 55,940
curve indicating that BMM-V-27 is a non-competitive orthosteric antagonist at CB2R.
The calculated Log DR-1 values were consistent with a reference line with a slope of 1
confirming BMM-V-27 is an orthosteric antagonist (Figure 2-27C). In combination with
no functional activity of BMM-V-27 at CB1R (Figure 2-27D, black squares), and no
change in cAMP level in HEK-CNG cells, results suggest that this scaffold could be
developed for selective CB2R neutral antagonists (Figure 2-27A, black rhombus).
Pharmacological Evaluation of BMM-V-27 in TANGO-bla Assay
The functional activity of BMM-V-27 in the CB2R β-arrestin signaling assay
(Table 2-4) paralleled the results from the cAMP assay wherein no change in the
emission ratio was measured (Figure 2-28A, black squares). A dose-response study using
BMM-V-27 against EC80 of CP 55,940 caused a four folds reduction in CP 55,940
emission ratio (EC50 = 5.9, ER = 0.9) at the higher BMM-V-27 concentrations confirming
neutral antagonism at β-arrestins signaling (Figure 2-28B). Additionally, BMM-V-27
was inactive in recruiting β-arrestin in U2OS + CB1 cells (Figure 2-28C, black squares)
indicating selectivity towards CB2R. In terms of functional activity, replacing ketone
with methylene switches pharmacological activity from inverse agonist to neutral
antagonist at CB2R G-protein and β-arrestin pathways. Thus, it is predicted that
BMM-V-27 adopt a specific conformation that allows ligand interaction with active and
inactive states of CB2R.
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Figure 2-26. Chemical Structure of BMM-V-27.

Table 2-4.
BMM-V-27

ACTOne
assay
(G-protein
signaling)
TANGO-bla
assay
(β-arrestins
recruitment)

Pharmacological Values for BMM-V-27.
Affinity Potency
at
and
CB1R
Efficacy
Ki (nM) at CB1R
2656
Inactive.

ND

Affinity
at CB2R
Ki (nM)

Potency and
Efficacy at
CB2R

Pharmacological
Activity

52

Inactive at
agonist study
and neutral
antagonist at
competition
study.
Inactive at
agonist study
and neutral
antagonist at
competition
study.
pEC50 = 5.9
(ER= 0.92).

Non-competitive
orthosteric
antagonist at
CB2R G-protein
signaling.

Inactive.

ND

ER = emission ratio, ND = not determined.
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Neutral antagonist
at CB2R
β-arrestins
signaling.

Figure 2-27. The Functional Activity of BMM-V-27 in ACTOne Assay.
A) Functional activity of BMM-V-27 in HEK-CNG + CB2 cells (black squares) and in
parental cell line HEK-CNG (black rhombus), CP 55,940 is used as a positive control in
each run (black circles). B) Antagonism of CP 55,940 G-protein activation in
HEK-CNG+CB2 cells due to increasing concentrations of BMM-V-27. C) Schild
analysis with black circles for DR-1 values and the black triangle for a reference line with
a slope of 1. D) Functional activity of BMM-V-27 in HEK-CNG + CB1 cells (black
squares) and in parental cell line HEK-CNG (black rhombus), functional activity of
positive control CP 55,940 (black circles). N = 6-10, error is SEM.
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Figure 2-28. The Functional Activity of BMM-V-27 in Tango-bla Assay.
A) Functional activity of BMM-V-27 in U2OS + CB2 cells (black squares), CP 5,940 is
used as a positive control in each run (black circles). B) Antagonist study of BMM-V-27
in U2OS + CB2 cells in the presence of the EC80 of CP55, 940. C) Functional activity of
BMM-V-27 in U2OS + CB1 cells (black squares), functional activity of positive control
CP 55,940 (black circles). N = 2-8, error is SD.
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Molecular Docking and Simulation of BMM-V-27 in the CB2R Inactive Crystal
Structure
The functional studies revealed that BMM-V-27 behaved as a neutral antagonist
for both the G-protein and β-arrestin CB2R signaling. To investigate the protein-ligand
molecular interactions behind the BMM-V-27 pharmacological activity, docking and
simulation studies were performed using a modified CB2R crystal structure and
Schrödinger software.
As presented in Figure 2-29, BMM-V-27 formed several π-π interactions with
residues Phe 91, Phe 87 (TM 2), Phe 183 (ECL2), and Trp 258 present in TM 6. The two
hydroxyl groups in B ring established direct H-bond interactions with Ser 285 (TM 7)
and Thr 114 residues (TM 3) (Figure 2-30). It’s worth mentioning that BMM-V-27
formed one π-π stacking with Trp 258, suggesting 27 might have the ability to interact
with active/inactive CB2R states, thus rendering BMM-V-27 neutral antagonist.
To further validate the binding mode of BMM-V-27 within CB2R, 400 ns
simulation was performed for the docked pose in the presence of POPC lipid bilayer,
SPC water molecules and neutralizing ions. Simulation results provided tantalizing
information regarding the interactions of BMM-V-27 with CB2R. Specifically, the
H-bond interactions with the hydrophilic residues Ser 285 and Thr 114 were maintained
in addition to the aromatic stacking with Trp 258 residue in TM6 (Figure 2-31). One
possible explanation for neutral antagonism of BMM-V-27 is that the position of phenyl
C ring might continuously change (Figure 2-32) due to the free rotation of the methylene
group that allows the molecule to interact with active and inactive CB2R states, thus no
functional activity was observed.
Measurement of Receptor Affinity and Pharmacology of BMM-V-29 in ACTOne
Functional Assay
The parent compound SMM-189 contains an sp2 carbon in the C1` position with
an electronegative atom attached to it (Figure 2-4). To further explore the SAR of this
class of compounds, the ketone group in SMM-189 was replaced with an oxime (Figure
2-33). This functional group preserves the sp2 carbon and electronegative group but also
adds steric bulk to the position. The introduction of the oxime to BMM-V-29 resulted in
comparable affinity relative to SMM-189 (121 nM versus 138 nM) but reduced CB1R
affinity from 4.77 to 5.09 μM with CB1: CB2 ratio of 37 (Table 2-5). However, the
functional group replacement did negatively impact functional activity. Surprisingly,
BMM-V-29 did not exhibit functional activity at CB2R as evidenced by no change in
cAMP levels suggesting BMM-V-29 is a neutral antagonist in HEK-CNG + CB2 cells
(Table 2-5 and Figure 2-34A, black squares). To confirm antagonist activity,
dose-response study was performed (from 13.9 nM to 973 nM) against non-selective
agonist CP 55,940. The antagonist study revealed that BMM-V-29 caused an upward
shift in absorbance intensity (% max = 45) with a dextral shift in the dose-response curve
of CP 55,940, confirming BMM-V-29 is non-competitive orthosteric antagonist at CB2R
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Figure 2-29. The 2D Ligand Interaction Map for BMM-V-27 Docked Pose.

Figure 2-30. The Docked Pose for BMM-V-27 with Modified CB2R Crystal
Structure.
The structure of BMM-V-27 is depicted in pink, the toggle switch residues are colored
green, other amino acid residues are shown in red, pi-pi stacking interactions are shown
in blue, hydrogen bonds are colored yellow, and CB2R crystal structure PDB 5ZTY was
used to generate the model.
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Figure 2-31. The 2D Ligand Interaction Map for BMM-V-27 with CB2R at 391 ns.

Figure 2-32. CB2R and BMM-V-27 Complex at 391 ns.
The structure of BMM-V-27 is depicted in pink, the toggle switch residues are colored
green, other amino acid residues are shown in red, pi-pi stacking interactions are shown
in blue, hydrogen bonds are colored yellow, and halogen bonds are shown in purple.
CB2R crystal structure PDB 5ZTY was used to generate the model.
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Figure 2-33. Chemical Structure of BMM-V-29.

Table 2-5.
BMM-V-29

Pharmacological Values for BMM-V-29.
Affinity
at CB1R
Ki (nM)

ACTOne
assay
(G-protein
signaling)

5096

Potency
and
Efficacy
at CB1R
Inactive.

TANGO-bla
assay
(β-arrestins
recruitment)

ND

Inactive.

Affinity
at CB2R
Ki (nM)

Potency and
Efficacy at
CB2R

Pharmacological
Activity

138

Non-competitive
orthosteric
antagonist at
CB2R G-protein
signaling.

ND

Inactive at
agonist study
and neutral
antagonist at
competition
study.
Inactive at
agonist study
and neutral
antagonist at
competition
study. pEC50
= 5.8 (ER =
1.3).

ER = emission ratio, ND = not determined.
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Neutral antagonist
at CB2R
β-arrestins
signaling.

Figure 2-34. The Functional Activity of BMM-V-29 in ACTOne Assay.
A) Functional activity of BMM-V-29 in HEK-CNG + CB2 cells (black squares) and in
parental cell line HEK-CNG (black rhombus), CP 55,940 is used as a positive control in
each run (black circles). B) CP 55,940 antagonism in HEK-CNG+CB2 cells using
different concentrations of BMM-V-29. C) Schild analysis with black circles for DR-1
values and black squares for a reference line with a slope of 1. D) Functional activity of
BMM-V-29 in HEK-CNG + CB1 cells (black squares) and in parental cell line
HEK-CNG (black rhombus), functional activity of positive control CP 55,940 (black
circles). N = 6-9, error is SEM.
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(Figure 2-34B). Schild analysis confirmed this type of antagonism since the calculated
Log DR-1 values were consistent with a reference line with a slope of 1 (Figure 2-34C).
When BMM-V-29 was tested for activity against CB1R, no change in the absorbance was
detected (Figure 2-34D, black squares) which was consistent with the weak binding
affinity at CB1R. An identical result was found for the parental cell line (Figure 2-34A,
black rhombus), thus confirming the response of BMM-V-29 is due to CB2R interactions
and not an off-target effect.
Pharmacological Evaluation of BMM-V-29 in TANGO-bla Assay
In the U2OS + CB2 cells, BMM-V-29 treatment had no effect on the emission
ratio (Table 2-5 and Figure 2-35A, black squares) indicating a lack of β-arrestins
recruitment. The high binding affinity towards CB2R with no functional activity suggests
that BMM-V-29 could be a neutral antagonist. To confirm that, competition antagonist
study was performed using increasing BMM-V-29 concentrations, against EC80 of CP
55,940, and results showed a two-fold reduction in the ER at high BMM-V-29
concentration (pEC50 of 5.8 and ER = 1.3, Figure 2-35B) confirming neutral antagonism
of the β-arrestins pathway. The emission ratio was unaffected in the U2OS + CB1 cells
indicating no pharmacological activity against CB1R (Figure 2-35C, black squares). In
sum, replacing ketone with the oxime group switches pharmacological profile from
inverse agonist to neutral antagonist at CB2R signaling pathways.
Molecular Docking and Simulation of BMM-V-29 in the CB2R Inactive Crystal
Structure
Functionally, BMM-V-29 demonstrated neutral antagonism at the G-protein and
β-arrestin pathways, thus ligand-protein interactions that influenced the pharmacological
activity of BMM-V-29 were examined via molecular modeling. Multiple ligand
conformations were generated and flexibly docked into modified CB2R crystal structure.
The docking study demonstrated that multiple aromatic π-π stacking interactions
were formed between BMM-V-29 and Phe 106 (TM 3), Phe 87 (TM 2), and Trp 258
residue in TM 6 (Figure 2-36). Moreover, the oxime group at C1` formed H-bond
interaction with Thr 114 residue in TM 3 and one of the hydroxy engaged in H-bond
interaction with Ser 90 in TM 2 through a water molecule (Figure 2-37). The docking
results suggest that BMM-V-29 formed π-π stacking with Trp 258, indicating possibility
of ligand interaction with active and inactive CB2R conformations. To further confirm
docking results, 400 ns simulation was conducted for the selected pose in the presence of
POPC lipid bilayer, SPC water molecules and neutralizing ions. At 391 ns (Figure 2-38),
BMM-V-29 formed aromatic π-π stacking with Phe 94, Phe 91, Phe 87 residues in TM 2,
and Phe 183 in ECL2. Additionally, the C phenyl ring formed one aromatic π-π stacking
with Trp 258 in TM6, suggesting the possibility that this interaction might change over
time, allowing equal affinity towards active and inactive CB2R conformations (Figure
2-39).
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Figure 2-35. The Functional Activity of BMM-V-29 in Tango-bla Assay.
A) Functional activity of BMM-V-29 in U2OS + CB2 cells (black squares), CP 55, 940 is
used as a positive control in each run (black circles). B) Antagonist study of BMM-V-29
in U2OS + CB2 cells in the presence of the EC80 of CP 55, 940. C) Functional activity of
BMM-V-29 in U2OS + CB1 cells (black squares), functional activity of positive control
CP 55,940 (black circles). N = 2-8, error is SD.
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Figure 2-36. The 2D Ligand Interaction Map for BMM-V-29 Docked Pose.

Figure 2-37. The Docked Pose for BMM-V-29 with Modified CB2R Crystal
Structure.
The structure of BMM-V-29 is shown in light orange, the toggle switch residues are
colored green, other amino acid residues are shown in red, pi-pi stacking interactions are
shown in blue, hydrogen bonds are shown in yellow, and CB2R crystal structure PDB
5ZTY was used to generate the model.
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Figure 2-38. The 2D Ligand Interaction Map for BMM-V-29 at 391 ns.

Figure 2-39. BMM-V-29 and CB2R Protein Complex at 391 ns.
The structure of BMM-V-29 is shown in light orange, the toggle switch residues are
colored green, other amino acid residues are shown in red, pi-pi stacking interactions are
shown in blue, and hydrogen bonds are shown in yellow. CB2R crystal structure PDB
5ZTY was used to generate the model.
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Measurement of Receptor Affinity and Pharmacology of BMM-V-43 in ACTOne
Functional Assay
The requirement for an electronegative atom attached to the sp2 carbon at the C1`
position was investigated by converting the ketone to an ethylene group (Figure 2-40).
Substitution of the oxygen in SMM-189 for a carbon increased affinity at both the CB2
(121 nM versus 46 nM) and CB1 (4.77 μM to 3.83 μM) receptors, although it remained a
weak binder at the later receptor (Table 2-6). The modification also increased the SR
(83) relative to the parent compound SMM-189 (39) indicating a key factor is the
retention of the sp2 carbon at the C1`; furthermore, in combination with the results from
the oxime derivative, it also suggests that increased steric bulk is not tolerated.
Within the series of compounds designed to develop the SAR of the C1` position,
BMM-V-43 is the only compound that retained inverse agonism activity with a pEC50
value of 6.2 and % max = 27 at CB2R (Table 2-6, Figure 2-41A, black squares).
Surprisingly, BMM-V-43 exhibited two folds increase in binding affinity towards CB2R
compared to SMM-189; however, the functional activity of BMM-V-43 was twofold
lower in potency and efficacy relative to our lead. In the CB1R assay, BMM-V-43 did
not change the basal cAMP level (Figure 2-41B, black squares) nor was there an effect in
the parental cell line (Figure 2-41A, black rhombus) which is consistent with the weak
binding affinity at CB1R. Thus, BMM-V-43 is a modestly potent and selective inverse
agonist at CB2R.
Pharmacological Evaluation of BMM-V-43 in TANGO-bla Assay
The functional activity of BMM-V-43 to recruit β-arrestin was consistent with
inverse agonist activity at CB2R (Table 2-6). Specifically, the treatment of U2OS + CB2
cells with increasing concentrations of BMM-V-43 failed to change the basal emission
ratio (Figure 2-42A, black squares) indicating a lack of β-arrestins recruitment. However,
the high affinity for CB2R but no functional activity suggested that BMM-V-43 might be
a neutral antagonist. This, in fact, was confirmed when the response to CP 55,940 (EC80)
as a function of increasing concentrations of BMM-V-43 showed a four-fold reduction in
CP 55,940 emission ratio (pEC50 = 5.9, ER = 0.9) at high BMM-V-43 concentration,
indicating neutral antagonism of the β-arrestins pathway (Figure 2-42B). In comparison,
BMM-V-43 did not affect the emission ratio in the U2OS + CB1 cells consistent with the
weak affinity at CB1R (Figure 2-42C, black squares). Overall, converting the ketone to
an ethylene group resulted in an inverse agonism at CB2R G-proteins signaling and
neutral antagonism at CB2R β-arrestins pathway.
Molecular Docking and Simulation of BMM-V-43 in the CB2R Inactive Crystal
Structure
BMM-V-43 was the only selective CB2R inverse agonist in this series evidenced
by an increase in cAMP accumulation at CB2R with no β-arrestins recruitment. In this
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Figure 2-40. Chemical Structure of BMM-V-43.

Table 2-6.
BMM-V-43

ACTOne
assay
(G-protein
signaling)
TANGO-bla
assay
(β-arrestins
recruitment)

Pharmacological Values for BMM-V-43.
Affinity
Potency
Affinity Potency and
at
and
at
Efficacy at
CB1R Efficacy at CB2R
CB2R
Ki (nM)
CB1R
Ki (nM)
3838
Inactive
46
Inverse agonist
with pEC50 =
6.2 (% max =
27).
ND
Inactive
ND
Inactive at
agonist study
and neutral
antagonist at
competition
study pEC50 =
5.9 (ER = 0.9).

ER = emission ratio, ND = not determined.
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Pharmacological
Activity
Inverse agonist at
CB2R G-protein
signaling.
Neutral antagonist
at CB2R
β-arrestins
signaling.

Figure 2-41. The Functional Activity of BMM-V-43 in ACTOne Assay.
A) Functional activity of BMM-V-43 in HEK-CNG + CB2 cells (black squares) and in
parental cell line HEK-CNG (black rhombus), CP 55,940 is used as a positive control in
each run (black circles). B) Functional activity of BMM-V-43 in HEK-CNG + CB1 cells
(black squares) and in parental cell line HEK-CNG (black rhombus), functional activity
of positive control CP 55,940 (black circles). N = 6-10, error is SEM.
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Figure 2-42. The Functional Activity of BMM-V-43 in Tango-bla Assay.
A) Functional activity of BMM-V-43 in U2OS + CB2 cells (black squares), CP 55,940 is
used as a positive control in each run (black circles). B) Antagonist study of BMM-V-43
in U2OS + CB2 cells in the presence of the EC80 of CP 55, 940. C) Functional activity of
BMM-V-43 in U2OS + CB1 cells (black squares), functional activity of positive control
CP 55,940 (black circles). N = 2-8, error is SD.
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study, the molecular ligand-protein interactions were investigated using Desmond and
Glide XP tools in Schrödinger software.
Using molecular docking (Figure 2-43), one of the chlorine atoms in ring A
formed halogen bond interaction with Ser 285 residue in TM 7 and phenyl C ring formed
π-π interactions with Phe 117, Trp 258, and Trp 194 residues in TM 3,6, and 5
respectively, indicating a stabilization of CB2R in the inactive state (Figure 2-44).
To further validate the docking results, MD simulation showed that BMM-V-43
established aromatic π-π stacking interactions with Phe 87, Trp 258, Trp 194 residues in
TM 2,6, and 5, respectively, in addition to maintaining the halogen bond with Ser 285
(TM 7) during the simulation. Moreover, H-bond interaction was formed between one of
the hydroxy groups in B ring and tyrosine Tyr 25 via bridging water molecule (Figure
2-45). The docking and simulation study suggest that phenyl C ring in BMM-V-43
structure constrains Trp 258 with multiple stacking interactions that stabilize CB2R in the
inactive conformation, thus rendering BMM-V-43 an inverse agonist at CB2R (Figure
2-46).
Conclusion
The main purpose of this project was to examine the structural requirement at C1`
position of our lead compound SMM-189 and evaluate the synthesized compounds for
affinity at hCB1/2 receptors, and functional activity at G-protein signaling using
ACTOne assay and β-arrestin recruitment using TANGO-bla reporter assays. The C1`
position in SMM-189 structure contains a ketone group, indicating sp2 carbon with an
electron-withdrawing group is favored. Switching ketone with an SP3 carbon while
maintaining the electronegative oxygen (menthol group), decreased the CB2R affinity (Ki
= 227 nM) and selectivity ratio (SR = 12) relative to SMM-189. Moreover, replacing
ketone with an SP3 carbon-containing hydrophobic groups (gem-dimethyl), greatly
enhanced affinity for CB1/2 receptors with a significant drop in SR, suggesting SP2
carbon is optimal for maintaining ligand selectivity towards CB2R. Furthermore, the
decrease in SR highlights what I hypothesize to be an important difference between
agonists and inverse agonists. Specifically, the conformation of the inactive receptor
ligand-binding pockets possesses unique amino acid patterns that can be exploited to
design highly selective inverse agonists. Additionally, substituting the thiophenyl C ring
with a phenyl greatly enhances the selectivity of the ligand towards CB2R, suggesting
increasing the steric bulk around the phenyl C might increase the agonist selectivity for
CB2R. Surprisingly, the removal of the two methyl groups (methylene) decreased the
ligand affinity for CB1/2 receptors; however, the selectivity ratio was significantly
increased (SR = 51) compared to SMM-189, providing an opportunity for a novel class of
cannabinoid ligands. The introduction of sp2 carbon with an electronegative group and
steric bulk (oxime group) resulted in a comparable affinity and selectivity to our lead
SMM-189. Lastly, replacing the oxygen attached to the sp2 carbon for a carbon (ethylene
group), enhanced the affinity and selectivity towards CB2R, suggesting sp2 carbon is
required for maintaining CB2R selectivity (Figure 2-47, and Table 2-7).
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Figure 2-43. The 2D Ligand Interaction Map for BMM-V-43 Docked Pose.

Figure 2-44. The Docked Pose for BMM-V-43 and Modified CB2R Crystal
Structure.
The structure of BMM-V-43 is colored in yellow, the toggle switch residues are shown in
green, other amino acid residues are colored red, pi-pi stacking interactions are shown in
blue, and halogen bonds are shown in purple. CB2R crystal structure PDB 5ZTY was
used to generate the model.
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Figure 2-45. The 2D Ligand Interaction Map for BMM-V-43 at 391 ns.

Figure 2-46. BMM-V-43 and CB2R Protein Complex at 390 ns.
The structure of BMM-V-43 is colored in yellow, the toggle switch residues are shown in
green, other amino acid residues are colored red, pi-pi stacking interactions are shown in
blue, hydrogen bonds are shown in yellow and halogen bonds are shown in purple. CB2R
crystal structure PDB 5ZTY was used to generate the model.
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Figure 2-47. The Pharmacological Profile of Several Functional Groups at C1`
Position of Biaryl-Aryl Menthone Scaffold.
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Table 2-7.
Receptors.

Binding Affinity and Selectivity of Compounds 19-43 at CB1/CB2

Compound Name
SMM-189

Ki (nM) ± SEM
CB1R
CB2R
4778 ± 246
121.3 ± 20

CB1/CB2
SR
39.4

BMM-V-19

2703 ± 2

227 ± 1

12

BMM-V-21

10.8 ± 1

8.1 ± 1

1.3

BMM-V-23

55.8 ± 1

4.9 ± 1

11

BMM-V-27

2656 ± 1

52 ± 1

51

BMM-V-29

5096 ± 3

138 ± 1

37

BMM-V-43

3838 ± 2

46 ± 1

83

N = 6-9, error is the SEM.
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In terms of functional activity, replacing ketone with a menthol group switches
the pharmacological profile from an inverse agonist to a neutral antagonist at G-protein
and β-arrestins signaling. Therefore, it is suggested that BMM-V-19 has an equal affinity
for active and inactive CB2R states that resulted in the neutral antagonism. Additionally,
substituting ketone with a gem-dimethyl group transforms the functional activity from
selective CB2R inverse agonist to a non-selective CB agonist at G-protein and β-arrestin
signaling, indicating that BMM-V-21 and BMM-V-23 interact with active CB2R state at
both signaling pathways. These results were further confirmed using docking and
simulation study that demonstrated BMM-V-21 and BMM-V-23 are positioned in an
agonist binding pose that does not constrain Trp 258 residue, allowing orientation change
of Trp 258 and outward movement of helix VI, thus rendering 21 and 23 agonists at
CB2R. Moreover, switching ketone with methylene group resulted in a neutral antagonist
activity at both CB2R signaling pathways, suggesting BMM-V-27 adopt a specific
conformation that permits ligand interaction with active and inactive CB2R states that led
to neutral antagonism. Interestingly, substituting ketone with an oxime group resulted in a
pharmacological transformation from inverse agonist to a neutral antagonist at both
CB2R signaling pathways. The docking and simulation results suggest that 29 has the
ability to interacts with active and inactive CB2R conformations, therefore no functional
activity was detected. Lastly, replacing ketone with the ethylene group maintained the
inverse agonist functional activity at CB2R G-protein signaling, while, neutral
antagonism was detected at CB2R β-arrestins pathway. These results were further
supported by the docking and simulation study which confirmed that the phenyl C ring in
BMM-V-43 structure blocked Trp 258 with multiple π-π stacking interactions that
stabilized CB2R in the inactive state, thus rendering BMM-V-43 an inverse agonist at
CB2R G-protein signaling (Table 2-8, and Table 2-9).
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Table 2-8.
Pathway.
Compound
Name
CP 55,940
SMM-189
BMM-V-19
BMM-V-21
BMM-V-23
BMM-V-27
BMM-V-29
BMM-V-43

Pharmacological Evaluation of Compounds 19-43 at the β-Arrestins
CB1R
pEC50 ± SD
ER ± SD
8.24 ± 0.27
4.51 ± 0.09
NA
NA
NA
NA
1.48 ± 0.14
7.3 ± 0.30
1.9 ± 0.06
NA
NA
NA
NA
NA
NA

CB2R
pEC50 ± SD
ER ± SD
7.43 ± 0.02
3.70 ± 0.06
5.69 ± 0.12
0.6 ± 0.14
5.74 ± 0.12
0.93 ± 0.47
7.095 ± 0.06
2.8 ± 0.13
7.29 ± 0.08
2.0 ± 0.12
5.98 ± 0.05
0.92 ± 0.22
5.89 ± 0.07
1.3 ± 0.25
5.94 ± 0.07
0.91 ± 0.27

The underline represents the potency of an antagonist in the presence of CP 55, 940 EC80.
N = 2-8, error is the SD, NA, not active.
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Table 2-9.
Pathway.

Pharmacological Evaluation of Compounds 19-43 at the G-Protein
CB1R

Compound
Name

C Ring

Activity in
ACTOne
Assay

SMM-189

Ketone

Phenyl

Potency
(pEC50 ±
SEM)
NA

BMM-V-19

Menthol

Phenyl

NA

NA

NA

NA

BMM-V-21

Thioph
enyl
Phenyl

NA

7.94 ±
0.19
7.70 ±
0.12
NA

-20 ± 2

Phenyl

6.49 ±
0.14
6.31 ±
0.16
NA

-82 ± 16

BMM-V-27

Gem-dimet
hyl
Gem-dimet
hyl
Methylene

BMM-V-29

Oxime

Phenyl

NA

NA

NA

NA

BMM-V-43

Ethylene

Phenyl

NA

NA

6.25 ± 6

27 ± 23

BMM-V-23

C1`

CB2R

Efficacy
(% max
± SEM)
NA

Potency
(pEC50 ±
SEM)
6.80 ±
0.09

Efficacy
(% max
± SEM)
54.8 ± 3

-70 ± 20

-25 ± 2
NA

CB2R
Inverse
agonist
CB2R
Neutral
antagonist
CB1/CB2
Agonist
CB1/CB2
Agonist
CB2R
Neutral
antagonist
CB2R
Neutral
antagonist
CB2R
Inverse
agonist

N = 6-10, error is the SEM. NA: not active; negative values indicate cAMP suppression.
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CHAPTER 3. ANTI-INFLAMMATORY EFFECTS OF SELECTIVE CB2
INVERSE AGONIST IN MURINE AND HUMAN MICROGLIA MODELS
Introduction
Neurodegeneration is a broad term of multiple disorders that involve neuronal
damage associated with protein aggregates, bacterial, viral infections, and mechanical
injury. A hallmark of these diseases is increased neuroinflammation arising from
sustained microglial activation. The risk of developing neurodegenerative diseases has
greatly increased worldwide in the past fifty years which parallels a significant increase
in people life expectancy (reviewed by (Fernández‐Ruiz, 2019)). New therapies to treat
these diseases have experienced a high failure rate and the lack of curative treatment is
associated with financial burden in the elderly population in which was estimated in 2018
to be $277 billion (Association, 2018). Therefore, there is an urgent need to discover and
develop novel therapeutic agents that successfully treat neurodegenerative diseases and
the underlying neuroinflammatory processes which exacerbate the disease condition.
Microglia are the frontline defense mechanism in the brain immune system which
protects the brain microenvironment from injury and maintains homeostasis. These cells
are considered to be fast responding to an insult or injury by converting their phenotype
and function. In the healthy brain, microglia exist in a resting, or M0 state (Figure 3-1),
that survey their surrounding environment for the presence of pathogens, misfolded
protein, and activation factors released from damaged neurons, generally characterized as
PAMPs and DAMPs, respectively. In the disease state, microglia recognize PAMPs and
DAMPs and change their phenotype into activated, or M1 state, that are mainly
characterized by the release of inflammatory cytokines, such as IL-1β, TNF-α, IL-6,
IFN-γ, along with increased expression of M1 surface receptors CD 16/32 and CD 68
with the production of NO and ROS. These pro-inflammatory mediators are protective in
the short term which under normal conditions, is resolved by microglia adopting an
alternative or M2 phenotype. Conversely, the M2 state is predominantly characterized by
the production of anti-inflammatory cytokines such as IL-4, IL-10, IL-13, TGF-β and
enhanced expression of M2 surface receptors CD 204, CD 206 with the production of
arginase 1 (Arg-1) enzyme. However, sustained presentation of PAMPs and DAMPs
results in prolonged microglial activation with the release of pro-inflammatory M1
cytokines and chemokines resulting in chronic inflammation or neuroinflammation.
Therefore, maintaining the balance between the M1/2 microglial states is crucial for a
healthy brain environment and any imbalance between the two states can trigger chronic
neuroinflammation. In fact, most neurodegenerative diseases such as Alzheimer’s disease
(AD), Multiple sclerosis (MS), Traumatic brain injury (TBI), and Parkinson’s disease
(PD) are characterized by the dominant presence of pro-inflammatory M1 microglia and
the lack of M2 alternative phenotype. These data suggest that biasing microglia away
from the M1 state to the beneficial M2 phenotype would restore homeostasis and provide
neuroprotection in these devastating diseases; for excellent reviews see (Cherry,
Olschowka, & O’Banion, 2014; Tang & Le, 2016).
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Figure 3-1. M1 and M2 Microglia Phenotypes.
CB2R modulation tends to suppress (A) M1 microglial phenotype that is associated with
the production of harmful pro-inflammatory mediators and (B) increase the M2
anti-inflammatory phenotype that supports the generation of wound-healing
cytokines/chemokines, thus supporting tissue repair and alleviate neuroinflammation. (C)
Dystrophic microglia exhibit a unique fragmented morphology that is related to the aging
process.
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In postmortem brains from AD patients, Benito et al. reported selective
upregulation of CB2R in microglia and astrocytes that surround neuritic plaques (Cristina
Benito et al., 2003; Solas, Francis, Franco, & Ramirez, 2013). A similar upregulation of
CB2R was found in MS (Palazuelos et al., 2008), PD (Garcia et al., 2011a; GómezGálvez, Palomo-Garo, Fernández-Ruiz, & García, 2016; Price et al., 2009a), HD
(Palazuelos et al., 2009a). The apparent preservation of microglia CB2R upregulation in
these diseases suggests a crucial regulatory role of CB2R in neurodegenerative diseases
(Cristina Benito et al., 2003) and in fact, numerous studies have supported the beneficial
anti-inflammatory effects of cannabinoids in neuroinflammation (these studies are
summarized in C Benito et al. review (C Benito et al., 2008)). As discussed above, in
neuroinflammatory conditions, the majority of microglia are activated to the M1
phenotype that releases harmful pro-inflammatory mediators and recruits other immune
cells to amplify the pro-inflammatory response. CB2R modulation tends to suppress M1
microglial phenotype and increase the M2 anti-inflammatory phenotype, thus supporting
tissue repair and alleviation of neuroinflammation. Thus, CB2R has been suggested as a
novel target for treating neurodegenerative diseases due to the ability to bias activated
microglia to an M2 phenotype and attenuate inflammation without the psychotropic side
effects associated with CB1R activation (Ashton & Glass, 2007).
Recently, our lab has discovered the 2,6 dihydroxy biphenyl aryl scaffold that
functions as a selective inverse agonist of CB2R in G-protein functional assay. Our lead
compound, SMM-189, exhibits promising anti-inflammatory activity in murine and
human microglia and in the in vivo murine mild traumatic brain injury model (Bu et al.,
2016a; Guley et al., 2019; Liu et al., 2017; C. Presley, A. Abidi, S. Suryawanshi, S.
Mustafa, B. Meibohm, & B. M. Moore, 2015; Reiner et al., 2015a). These promising in
vitro and in vivo anti-inflammatory responses prompted us to further investigate the
structure-activity relationship of biaryl/aryl menthone scaffold. Therefore, the purpose of
this chapter is to examine SMM-189 analogs with A ring modifications (Figure 3-2) in
the biaryl/aryl menthone scaffold. The new analogs were subjected to pharmacological
evaluation in the CB1R and CB2R cAMP and β-arrestin reporter assays, CB1R and
CB2R receptor affinities. One compound exhibited the greatest potency and efficacy was
selected for the measurement of the anti-inflammatory activity and effects on signaling
cascades in LPS stimulated human and murine microglia
To achieve these goals, and further develop CB2R inverse agonist as potential
therapeutic agents against neuroinflammation, the following research aims were
determined for this chapter; 1) evaluate binding affinity of twenty synthesized analogs of
SMM-189 for the CB1/2 receptors using competition radioligand displacement assays
against non-selective agonist [3H] CP 55, 940; 2) determine the pharmacological activity
in G-protein and β-arrestins pathways using ACTOne and TANGO-bla functional assays,
respectively; 3) investigate the effect of a selected analog of SMM-189 for M1/M2
microglia marker bias, microglia cells migration, ROS production and morphological
changes in murine (C8B4) and human (SV40) microglia cells and; 4) measure the protein
phosphorylation kinetics of six signaling proteins and propose a signaling mechanism
responsible for anti-inflammatory properties of selective CB2R inverse agonists in
microglia.
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Figure 3-2.

A,B, and C Rings in SMM-189 Structure.
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Materials and Methods
Reagents
The HEK-CNG parental, HEK-CNG+CB1 (human), and HEK-CNG+CB2
(human) cell lines were purchased from Codex BioSolutions, Inc (Gaithersburg, MD).
Tango™ CNR2-bla and CNR1-bla U2OS human cell lines were purchased from
Invitrogen (Carlsbad, CA). C8-B4 (ATCC® CRL-2540™) was purchased from ATCC
(Manassas, Virginia). Immortalized Human Microglia - SV40 was purchased from ABM
(Richmond, BC). Puromycin, DMEM, penicillin/streptomycin, gentamicin, PBS, 0.25%
Trypsin/EDTA, Hank’s Buffer, HEPES, EDTA, Tris base, sucrose, MgCl2, Millipore
filter plates and punch kits, EcoLite scintillation cocktail, and Poly-d-lysine coated
96-well plates catalog # 356461 were purchased from Fisher Scientific (Waltham, MA).
G418 was purchased from KSE Scientific (Durham, NC). FBS was purchased from
Atlanta Biologicals (Flowery Branch, GA). Ro 20-1724, acetonitrile, DMSO,
polyethylene amine, and fatty acid-free BSA were purchased from Sigma Aldrich (St.
Louis, MO). ACTOne Membrane Potential Dye was purchased from Codex BioSolutions
(Gaithersburg, MD). Forskolin and CP 55,940 were purchased from Tocris (Bristol, UK).
LiveBLAzer™-FRET B/G Loading Kit, Solution D, Recovery™ Cell Culture Freezing
Medium, FreeStyle™ Expression Medium, McCoy's 5A Medium (modified) (1X), fetal
bovine serum (FBS) dialyzed, Non-essential amino acids (NEAA), sodium pyruvate,
HEPES (1 M, pH 7.3), 0.05% Trypsin/EDTA, Zeocin ™, Hygromycin, Geneticin were
purchased from Invitrogen (Carlsbad, CA). Black-wall, clear-bottom, 96-well assay
plates #3603 were purchased from Corning (Corning, NY). Tritiated [3 H] CP 55,940
was purchased from PerkinElmer (Waltham, MA). The 96-well filter plates and punch
tips were purchased from Millipore (Billerica, MA). Pierce BCA protein assay kit and
Fisherbrand™ 7mL Borosilicate Glass Scintillation Vial were purchased from
Thermofisher (Waltham, MA). Ecolite(+) LC Fluid, MP Biomedicals was purchased
from Tocris (Minneapolis, MN). Dojindo Molecular Technologies IncSupplier Diversity
Partner Cell Counting Kit-8 (NC9864731) was purchased from Thermofisher (Waltham,
MA). Lipopolysaccharide (LPS) from Escherichia coli O111: B4 (L2630) was purchased
from Sigma Aldrich (St. Louis, MO). Antibodies against murine CD 16/32 (ab25235),
CD 68 (ab213363), CD 204 (ab123946) and CD 206 (ab64693) were purchased from
Abcam (Cambridge, UK). The human CD 16 antibody was purchased from R & D
systems. Meso-Scale Discovery (MSD) high bind plates (L15XB), anti-rat (R32AH-5),
and anti-rabbit (R32AB-5) SULFO-TAG antibodies were purchased from Meso-Scale
Discovery (Gaithersburg, MD). Prigrow III Medium (TM003) was purchased from ABM
(Richmond, BC). CREB phospho-S133 kit (64CREPET), Advanced ERK phospho-T202
/Y204 kit (64AERPET), NFkB phospho-S536 kit (64NFBPET), P38
phospho-T180/Y182 kit (64P38PET), Phospho-JNK (Thr183 / Tyr185) (64JNKPEG) and
Phospho-c-Jun (Ser63) cellular kit (64JUNPEG) were purchased from Cisbio (Bedford,
MA). 12 wells BioCoat™ Collagen I Multiwell Plates (08-774-2) was purchased from
Thermofisher (Waltham, MA). Schrödinger Release 2019-3, Glide, LigPrep, Maestro,
Schrödinger, LLC, New York, NY, 2019.
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Cell Culture
CNR2-bla and CNR1-bla U2OS cell lines were cultured in McCoy's 5A medium
with 10% dialyzed FBS, 1%P/S, 0.1 mM NEAA, 25 mM HEPES, 1 mM sodium
pyruvate, 200 μg/ml Zeocin ™, 50 μg/ml Hygromycin, 100 μg/ml Geneticin. CNR2-bla
and CNR1-bla U2OS cells were passaged every 2 to 3 days or when confluence reach
80%. HEK-CNG + CB1 and HEK-CNG + CB2 cells were cultured in DMEM with 10%
FBS, 1% P/S, 25 μg/mL G418, and 5 μg/mL puromycin. HEK-CNG cells were cultured
in DMEM with 10% FBS, 1% P/S, and 25 μg/mL G418. HEK-CNG+CB1 and
HEK-CNG+CB2 cells were passaged every 2–3 days or when confluence reached 80%.
C8B4 cells were cultured in DMEM with 10% FBS, 1% P/S and passaged every one or
two weeks or when confluence reaches 80%. Immortalized SV40 human microglia were
maintained in Prigrow III media with 1% P/S and 10% FBS and were passaged every 2–3
days or when confluence reached 80%. Cell culture flasks were changed every five
passages or after two weeks of use.
ACTOne (G-Protein) Functional Assay
The ACTOne functional assay is used to measure the G-protein signaling as a
function of cAMP production following ligand binding to hCB1/2 receptors. In this
assay, forskolin is used to activate adenylyl cyclase and phosphodiesterase (PDE)
inhibitor (Ro 20-1724) is added to prevent the endogenous hydrolysis of cAMP by PDE
enzymes. The HEK-CNG (parental cell line), HEK-CNG + CB1, and HEK-CNG + CB2
cells were plated in clear poly-D-lysine coated 96-well plates in plating media (DMEM,
10% FBS, 1% P/S) at 50,000 cells/100 μL medium and plates were incubated for 16-18
hours at 37°C / 5% CO2. The next day, 100 μL of ACTOne membrane potential dye was
added to each well and the plates were maintained at room temperature for 1 h in the
dark. 5X of tested compounds were prepared from 1 × 10−6 to 1 × 10−9 with 25 μmol/L
Ro 20-1724, and 800 nmol/L forskolin in PBS with 2.5% (v/v) DMSO. Once test
compounds were added, plates were read using a BioTek (Winooski, VT) plate reader
(Ex 540 nm, Em 590 nm) for one hour. The data at 50 mins were combined and analyzed
to determine the compound's pharmacological activity. Six to nine biological replicates
were used for data analysis. The gold standard CP 55,940 was used as a positive control
in each experimental run and plate read is considered acceptable if CP 55,940 has EC50
from 1 to 10 nM and % of cAMP suppression from 70 to 95 for both cell lines.
Tango™ -BLA (β-Arrestins) Functional Assay
CNR2-bla and CNR1-bla U2OS cells were plated in black-wall, clear-bottom,
96-well assay plates in FreeStyle™ Expression Medium at 50,000 cells/100 μL well and
incubated for 16-18 hours at 37°C / 5% CO2. The next day, 10X stock of test compounds
were prepared in FreeStyle™ Expression Medium with 0.5% DMSO. The final
concentrations of tested compounds were 1 x 10-6 to 1 x 10-9. Test compounds were
added to test wells, full agonist control CP 55,940 (at 5 μM) was added to the stimulated
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wells and assay medium with 0.5% DMSO was added in the cell-free and unstimulated
wells. The plates were incubated in humidified 37°C/5% CO2 for 5 hours. After that, a
6X loading solution was prepared as described in assay protocol and assay plates were
removed from the humidified incubator and 20 μL of loading solution was added to each
well. The plates were incubated at room temperature for an additional 2 hours and
maintained in the dark to protect plates from light and evaporation. Plates were read
using Synergy 2 BioTek (Winooski, VT) plate reader (Ex 409/20 nm, Em 460/40 nm, Em
530/30 nm) and fluorescence reading were set to a bottom-read mode with optimal gain
and 5 reads. CP 55,940 served as a positive control for all runs and the acceptable run
was defined by CP 55,940 EC50 between 30-40 nM for CB2 and 1-10 nM for CB1, with
% activation range between 80-100% for both cell lines. Three to nine biological
replicates were used for data analysis.
In order to determine antagonist activity, cells were plated at 50,000 cells/100 μL
well and incubated for 16-18 hours at 37°C / 5% CO2. Following day,10X stock of
antagonist compounds were prepared in assay medium with 0.5% DMSO and 10 μL of
antagonists were added to each well and incubated for 30 minutes in humidified 37°C/5%
CO2. 10X stock of EC80 concentration of CP 55,940 was prepared in an expression assay
medium with 0.5% DMSO. After 30 minutes of incubation with the antagonist, 10 μL of
CP 55,940 EC80 were added to each well and incubated in humidified 37°C/5% CO2 for 5
hours. After that, 6X loading solution was added to each well and the plates were
incubated at room temperature for an additional 2 hours and were covered to protect
plates from light and evaporation. Plates were read using Synergy 2 BioTek (Winooski,
VT) plate reader (Ex 409/20 nm, Em 460/40 nm, Em 530/30 nm) and fluorescence
reading were set to a bottom-read mode with optimal gain and 5 reads. At least four
biological replicates were used for data analysis.
Membrane Preparation
The membrane preparations used in the binding experiments were prepared from
the functional cell lines HEK-CNG + CB1 or HEK-CNG + CB2 to allow for a direct
correlation between EC50 and Ki. Briefly, HEK-CNG + CB1 or HEK-CNG + CB2 cells
were plated in 500 cm2 culture dishes and incubated for two days or when it reached
80-90 % confluence. Media was removed and cells were washed with 10 mL of ice-cold
PBS. Then, cells were scrapped after the addition of 10 mL of ice-cold PBS with
10 mmol/L EDTA and the cell suspension was centrifuged at 4°C, 500g for 5 min. The
supernatant was discarded, and the pellet homogenized in 10 mL of solution A (50 mM
Tris HCL, 320 mM sucrose, 2 mM EDTA and 5 mM MgCl2). Then, the cell suspension
was centrifuged at 4°C, 1600g for 10 min. The supernatant was saved, and the cell pellet
washed three times in 8 mL of solution A. All supernatants were combined and
centrifuged at 4°C, 50,228g for 3 h. The supernatant was discarded and the pellet
suspended in 3 mL of solution B (50 mM Tris HCL, 10% sucrose, 2.5 mM EDTA and 5
mM MgCl2). Protein concentration was determined using a Pierce BCA protein assay kit
and membrane aliquots were stored at −80°C. Scatchard analysis was carried out on CB1
and CB2 membrane preparations and CB1 membrane preparation Kd was 1.4 nmol/L and
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Bmax was 1.7 pmol/mg. CB2 membrane preparation Kd was 2.3 ± 0.8 nmol/L with Bmax
1.25 ± 0.35 pmol/mg.
Receptor Radioligand Binding Assay
Millipore filter plates were filled with 210 μL/well of 0.05% (w/v) polyethylene
amine in deionized water and incubated for 1 hour at room temperature. Plates were then
washed five times with 250 μL/well of deionized water then filtered using vacuum
manifold before starting the experiment. After plate coating, 125 μL binding buffer was
added to each well, followed by addition of 5 μL of [3H]-CP 55,940, 10 μg of membrane
protein in binding buffer, and 50 μL of test compound in binding buffer (final
concentration ranging from 1 nmol/L to 10 μmol/L). Plates were incubated at 30°C for
1.5 hours, then solutions were removed via vacuum and washed nine times with binding
buffer. The plates were vacuumed dry and punch tips were used to punch out filters into 5
mL of Eco-lite scintillation cocktail in 7ml scintillation vials. Counts per minute (CPM)
were measured the next day using PerkinElmer Liquid Scintillation Analyzer Tri-Carb
2810TR, 3-min dwell time. At least six biological replicates were used for data analysis.
Cytotoxicity Assay
C8B4 or SV40 cells were plated at 5000-10,000 cells/well (100 μl/well) on a 96
well plate and incubated for 24 hours at 37 °C 5% CO2. On the second day, the 10% FBS
media was replaced with 1% FBS media and plates were incubated overnight at 37 °C
5% CO2. Following day, compound 45 was added at final concentrations 10-4 to 10-6.5 and
plates were incubated for an additional 24 hours at 37 °C 5% CO2. After 24 h of
incubation, 10 μL of CCK-8 Reagent was added to each well and the plate was incubated
for at least 2 hours in the incubator followed by absorbance measurement at 450nm
wavelength using BioTek plate reader.
M1 and M2 Murine and Human Microglia Cell Surface Markers
C8B4 or SV40 cells were plated on 96-well Meso Scale Discovery high bind plate
at a density of 20,000 cells in 50 μL (10,000 cells in 100 μL) per well and incubated at 37
°C 5% CO2 overnight. The following day, a 10% FBS medium was removed, replaced
with 100 μL of 1% FBS medium and the plates were incubated for 18-24 hours at 37 °C
5% CO2. After 24 h, LPS (final concentration 100 ng/mL) was added to each well and
stimulated for one hour (except control wells received 1% FBS media). After 1h of LPS
stimulation, compound 45 was added at 20 μM for C8B4 and 35 μM for SV40 cells and
plates were incubated for an additional 24 hours at 37 °C 5% CO2. The expression of M1
(CD 16/32, CD 16, CD 68) and M2 markers (CD 204, and CD 206) was assessed using
30 μL per well of antibody prepared in PBS at a concentration of 2 μg/mL. After a
two-hour incubation on a shaker plate at 130 rpm, wells were washed using 150 μL PBS,
and 30 μL per well of secondary antibody (anti-rat or anti-rabbit) containing sulfo-tag in

81

PBS was added at a concentration of 2 μg/mL. Plates were then incubated for an
additional two hours, washed three times with 150 μL per well of PBS, and read in 2X
surfactant-free read-buffer using a SECTOR Imager 2400 (Meso Scale Discovery).
Scratch Assay
SV40 cells were plated at 50,000 cells/ml on 12 wells collagen I coated plates and
incubated at 37 °C 5% CO2 overnight. On the second day, Prigrow III 10% FBS media
was replaced with 1% FBS media and the plates were incubated for 18-24 hours at 37 °C
5% CO2. On the third day, a scratch was made using 100 μl pipette tip and wells were
gently washed twice with 1% FBS Prigrow III media to remove detached and floating
cells. Cells were then stimulated with LPS (100 ng/ml) for LPS control and treated wells
for 30 mins (control wells received 1% FBS media only). After LPS stimulation,
compound 45 (at 10 μM) was prepared in 1% FBS Prigrow III media containing LPS and
added to the treatment group. Plates were incubated for an additional 24 hours at 37 °C
5% CO2 and images were taken at 0 hours and 24 hours and the number of cells migrated
was analyzed using ImageJ.
ROS Detection
SV40 cells were plated at 30,000 cells/ml on 96 well black wall clear bottom
collagen I coated plate and incubated for 24 hours at 37 °C in 5% CO2. On the second
day, Prigrow III 10% FBS media was replaced with serum-free media and the plates were
incubated for 18-24 hours at 37 °C in 5% CO2. On the following day, media was
removed and dye was added to the cells at 10 μM concentration and incubated for 30
minutes at 37 °C, in 5% CO2. After that, plates were washed twice with serum-free media
(phenol red-free) and treatment was added to each well. Serum-free media was added to
the negative control, LPS (100 ng/ml) was added to LPS control and compound 45 (at 10
μM) + LPS (100 ng/ml) was added to the treatment group. Two reading were taken, at 45
minutes and at 24 hours. The fluorescence measurement was made using BioTek Synergy
2 (BioTek Instruments, Inc. Winooski, VT) with 485/20 excitation and 528/20 emission
filters and set to bottom read.
Cytoskeleton Staining
SV40 cells were plated on 12 wells collagen I coated plate and incubated for
18-24 hours at 37 °C in 5% CO2. The following day, Prigrow III 10% FBS media was
replaced with 1% FBS media and the plates were incubated for 24 hours at 37 °C in 5%
CO2. On the third day, cells were stimulated with LPS (1 μg/ml) for LPS control and
compound 45 (at 10 μM) + LPS (1 μg/ml) was added to the drug-treated wells. Plates
were incubated for an additional 24 h at 37 °C in 5% CO2 and fluorescence images were
taken using a BZ-X microscope. Cells were stained using actin cytoskeleton staining kit
(FAK100) according to manufacturer protocol. TRITC-conjugated Phalloidin was used to
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detect F-actin and DAPI was used to stain the nucleus. Ten fields were taken for each
group.
SV40 Molecular Pathway Study
The signaling pathways were measured to determine the level of phosphorylated
proteins c-Jun, ERK1/2, p-38, JNK, CREB, and NF-κB. The SV40 cells were plated at
50,000 cells/100 μL per well in Prigrow III media containing 10% FBS and plates were
incubated for 18-24 h at 37 °C in 5% CO2. The next day, full growth media was gently
removed and replaced with 100 μl of Prigrow III media containing 1% FBS media and
plated were incubated overnight at 37 °C 5% CO2. On the third day, LPS (100 ng/ml)
was added to LPS control and treated wells for 30 mins to stimulate the cells (control
wells received Prigrow III media with 1% FBS only). After 30 minutes, compound 45 (at
35 μM) was prepared in 1% FBS media containing LPS (the final concentration of LPS is
100 ng/ml). Six-time points were measured at 45, 60, 90, 150, 210 and 390 minutes.
After completion of the kinetic study, SV40 media was gently removed and cells were
lysed using Cisbio lysis buffer for (30-60) minutes. 16 μL of lysate was transferred into
low volume 96-well HTRF white plates and 2 μL of d2 (acceptor) and 2μL of
Eu3+Cryptate (donor) antibodies provided for the Advanced p-ERK1/2 (Thr202/Tyr204),
p-CREB (Ser133), p-p38 (Thr180/Tyr182), p-NF-κB (Ser536), p-JNK (Thr183/Try185),
p-c-Jun (Ser63) kits were added. The positive control was included in each assay by
replacing the cell lysate with supplemented lysis buffer. The assay was incubated at room
temperature overnight and the HTRF signal was analyzed with BioTek Synergy 2
Multidetection Microplate Reader (BioTek Instruments, Inc. Winooski, VT) with flash
lamp excitation 330/80 nm and emission at 620/10 nm and 665/8 nm.
Data Analysis
For the binding assays, Ki values were determined using Cheng and Prusoff
equation (Cheng & Prusoff). For the ACTOne data, the analysis was done using
nonlinear regression analysis and fluorescent measurements at 50 mins. The data were
normalized using a scaling equation:
ܺᇱ ൌ  ܣ

ሺܺ െ ܺሻሺ ܤെ ܣሻ

ܺ െ ܺ

For the agonist study, A= Blank well-containing dye and cells only, B = Forskolin
stimulation, X` = Normalized value, X max = 100 %, X = min 0 %.
For the Tango-BLA assay, the analysis was done using fluorescent measurements.
The background (cell-free wells) was subtracted from both emission channels (460 nm
and 530 nm). Blue/Green Emission Ratio was calculated for each well by dividing the
background-subtracted blue emission values by the background-subtracted green
emission values.
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Background-Subtracted Fluorescence (Fl) = Fl Sample – Fl Cell-free control
େ୭୳୫ୟ୰୧୬୫୧ୱୱ୧୭୬ሺସ୬୫ሻ

Emission Ratio (ER) = ୪୳୰୭ୣୱୡ୧୬୫୧ୱୱ୧୭୬ሺହଷ୬୫ሻ
For the Cisbio pathway study, these two equations were used for data analysis.
HTRF Ratio =

ୗ୧୬ୟ୪ሺହ୬୫ሻ
ୗ୧୬ୟ୪ሺଶ୬୫ሻ

Ͳͳ כǡͲͲͲ, CV % =

ୗ୲ୟ୬ୢୟ୰ୢୈୣ୴୧ୟ୲୧୭୬
ୣୟ୬ୖୟ୲୧୭

ͲͲͳ כ

Molecular Docking of Compound 45
The CB2R crystal structure PDB 5ZTY, (Li et al., 2019) was modified at the third
intracellular loop (ICL3) to remove the T4-lysozyme protein, then protein structure was
processed and modified using Protein Preparation Wizard. The structure of compound 45
was converted into 3D using LigPrep and several conformations were generated and
minimized. The docking was performed using Glide XP for molecular docking (Friesner
et al., 2006).
Results and Discussion
Binding Affinity Evaluation of Compounds 29-48 for the CB1 and CB2 Receptors
We have previously reported a series of alkyl and phenyl analogs of SMM-189
that focused on C ring modification. This series was measured for affinity towards CB1
and CB2 receptors and functional activity at the G-protein pathway using ACTOne
cAMP functional assay. The study results demonstrated that small alkyl groups at
position 4 were optimum for the inverse agonist activity (C. S. Presley et al., 2015). The
goal of this section was to investigate the aromatic A ring structural requirement in
SMM-189 scaffold, to achieve this a series of compounds were synthesized having
phenyl rings substituted 2`,3` and 5` positions and heteroaromatic rings. Compounds
affinities were evaluated in competition radioligand displacement assays against hCB1/2
receptors using non-selective agonist [3H] CP55, 940. All membrane preparations were
prepared in-house from ACTOne assay cell lines to achieve a better correlation between
affinity and potency. The results of the radioligand displacement studies are in Table 3-1.
The lead compound SMM-189 contains a 3,5-dichlorophenyl A ring suggesting
electron-withdrawing groups are favored; however, substitution of this group with
3,5-difluorophenyl (29) surprisingly reduced CB2R affinity by an order of magnitude
(121.3 nM versus 1,634 nM) and increased CB1R affinity from 4.78 μM to 1.08 μM with
a CB1R/CB2R selectivity ratio (SR) of 0.66 compared to 39.4 for SMM-189.
Substitution with a 2,5-dichlorophenyl (30) caused a slight decrease in CB2R affinity (Ki
= 233 nM) but abolished affinity at CB1R with a SR of 42.9. The decrease in the affinity
of 29 may reflect a reduction in the size of the electronegative group, thus the
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Table 3-1.
Receptors.

Binding Affinity Evaluation of Compounds 29-48 at CB1 and CB2

Compound
Number
SMM-189 (28)

Ki ± SEM (nM)
CB1R
CB2R
4778 ± 246
121.3 ± 20

CB1R/CB2R
SR
39.4

29
30

1076 ± 2
>10000

1634 ± 1
233 ± 1

0.66
42.92

31
32

4015 ± 3
>10,000

320 ± 1
204 ± 1

12.55
49

33

1904 ± 2

215 ± 1

8.86

34
35

>10000
>10000

1839 ± 2
>10000

5.44
1

36
37

>10000
>10000

4740 ± 2
2494 ± 3

2.11
4

38
39
40

>10000
3242 ± 243
>10000

1328 ± 2
>10000
2896 ± 349

7.53
0.32
3.45

41
42

>10000
>10000

>10000
>10000

1
1

43

>10000

447 ± 1

22.37

44

9526 ± 19

975 ± 1

9.77

45
46
47

>10000
3735 ± 2
>10000

154 ± 1
187 ± 1
8383 ± 50

64.93
19.97
1.19

48

>10000

>10000

1

N = 6-9, error is SEM.
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3,5-bis-(trifluoromethyl) phenyl group was introduced (33). This A ring substitution
restored CB2R affinity (Ki = 215 nM) but also increased affinity for CB1R to 1.90 μM
with poor receptor selectivity (SR = 8.86). The best A ring functional group substitution
in the C ring phenyl series was the 3-trifluoromethyl phenyl (32) resulting in CB2R
affinity of 204 nM with a SR of 49 and no measurable CB1R affinity. Conversion of the
3-trifluoromethyl in 32 to methyl (31) modestly decrease CB2R affinity (Ki = 320 nM)
but significantly increased CB1R affinity to 4.01 μM.
Surprisingly, the 3-hydroxymethyl phenyl substitution (37), designed to mimic
the methylenehydroxy on HU-210 and the hydroxy in CP-55,940, had a poor affinity for
CB2R (Ki = 2.49 μM) and did not displace CP 55,940 at the CB1R. Changing the
substituents on the phenyl A ring to 4-fluoro-3-cyano (34), 3,4-methylenedioxy (35), and
1,4-dihydrodioxin (36) all yield analogs with poor CB2R affinities ranging from 1.84 to
4.74 μM with no affinity for the CB1R. These results suggest that substitution with
bulkier substituents in the 4 position are not tolerated in the ligand-binding pocket (LBP)
in CB2R. Replacement of the 3,5-dichlorophenyl in SMM-189 with A ring heterocycles
was equally ineffective at increasing CB2R affinity and SR wherein the 3-furanyl (38)
had a Ki at CB2R of 1.33 μM and the 3-pyridyl (40) 2.9 μM with SRs of 7.53 and 3.45,
respectively. Interestingly, the 3-thiophenyl (39) had weak affinity for CB1R (Ki = 3.42
μM) but did not displace CP 55,940 in the CB2R assay. The 2-fluoropyridyl (41) and the
2-chloropyridyl (42) analogs of SMM-189 exhibited no affinity for either receptor. It is
expected that the pyridine group would be protonated under the assay conditions raising
the possibility of unfavorable charge-charge interactions in the LBP of both receptors.
With respect to the furanyl and thiophenyl groups, the ClogP of the 3-thiophenyl (39) and
the 3-methylphenyl (31) are 4.07 and 4.63, respectively, suggesting that ring contraction
reduces contacts within the CB2R LBP negatively affecting receptor affinity. This trend
does not hold for the 3-furanyl analog (38) which exhibited weak affinity at CB2R,
however, (as will be discussed in the functional ACTOne section below), this substitution
switch functional activity from an inverse agonist to a weak agonist. Thus, it is predicted
that the 3-furanyl group recognizes a different conformation of the CB2R LBP
representing a new lead structure for agonist development.
We have previously reported that substitution of the C1’ position in the classical
cannabinoid series (Figure 3-3) with a thiophenyl group yielded a compound with a high
affinity for both the CB1R and CB2R with Kis of 1.08 and 0.27 nM, respectively
(Krishnamurthy et al., 2008). It was later found that these analogs were full agonists at
CB1R and neutral antagonists at CB2R indicating that they interact with both the active
and inactive conformations of the CB2R. Based on the high affinity and potential to
interact with the inactive conformation, the C ring phenyl (Figure 3-2) was replaced with
a thiophenyl group in the above analogs bound to CB2R. This functional group
transformation significantly decreased affinity of the 3-methylphenyl A ring analog (44)
from 4.05 μM for CB1R and 320 nM for CB1R for C ring phenyl analog (31) to 9.53 μM
and 975 nM, respectively, for the thiophene derivative. The substitution also decreased
affinity and SR for the 2,5-dichlorophenyl analog 30 from 233 nM to 447 nM at CB2R
with the SR dropping from 42.9 to 22.3. Interestingly, the 3-trifluoromethyl (45) and
bis-3,5-trifluorophenyl (46) analogs with a C ring thiophene demonstrated increased
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Figure 3-3. Chemical Structure of Compound 4.
Reprinted with permission. Krishnamurthy, M., Gurley, S., & Moore II, B. M. (2008).
Exploring the substituent effects on a novel series of C1′-dimethyl-aryl
Δ8-tetrahydrocannabinol analogs. Bioorganic & medicinal chemistry, 16(13), 6489-6500.
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affinity and SR compared to their C ring phenyl analogs 32 and 33 with Ki values of 154
and 187 nM, respectively, and SRs of 64.9 and 20. The effects of the thiophenyl
substitution also had a significant impact on the potency and efficacy of the compounds
in the ACTOne functional assay.
Functional Activity Evaluation of Compounds 29-48 in ACTOne and TANGO-bla
Assays
The main objective of this section is to evaluate the pharmacological activity of
twenty synthesized compounds at G-proteins and β-arrestins signaling using ACTOne
and TANGO-bla reporter assays. For ACTOne assay, each of the twenty compounds was
evaluated in hCB1, hCB2, and parental HEK-CNG cell lines, and compounds potency
and efficacy are summarized in Table 3-2.
Using HEK-CNG + CB2 cells, replacing C phenyl ring with a thiophenyl group
greatly enhanced compounds potency, and efficacy in some cases. For example, 43
bearing a thiophenyl group in C ring demonstrated higher potency (pEC50 = 6.8, % max =
61) and comparable efficacy relative to its phenyl analog 30 (pEC50 = 6.4, % max = 66).
Moreover, 44 bearing a thiophenyl group in C ring showed higher potency and efficacy
(pEC50 =6.7, % max = 52) compared to the phenyl analog 31 (pEC50 = 5.7, % max = 40).
Interestingly, 45 bearing C thiophenyl group demonstrated the highest potency in this
series (pEC50 = 7.4, % max = 57), with slightly lower efficacy relative to the phenyl
analog 32 (pEC50 = 6.6, % max = 66). However, this trend does not hold for 46,
conversion C phenyl ring of 33 with a thiophenyl group 46 reduced the potency (6.4
versus 6.1), but significantly increased efficacy to 50. Additionally, replacement 3,5
dichloro phenyl (SMM-189) with 3,5 difluoro phenyl (29) resulted in a significant
reduction in potency (6.81 versus 5.8) and comparable efficacy (% max = 63). Changing
the substituents on the phenyl A ring to 4-fluoro-3-cyano (34), and 1,4-dihydrodioxin
(36), all yield analogs with lower potency pEC50 = 5.5, and 5.3, respectively.
Surprisingly, replacing phenyl A ring with the 3-furanyl analog (38) switch functional
activity from an inverse agonist to a weak agonist, suggesting this 3-furanyl group adopts
a different conformation at CB2R, thus rendering 38 an agonist. It is worth noting that
none of the compounds demonstrated activity in HEK-CNG + CB1 and HEK-CNG cells
confirming compounds selectivity towards CB2R.
For β-arrestins signaling (Table 3-3), we selected nine compounds that
demonstrated the highest potency, efficacy in ACTOne functional assay and screened
them in U2OS + CB1 and CB2 cells. Using agonist β-arrestins study, all nine compounds
demonstrated a lack of functional activity in U2OS + CB2 cells. The high CB2R affinity
with no functional activity prompts us to investigate the activity using a competition
study in the presence of CP 55,940 EC80. Competition results showed that compounds
29-33 and 43-46 demonstrated neutral antagonism at CB2R β-arrestin signaling with
pEC50 ranging from 5 to 5.8 at CB2R. These results confirmed a less complicated
signaling pathway for CB2R inverse agonists. Additionally, none of the compounds
altered the emission ratio in U2OS + CB1 cells, indicating no CB1 off-targets effects.
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Table 3-2.
Pharmacological Evaluation of Compounds 28-48 at G-Protein
Signaling Using ACTOne Functional Assay.
CB1R

Ligand
Number
SMM-189

R1
3`,5`dichloro phenyl

29

R2

CB2R

Phenyl

pEC50
± SEM
-

% Max
± SEM
-

3`,5` difluoro phenyl

Phenyl

-

-

30

2`,5` dichloro phenyl

Phenyl

-

-

31

3` methyl phenyl

Phenyl

-

-

32

3`Trifluoromethyl phenyl

Phenyl

-

-

33

Phenyl

-

-

34

3`,5` bis(trifluoromethyl)
phenyl
4` fluoro-3`-cyano phenyl

Phenyl

-

-

35

3,4 methylenedioxy phenyl

Phenyl

-

-

36

Phenyl

-

-

37

6`-(2`,3` dihyrdrobenzo[1,4] dioxin)
3` hydroxymethyl phenyl

Phenyl

-

-

38

3`-Furanyl

Phenyl

-

-

39
40

3`- Thiophenyl
3 pyridyl

Phenyl
Phenyl

-

41

2` fluoropyridine

Phenyl

42

2` chloropyridyl

43

2`,5` dichloro phenyl

44

3` methyl phenyl

45

3` Trifluoromethyl phenyl

46
47

3`,5` bis(trifluorormethyl)
phenyl
3` hydroxymethyl phenyl

48

3 pyridyl

pEC50 ±
SEM
6.81 ±
0.09
5.77 ±
0.13
6.44 ±
0.08
5.78 ± 1

% Max ±
SEM
54.8 ± 3

6.62 ±
0.04
6.43 ±
0.07
5.55 ±
0.27
NA

66 ± 3

63 ± 2
66.5 ± 3
40.3 ± 3

22.9 ± 2
52.3 ± 2
NA

5.31 ±
0.39
NA

49 ± 2

-18.5 ± 0.28

-

5.56 ±
0.45
NA
NA

-

-

NA

NA

Phenyl

-

-

NA

NA

2
Thiophene
2
Thiophene
2
Thiophene
2
Thiophene
2
Thiophene
2
Thiophene

-

-

61 ± 3

-

-

-

-

-

-

-

-

6.85 ±
0.16
6.70 ±
0.14
7.41 ±
0.06
6.17 ±
0.37
NA

-

-

NA

NA

N = 4-12, error is the SEM. Negative values indicate cAMP suppression. All the
compounds were inactive at CB1R.
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NA
NA

51.7 ± 3
57.2 ± 5
49.7 ± 4
NA
NA

Table 3-3.
Pharmacological Evaluation of Compounds 28-33 and 43-46 at
β-Arrestins Pathway Using TANGO-bla Assay.
Ligand
Number
CP 55,940

CB1R
pEC50 ±
ER ±
SEM
SEM
8.24 ± 0.27
4.51 ± 0.09

CB2R
pEC50 ±
ER ± SEM
SEM
7.43 ± 0.03
3.70 ± 0.06

SMM-189 (28)

-

-

5.69 ± 0.18

0.60 ± 0.08

29

-

-

5.05 ± 4

2.22 ± 0.44

30

-

-

5.22 ± 0.55

1.03 ± 0.20

31

-

-

<5

2.30 ± 0.12

32

-

-

5.46 ± 0.22

1.41 ± 0.52

33

-

-

5.85 ± 0.07

0.91 ± 0.19

43

-

-

<5

1.46 ± 0.22

44

-

-

5.21 ± 0.81

2.68 ± 0.09

45

-

-

5.07 ± 0.67

1.19 ± 0.23

46

-

-

5.89 ± 0.06

0.94 ± 0.09

The underline is the potency and efficacy in the presence of CP55, 940 EC80 (antagonist
study). N = 3-7, error is the SEM. Compound 28-33 and 43-46 were inactive at CB1R.
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Effects of Compound 45 Treatment on M1/M2 Murine Microglia Cell Surface
Markers
The measurements of affinity, potency, and efficacy of the SMM-189 analogs
revealed that compound 45 had improved activity compared to the parent compound. To
further investigate if, in fact, 45 was an improved derivation of SMM-189, the effects on
microglia polarization, as determined by the expression of M1 and M2 markers, were
first measured in murine microglia. The murine microglia C8B4 cell line was selected for
the cell surface markers evaluation since this line expresses the closest features to the
native mouse microglia (Alliot, Marty, Cambier, & Pessac, 1996). Before examining
C8B4 cell surface markers, a dose-response experiment was conducted to measure the
cytotoxicity (Figure 3-4), i.e. EC50, of compound 45, yielding a value of 20 μM which
was used for C8B4 surface markers measurements. Thus, using the determined EC50, the
M1/2 cell surface markers evaluation was performed using on cell polarization assay.
This experimental approach was developed and optimized in our lab using the Meso
Scale Discovery (MSD) that utilizes electrochemiluminescence (ECL) reaction as a
detection method. This approach provides a sensitive and rapid reading in addition to
maintaining the microglia phenotype intact, providing an accurate assessment of changes
in M1/2 surface markers upon compound 45 treatment in stimulated microglia.
In this experiment, C8B4 cells were stimulated with LPS (at 1 μg/ml) for 1 hour,
followed by treatment with compound 45 (at 20 μM) for 24 hours. The following day, the
M1 pro-inflammatory (CD 16/32 and CD 68) and M2 anti-inflammatory (CD 204 and
CD 206) markers were evaluated. As presented in Figure 3-5, compound 45 significantly
suppressed the M1 associated markers CD 16/32 and CD 68 relative to LPS control (P <
0.01, P < 0.001). Moreover, treatment with compound 45 significantly enhanced the
expression of M2 markers CD 204 and CD 206 in comparison to LPS (P < 0.0001).
These murine data were consistent with our previous findings with SMM-189 (C.
Presley, A. Abidi, S. Suryawanshi, S. Mustafa, B. Meibohm, & B. M. Moore, 2015)
suggesting CB2R inverse agonists modulate inflammation by biasing microglia toward
M2 anti-inflammatory state, thus enhancing neuroprotection.
Effects of Compound 45 Treatment on M1/M2 Human Microglia Cell Surface
Markers
Recently, it has been reported by Soethoudt et al. that some CB2R ligands,
specifically agonists, exhibit interspecies differences between mice and human which can
complicate data translation from preclinical models to the clinic. Interspecies differences
in receptor coupling can result in divergent ligand responses which should be considered
carefully when testing novel drugs (Soethoudt et al., 2017). Therefore, this section
evaluated potential interspecies differences utilizing immortalized human microglia
(SV40). One of the hypotheses in my dissertation was that CB2R inverse agonists could
circumvent differences in pathway coupling observed for CB2R agonists. Therefore, the
efficacy of compound 45 in regulating the expression of M1/2 markers was measured for
comparison to murine microglia.
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Figure 3-4.
N = 3, SD.

C8B4 Cytotoxicity Assay for Compound 45.

Figure 3-5. M1/M2 Phenotype Characterization Using on Cell Polarization Assay
in Stimulated Murine Microglia (C8B4) Treated with Compound 45.
(A) Compound 45 (at 20 μM) decreased both M1 markers CD 16/32 and CD 68 24h post
treatment which are significantly different from LPS (1 μg/ml) control (** P < 0.01, ***
P < 0.001). (B) Compound 45 (at 20 μM) also significantly increased the M2 associated
markers CD 204 and CD 206 compared to LPS (1 μg/ml) at 24 h (**** P < 0.0001).
Asterisks above columns are comparisons to LPS control. N = 6-9, error is SEM.
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A cytotoxicity assay was performed using increasing concentrations of compound
45 and EC50 of compound 45 was 35 μM, (Figure 3-6) and which was used in the SV40
study. For M1/2 surface markers evaluation, SV40 cells were stimulated with LPS (at
100 ng/ml) for 1 hour followed by treatment with compound 45 (at 35 μM) for 24 hours.
The following day, primary and secondary antibodies were used to measure the
expression of microglia cell surface markers. From the result presented in Figure 3-7, it
is apparent that treatment with compound 45 significantly decreased the expression of
M1 markers CD 16 and CD 68 relative to LPS control (P < 0.001, P < 0.0001).
Additionally, the expression of M2 markers CD 204 and CD 206 was significantly
enhanced in comparison to LPS control (P < 0.01). Our present findings are comparable
to the murine results demonstrating that compound 45 had equivalent efficacy in both
murine and human microglia in terms of suppression of M1 pro-inflammatory markers
and enhancement of M2 associated markers. Together, these data support the hypothesis
that CB2R inverse agonists are a unique class of ligand that modulates the
neuroinflammation by polarizing microglia from M1 pro-inflammatory to the M2
anti-inflammatory state. Moreover, the consistency of results between species indicates
that the inverse agonists signaling mechanism might be less convoluted relative to the
agonists, thus facilitating data translation from animal to human models.
Effects of Compound 45 Treatment on Migration Ability of Human Microglia
In a previous study done by Walter et al., authors reported the presence of CB2R
in the leading edges of microglial lamellipodia suggesting CB2R modulates microglia
migration ability (Walter et al., 2003). Moreover, it has been reported in the cannabinoids
literature that several CB2R agonists such as 2AG and AEA triggered migration in
microglia (Walter et al., 2003) and macrophages (Kishimoto et al., 2003). These studies
proposed that CB2R agonists produce their anti-inflammatory responses by induction of
microglial migration that recruits beneficial immune cells at the site of injury, thus
reducing neuroinflammation (Ken Mackie & Stella, 2006; Walter et al., 2003).
Therefore, the purpose of this study was to determine the effects on the migration
of microglia after compound 45 treatment using scratch assay. In this experiment, the
scratch was made using 100 μl pipette tip, followed by 30 mins stimulation with LPS (at
100 ng/ml). Then, cells were treated with LPS alone (at 100 ng/ml) or in combination
with compound 45 (at 10 μM) and plates were incubated for 24 hours. The scratch was
evaluated at two-time points 0, 24 h and the number of migrated cells were counted using
ImageJ. The results of this investigation revealed that LPS alone triggered a remarkable
increase in the number of migrating cells (Figure 3-8A) consistent with the study
reported by Karlstetter et al. who suggested the increase in cell migration is indicative of
M1 activated phenotype (Karlstetter et al., 2011). Interestingly, treatment with compound
45 significantly reduced microglial migration compared to LPS (Figure 3-8B, P < 0.01)
at 24 hours. Our data strongly suggests that CB2R inverse agonists have a distinct
mechanism to modulate neuroinflammation via CB2R. Moreover, I hypothesized that
CB2R inverse agonists alleviate neuroinflammation by attenuating microglial migration,
thus suppressing the activation of other immune cells (macrophages, B-cells,
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Figure 3-6.
N = 3, SD.

SV40 Cytotoxicity Assay for Compound 45.

Figure 3-7. M1/M2 on Cell Polarization Assay Using Immortalized Human
Microglia (SV40).
(A) In SV40 cells, compound 45 (at 35 μM) demonstrated a significant decrease in M1
associated markers CD 16 and CD 68 at 24h compared to LPS (100 ng/ml) control (*** P
< 0.001, **** P < 0.0001). (B) The expression of the M2 CD 204 and CD 206 markers
was also significantly increased with compound 45 (at 35 μM) in comparison to LPS
(100 ng/ml) control at 24 h (** P < 0.01). Asterisks above columns are comparisons to
LPS control. N = 6-8, error is SEM.
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Figure 3-8. Effects of Compound 45 Treatment on Migration of SV40 Cells.
(A) Scratch was made using 100 μl pipette tip followed by two washes with 1% FBS
media to remove detached and floating cells. Then, cells were stimulated with LPS (100
ng/ml) only. (B) Scratch was made, wells were washed two times with 1% FBS media
followed by stimulation with LPS (100 ng/ml) for 30 minutes. Then, LPS (at 100 ng/ml)
+ compound 45 (at 10 μM) were added to the treated wells. Plates were incubated for 24
hours, images were taken at two-time points 0 and 24 hours and ImageJ was used to
analyze data. Asterisks above columns are comparisons to LPS control (* P < 0.05, ** P
< 0.01). N = 7, error is SEM.
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natural killer cells, lymphocytes) that contribute to the amplified inflammatory signal and
neurotoxicity.
Effects of Compound 45 Treatment on Reactive Oxygen Species (ROS) Production
by Human Microglia
Prior studies have reported that M1 activated microglia contribute indirectly to the
neurotoxicity in neurodegenerative diseases via released pro-inflammatory mediators
such as cytokines, NO and, importantly, ROS (Klegeris, Walker, & McGeer, 1994; Qin et
al., 2002). CB2R modulation caused a reduction in ROS which has been reported by
Ribeiro, Rachel, et al. that both CB2R agonists and inverse agonists blocked the
generation of ROS in both murine and human microglial cells suggesting these ligands
produced their anti-inflammatory effects via CB2R. However, other potential targets that
might involve in these beneficial effects remain to be elucidated (Ribeiro, Wen, Li, &
Zhang, 2013).
Herein, we sought to determine the effect of compound 45 treatment on ROS
generation using dichlorofluorescin diacetate (DCFD) detection assay. In this experiment,
SV40 cells were treated with media only (negative control), LPS (100 ng/ml), and
compound 45 (at 10 μM) for 24 hours. Two readings were taken, the first at 45 minutes
and the second at 24 hours. The results of this study, presented in Figure 3-9, are
consistent with previous reports in that LPS treatment markedly increased ROS
production at 45 minutes and 24 hours compared to untreated control. Application of
compound 45 significantly attenuated the ROS generation at 45 minutes (P < 0.001) and
after 24 hours of treatment (P < 0.0001). The present findings support our previously
discussed results that compound 45 produces anti-inflammatory responses through
enhancing M2 microglia phenotype, suppressing microglial migration and attenuating
ROS production in LPS stimulated human microglia. Additionally, attenuation of ROS
by compound 45 is consistent with a study done by Ribeiro et al. (Ribeiro et al., 2013)
indicating CB2R inverse agonists can serve as novel anti-inflammatory agents to treat
neuroinflammatory conditions.
Morphological Changes of Human Microglia after Compound 45 Treatment
Microglia are reactive cells that rapidly respond to various stimuli and change
their morphology and function upon stimulus induction. In certain instances,
morphological changes in microglia correlate with their activation states and the release
of pro- or anti-inflammatory markers; however, gene induction can also occur in the
absence of clear morphological changes (Kettenmann, Hanisch, Noda, & Verkhratsky,
2011). In our previous study, we have investigated the morphological changes of
stimulated primary human microglia after SMM-189 treatment. The results demonstrated
that SMM-189 significantly enhanced the number of rod-like cells relative to LPS,
suggesting SMM-189 is polarizing microglia towards the M2 phenotype (C. Presley, A.
Abidi, S. Suryawanshi, S. Mustafa, B. Meibohm, & B. M. Moore, 2015).
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Figure 3-9. Effects of Compound 45 Treatment on ROS Production by SV40
Cells.
(A) Reactive oxygen species measurement at 45 minutes. Serum-free media were added
to the negative control, LPS (100 ng/ml) was added to LPS control and LPS (100 ng/ml)
+ compound 45 (at 10 μM) were added to the treatment group. Asterisks above columns
are comparisons to LPS control (*** P < 0.001). (B) Reactive oxygen species
measurement at 24 hours (* P < 0.05, **** P < 0.0001). N = 6, error is SEM.
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Therefore, the present study was designed to determine the effect of compound 45
treatment on activated microglia morphology using cytoskeleton staining and
fluorescence microscopy. In this experiment, cells were treated with media only (control),
LPS (1 μg/ml), or compound 45 (at 10 μM) with LPS and plates were incubated for 24
hours. To end the experiment, cells were fixed, permeabilized and stained with phalloidin
(cytoskeleton) and DAPI (nuclear) according to the manufacturer's protocol. Our results
revealed that the treatment with LPS induced a drastic change in microglia cell
morphology compared to untreated cells. Moreover, the LPS stimulated cells (Figure
3-10B) were characterized by enlarged, flat, rounded cell bodies with fewer projections,
i.e. amoeboid morphology, suggesting that these cells transitioned to an M1 activated
phenotype (Abd‐El‐Basset & Fedoroff, 1995; Chen et al., 2012). Conversely, compound
45 (Figure 3-10C) induced a remarkable transformation of microglia into ramified
morphology with a small cell body and several elongated cell projections, indicating
microglia adopted an anti-inflammatory M2 phenotype upon compound 45 treatment
(Neubrand et al., 2014). It is worth noting that all the three treatment groups showed
similar nucleus distribution confirming that morphological changes are due to alteration
in cell size and shape rather than a change in cell number. Overall, these findings support
the notion that CB2R inverse agonists can regulate neuroinflammation by polarizing the
pro-inflammatory M1 microglia phenotype towards the beneficial M2 phenotype, thus
providing neuroprotection.
Effects of Compound 45 Treatment on Phosphorylation of Six Signaling Proteins in
Human Microglia
A review of the literature demonstrates a paucity of data on the anti-inflammatory
signaling mechanism of CB2R inverse agonists in microglia (Ribeiro et al., 2013). The
majority of the studies focused on CB2R agonists as anti-inflammatory agents in which
are reviewed by (Leleu-Chavain et al., 2012). Therefore, we sought to investigate the
phosphorylation of several signaling molecules that are involved in microglia activation
and CB2R signaling pathways including p-NF-κB, p-ERK1/2, p-CREB, p-p38, p-cJun,
and p-JNK.
In this study, SV40 cells were stimulated with LPS (100 ng/ml) for 30 minutes
followed by treatment with compound 45 (at 35 μM) at six different time points 45, 60,
90, 150, 210 and 390 minutes (Figure 3-11). At the end of the experiment, cells were
lysed with the manufacturer's lysis buffer and the protein phosphorylation levels were
measured for LPS control and compound 45 treated wells. The addition of compound 45
post LPS stimulation resulted in a general insignificant decrease in p-NF-κB protein
levels over the course of the kinetic experiment at 45, 60, 150, 210 and 390 minutes
intervals with the exception of 90 minutes wherein a significant decrease was observed
compared to LPS (P < 0.05). The level of phosphorylated ERK1/2 was unaffected by
compound 45 treatment at 45, 60 and 90 but after 90 minutes a time-dependent decrease
of the p-ERK1/2, that dropped below the basal levels, was significant at 390 minutes
compared to LPS (P < 0.01). Compound 45 treatment initially increased the p-CREB at
45, 60 and 90 compared to LPS but the increase was insignificant. Additionally,
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Figure 3-10. Morphological Assessment of Compound 45 Treatment in LPS
Stimulated SV40 Cells.
Cell treatments were A) control, B) LPS (1 μg), C) LPS + compound 45 (at 10 μM) and
images acquired after 24 h. Cells were stained with the nuclear stain DAPI (blue) and
actin filaments visualized with phalloidin (green). B) LPS treatment reveals an increase
in size with rounded shape morphology. C) Treatment with compound 45 increased the
ramified and rod-shaped morphology. White bars in each photomicrograph represent 100
μm and ten fields were taken per group.
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Figure 3-11. Effects of Compound 45 Treatment on Signaling Proteins in LPS
Stimulated SV40 Cells.
Cells were treated with compound 45 (at 35 μM) and the protein phosphorylation levels
of (A) p-NF-κB, (B) p-ERK1/2, (C) p-CREB, (D) p-p38, (E) p-cJun, (F) p-JNK were
measured at 45, 60, 90, 150, 210 and 390 minutes. Asterisks above columns are
comparisons relative to LPS (100 ng/ml) control (* P < 0.05, ** P < 0.01, *** P < 0.001,
**** P < 0.0001). N= 6 and error is SEM.
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compound 45 triggered a sharp and steady increase in p-p38 levels at 90 (P < 0.01), 150
(P < 0.0001), 210 (P < 0.0001) and 390 minutes (P < 0.01) compared to controls.
Moreover, initial decreased in p-c-Jun was seen at 45, 60 and 90 minutes followed by a
time-dependent rise that reached significance at 150 (P < 0.05), 210 (P < 0.001) and 390
(P < 0.01) minutes relative to LPS alone. Taken together, the above results revealed that
compound 45 suppressed the phosphorylation of NF-κB and ERK1/2, while p-38, JNK,
c-Jun, and CREB, exhibited early and late increases compared to LPS alone. Moreover,
this study strengthens the idea that CB2R inverse agonists have a unique mechanism of
action in regulating microglia responses to pro-inflammatory stimuli by suppressing the
pro-inflammatory NF-κB, ERK1/2 and enhancing the anti-inflammatory p-38, JNK, c-Jun,
and CREB proteins activation.
Molecular Docking of Compound 45 into the Modified CB2R Crystal Structure
To further understand the ligand-protein interactions behind the inverse agonist
activity of compound 45, a molecular docking study was performed using Schrödinger
software. In this study, compound 45 was prepared using LigPrep tool that generates
multiple ligand conformations followed by energy minimization. Next, compound 45 was
docked into a modified CB2R crystal structure using Glide XP that generated several
binding modes and docking results were subjected to interaction analysis.
The docking results (Figure 3-12) showed that compound 45 engaged in several
aromatic stacking interactions with amino acid residues in TM 2, 3, and 6. Moreover, the
aromatic A ring formed π-π stacking with Phe 87, and the B aromatic ring established
aromatic stacking with Phe 183 (ECL2). The C ring constrained the toggle switch
residues Phe 117 and Trp 258 via multiple π-π stacking interactions (Figure 3-13) that
stabilize the CB2R in the inactive state, thus explaining the inverse agonist activity of
compound 45 in the ACTOne functional assay. To validate docking results, a molecular
dynamic (1 μs) simulation was performed by Dr. Hevener that showed similar
ligand-protein interaction with toggle switch residue Trp 258 suggesting this docking
pose is stable during the simulation (data not shown).
Conclusion
The objective of this research project was to identify structural modifications of
our lead CB2R inverse agonist SMM-189 that improve affinity, selectivity, potency and
evaluate the in vitro efficacy in regulating microglia responses in comparison to LPS
stimulation. A series of twenty analogs having different A and C ring functional groups
in the biaryl/aryl menthone scaffold were synthesized to investigate the structure-activity
relationship. In general, the inclusion of electron-withdrawing groups in the 2, 3, and 5
positions of the A ring was tolerated; however, functional groups occupying the 4
positions, with or without other substitutions, on the A ring abolished activity.
Interesting, heterocyclic replacement of the 3,5-dichlorophenyl A ring in SMM-189
either abolished or resulted in analogs with poor affinity to either receptor. Contraction of
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Figure 3-12. The 2D Ligand Interaction Map for Modified CB2R Crystal
Structure with Compound 45.

Figure 3-13. Compound 45 Docked Pose with CB2R Modified Crystal Protein.
The structure of compound 45 is depicted in olive, the toggle switch residues are colored
green, other amino acid residues are shown in red, pi-pi stacking interactions are shown
in blue, and the CB2R crystal structure PDB is 5ZTY.

102

the C ring phenyl to thiophene yielded compounds with modestly increased affinity
relative to the parent phenyl analog and increased SR for CB2R. Compound 45 bearing
trifluoromethyl substitution at C-3`and a thiophene C ring had the best affinity and
selectivity for CB2R (Ki = 154 nM, SR = 64.9). The increased affinity of 45 also
translated to higher potency in the ACTOne functional assay (pEC50 = 7.4, % max = 57)
in HEK-CNG + CB2 cells, whereas no functional activity was detected in HEK-CNG and
HEK-CNG + CB1 cells. Moreover, testing compound 45 in TANGO-bla assay revealed
neutral antagonism pharmacological profile at β-arrestins signaling, confirming less
convoluted signaling pathway of this class of compounds. Additionally, the molecular
docking study of compound 45 revealed that the thiophene C ring constrained the toggle
switch residue Trp 258 via π-π stacking interaction that stabilized CB2R in the inactive
state (Li et al., 2019) and led to 45 inverse agonism activity at CB2R.
Prior studies have noted the importance of microglia surface markers in
neurodegenerative diseases, and it has been reported that pro-inflammatory
immunoglobulin Fc receptors CD 16, CD 32 are highly expressed in microglia associated
with plaques in AD patients (Melief et al., 2012; Peress, Fleit, Perillo, Kuljis, & Pezzullo,
1993; Zotova et al., 2013) and in amyotrophic lateral sclerosis (ALS) (Frakes et al., 2014)
Additionally, CD 68 is considered a unique marker for the M1 activated phenotype and
upregulation of this receptor in AD has also been observed (Zotova et al., 2013; Zotova et
al., 2011). On contrary, acquisition of the M2 phenotype has been reported to be
beneficial in AD mouse model by reducing neuroinflammation and Aβ aggregates
(Kiyota et al., 2010). Overall, the literature data suggest that microglia in AD are
predominately biased to a pro-inflammatory phenotype and not an M2 pro-wound healing
phenotype. Taking the advantage of selective upregulation of CB2R in AD patients
brains (Cristina Benito et al., 2003), MS (Palazuelos et al., 2008), PD (Garcia et al.,
2011a; Gómez-Gálvez, Palomo-Garo, Fernández-Ruiz, & García, 2016; Price et al.,
2009a), and HD (Palazuelos et al., 2009a), we have previously showed that CB2R inverse
agonist SMM-189 suppressed the pro-inflammatory markers CD 16/32, CD 11, CD 45,
CD 80 and enhanced the M2 associated markers CD 206, and CD 209 in murine (C.
Presley, A. Abidi, S. Suryawanshi, S. Mustafa, B. Meibohm, & B. M. Moore, 2015) and
human microglial cells (Reiner et al., 2015a). Therefore, we investigated the effect of
compound 45 on microglia M1/M2 surface markers. Treatment of activated microglia
with compound 45 attenuated the expression of CD 16/32, CD 68 (M1 markers) and
enhanced the expression of CD 206, and CD 204 (M2 markers) in murine and human
cells. The present findings are in agreement with C. Presley et al. and Reiner et al. who
suggested that CB2R inverse agonists alleviate neuroinflammation by biasing the
microglia towards M2 anti-inflammatory phenotype (the proposed mechanism of
neuroprotection associated with CB2R inverse agonist is described in Figure 3-14).
As discussed in the Walter et al. study, CB2R is highly expressed in the leading
edges of microglia, and the authors reported that CB2R agonists 2AG and AEA caused a
dose-dependent increase in BV2 cells migration that was correlated with
ERK1/2activation. The authors suggest CB2R agonists activate an ERK1/2 signaling
pathway resulting in the recruitment of microglia, and other immune cells, to the site of
injury (Walter et al., 2003). Therefore, we assessed whether compound 45 would affect
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Figure 3-14. Proposed Neuroprotection Mechanism for Selective CB2R Inverse
Agonists in Neurodegenerative Diseases.
In a neuroinflammatory condition, M1 activated microglia are dominant with the
enhanced expression of M1 surface markers such as CD 16, CD 68, in addition to the
production of harmful proinflammatory cytokines such as TNF-α and IL-1β that cause
neurotoxicity and amplify the inflammatory signal. Application of CB2R inverse agonists
polarize microglia toward M2 anti-inflammatory phenotype that is characterized by
enhanced M2 surface markers, release M2 cytokines, tissue repair, and, importantly,
neuroprotection.
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the migration ability of human microglia. Interestingly, compound 45 significantly
reduced the cell migration relative to LPS, confirming the notion that CB2R inverse
agonists may alleviate neuroinflammation via a distinct mechanism compared to CB2R
agonists. Moreover, the application of compound 45 suppressed the M1 associated ROS
production, which has been reported to cause neurotoxicity and cell damage in
Alzheimer's disease (Xie et al., 2002). A possible explanation for these results might be
that CB2R inverse agonists disrupt the neuroinflammatory cycle by biasing the microglia
towards M2 state, decreasing the microglia migration ability (i.e. decrease the recruitment
of other immune cells), suppressing ROS production, which together reduces the
damaging effects of neuroinflammation. It would be interesting to determine if these
anti-inflammatory effects from CB2R modulation are solely due to receptor inactivation
or other novel molecular targets.
In addition, it was important to ask whether compound 45 would affect microglia
morphology that could be correlated to a specific M2 phenotype. Therefore, I evaluated
the morphological changes after LPS treatment in the presence and absence of compound
45. The study showed that the morphology of microglia after LPS treatment transitioned
to a classical M1 activation phenotype characterized by enlarged, rounded cell
morphology with small, short processors (Wilms, Hartmann, & Sievers, 1997). Several
reports have suggested that amoeboid microglia morphology is associated with elevated
pro-inflammatory markers and chronic inflammation (M Mecha et al., 2015; Tam & Ma,
2014). In stark contrast, compound 45 triggered a morphological transformation in
stimulated microglia to a ramified microglia morphology with multiple cell projections
and one main lamellipodium suggesting the acquisition of the M2a phenotype (M Mecha
et al., 2015). My results strongly indicate that compound 45 polarizes or biases microglia
towards a specific M2 phenotype (M2a, based on microglia morphology) that has been
associated with increased IL-4 production, enhanced mannose receptor (CD 206)
expression, and neuroprotection (M Mecha et al., 2015; Zhou, Spittau, & Krieglstein,
2012). However, future work is needed to identify specific anti-inflammatory cytokines
that can accurately distinguish between multiple M2 (M2a, M2b, and M2c) phenotypes
(Walker & Lue, 2015).
In sum, my results showed that compound 45 altered the microglia phenotype
towards M2 state by increasing the expression of M2 markers, reducing M1 associated
markers, suppressing ROS production, and attenuating migration relative to LPS. These
results were consistent with the reported anti-inflammatory properties of cannabinoids in
the literature which has been reviewed by (Berdyshev, 2000). However, the underlying
mechanisms by which cannabinoids produce their anti-inflammatory effects are not fully
understood. As presented in Figure 3-15, compound 45 suppressed the pro-inflammatory
ERK1/2, and NF-κB, which were similar to the Ribeiro et al. study wherein it was
suggested that reduction in p-ERK1/2 and p-NF-κB are responsible for cannabinoids
anti-inflammatory effects in microglia (Ribeiro et al., 2013). Moreover, it has been
reported that ERK1/2 signaling activation is correlated with enhanced cell migration
(Klemke et al., 1997; Walter et al., 2003) confirming compound 45 reduced microglia
migration through ERK1/2 dephosphorylation. Additionally, enhanced p-p38, p-CREB,
p-c-Jun, and p-JNK were seen after compound 45 treatment of LPS activated microglia
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Figure 3-15. Proposed Signaling Mechanism for Anti-inflammatory Effects of
Compound 45 in Microglia.
Inverse agonists bind to the inactive state of CB2R, sequester Gαi which in turn increases
the cAMP level and PKA activity (possibly via unmasking of constitutive activity of
other GPCRs expressed in the cell). Activation of PKA regulates the suppression of
p-NF-κB, p-ERK1/2, and activation of p-CREB, p-p38, p-cJun, and p-JNK, which is
hypothesized to contribute to the decreased in CD 16, CD 68 M1 associated markers, and
stimulation of CD 204, and CD 206 M2 anti-inflammatory receptors. Therefore, CB2R
inverse agonists provide neuroprotection in neurodegenerative diseases by switching the
microglia phenotype from the M1 activated state to the alternative M2 phenotype.
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and studies related and unrelated to cannabinoid pharmacology have reported that these
signaling molecules enhanced the anti-inflammatory microglia (M2) phenotype (Correa
et al., 2010; A. Howlett, 2005; Lépicier, Bouchard, Lagneux, & Lamontagne, 2003;
Reiner et al., 2015a; Wu, Tang, Liu, Mao, & Wang, 2018).
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CHAPTER 4. IMMUNOREGULATION OF LPS ACTIVATED HUMAN
MICROGLIA USING SELECTIVE CB2 AGONISTS, AND INVERSE AGONISTS
Introduction
Of all the systems in the body, CB2R has the highest expression in the immune
cells, as reviewed by Munro and colleagues (Munro et al., 1993a), which is of great
significance in the CNS considering this upregulation is selective for activated microglia
under neuroinflammatory diseases. An example of this biological response in AD is
presented in the schematic shown in Figure 4-1, created based on the results reported by
Benito et al., Gómez-Gálvez and colleagues (Cristina Benito et al., 2003; Gómez-Gálvez,
Palomo-Garo, Fernández-Ruiz, & García, 2016). Additionally, the importance of CB2R
in neuroinflammation is evidenced by previous studies that have shown CB2R agonists
have the ability to modulate neuroinflammation in multiple disease models (LeleuChavain et al., 2012). For example, HU-308 was discovered in 1999 and characterized as
selective CB2R agonist lacking CB1R activity (Hanuš et al., 1999). Application of
HU-308 in inflammatory models demonstrated anti-inflammatory properties in vitro and
in vivo supporting the notion that CB2R is a novel therapeutic target for
neurodegenerative diseases (Garcia et al., 2011a; Gómez-Gálvez, Palomo-Garo,
Fernández-Ruiz, & García, 2016; Taylor et al., 2015). Moreover, JWH-133 was
discovered in the same year and demonstrated to possess a similar selective CB2R
activation (Huffman et al., 1999). This compound has shown to be neuroprotective in
animal models of AD (Martín-Moreno et al., 2012), HIV (Ramirez et al., 2013), PD
(Chung et al., 2016), and other in vitro inflammatory models (Correa et al., 2009; Correa,
Mestre, Docagne, & Guaza, 2005; C. Presley, A. Abidi, S. Suryawanshi, S. Mustafa, B.
Meibohm, & B. M. Moore, 2015).
More recently, CB2R inverse agonists have emerged as anti-inflammatory agents
with promising neuroprotective properties in various disease models. The first selective
CB2R inverse agonist SR144528 was discovered in 1998 (Rinaldi-Carmona et al., 1998)
and subsequently demonstrated to have anti-inflammatory effects in EAE infected mice
(Lou, Chen, He, Zhao, & Xiao, 2011) and LPS stimulated microglia (C. Presley, A.
Abidi, S. Suryawanshi, S. Mustafa, B. Meibohm, & B. M. Moore, 2015; Ribeiro et al.,
2013). As described in the previous chapters, SMM-189 was discovered in our lab and
characterized as a selective CB2R inverse agonist that exhibits promising antiinflammatory properties in vitro (C. Presley, A. Abidi, S. Suryawanshi, S. Mustafa, B.
Meibohm, & B. M. Moore, 2015) and in mTBI model (Guley et al., 2019; Liu et al.,
2017; Reiner et al., 2015a). All of the above studies support the crucial role of CB2R in
neuroinflammation, however, the underlying immunoregulatory mechanisms of CB2R
ligands are poorly understood.
In 2015, Presley et al. investigated the effects of selective CB2R agonists
(HU-308, JWH-133, Figure 4-2) and inverse agonists (SR144528, SMM-189, Figure
4-2) on M1/2 surface markers using LPS stimulated murine microglia. The study results
revealed that CB2R agonists HU-308 and JWH-133 suppressed the expression of M1 CD
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Figure 4-1. Microglia in the Healthy and AD Brains.
A) In the healthy brain, resting microglia serve as an active sensor that detects minor
changes in the brain microenvironment and characterized by a ramified morphology with
balanced M1/2 phenotypes. B) In Alzheimer's brain, beta amyloids (Aβ) trigger
polarization of microglia into activated M1 phenotype that is mainly characterized by
amoeboid morphology with increased pro-inflammatory markers (neurotoxic) and
importantly, upregulation of CB2R.
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Figure 4-2. Chemical Structures and hCB2R Signaling Bias for CB2R Agonists
and Inverse Agonists.
(A) HU-308, (B) JWH-133, (C) SR144528, and (D) SMM-189.
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16/32 and M2 CD 206 markers in drug-treated cells. Conversely, CB2R inverse agonists
SR144528 and SMM-189 attenuated only the expression of M1 CD 16/32, while the M2
CD 206 significantly enhanced in comparison to the LPS activated cells alone (C.
Presley, A. Abidi, S. Suryawanshi, S. Mustafa, B. Meibohm, & B. M. Moore, 2015). The
authors suggested that CB2R agonists modulated neuroinflammation by suppressing M1
and M2 microglial markers which were consistent with the responses of JWH‐133 in
Kupffer cells (Louvet et al., 2011). However, CB2R inverse agonists biased microglia
toward M2 pro-wound healing state which was subsequently verified in the in vivo
studies (Guley et al., 2019).
The selection of CB2R ligands in the majority of publications has largely been
based on the functional activity which, historically, has been limited to agonists and
antagonists. More recently, the functional effects of inverse agonists, formally used as
neutral antagonists, are gaining attention in research labs with extensive knowledge of
cannabinoid pharmacology. However, the recognition of CB2R downstream signaling
complexity and the biological consequences of “ligand bias” remains largely
unaddressed. In fact, it was not until 2017 that detailed profiling was performed for
commonly used CB2R ligands that showed compounds functional selectivity towards
certain signaling pathways. The results of Soethoudt et al. study revealed that 2 of the
most commonly used selective CB2R agonists, JWH-133 and HU-308, differed in their
efficacy in activating downstream signaling cascades. For example, a comparison of
HU-308 and JWH-133 revealed different potencies at cAMP inhibition (pEC50 8.53 and
8.38, respectively) and β-arrestin recruitment (pEC50 7.45 and 7.81, respectively). These
results translate to a β-arrestin-cAMP bias factor (BF) of 27.2 for HU-308 and 90.4 for
JWH-133. In other words, HU-308 is a relatively balanced CB2R agonist toward these
pathways while JWH-133 exhibits a strong bias towards β-arrestin recruitment
(Soethoudt et al., 2017). Another interesting result from the screening of these 2
compounds is that HU-308 triggered a significant activation (pEC50 = 6.58) of G-protein
inward rectifying potassium channels (GIRK) while JWH-133 lacked this activity. The
gold standard CB2R inverse agonist SR144528 showed an inverse agonist activity
towards the G-protein signaling pathway and only inhibitory activity against β-arrestins
when assayed against CP 55,940 at the EC80 (Soethoudt et al., 2017). It remains an open
question of how pathway bias operates in native systems, relative to reporter assays since
the proteome of native systems can vary significantly between cell types.
The CB2R is a very promising target for the development of novel therapies to
treat neuroinflammation via the regulation of microglial function. However, there is a
paucity of data on how and which pathways are affected, either activated or inhibited, by
agonist and inverse agonist of CB2R. The current lack of a detailed mechanism of CB2R
action on stimulated microglia is further confounded by the fact that different ligands can
exhibit a bias to different downstream pathways. Therefore, there is an urgent need to
understand the interplay between ligand bias, functional activity, and biological
responses. Thus, the aim of this chapter is to examine whether CB2R agonists and inverse
agonists with known bias will produce distinct biological responses under the same
experimental paradigm. In this project, pharmacological evaluation of selective CB2R
agonists HU-308, JWH-133 and inverse agonists SR144528 and SMM-189 were
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performed using ACTOne and TANGO-bla assays. The anti-inflammatory effects of the
four CB2R ligands were investigated in LPS stimulated human microglia using on cell
polarization assays to assess M1 and M2 microglia surface markers. Moreover, ROS
production and microglia migration were measured in the presence and absence of drugs
treatment. To further elucidate the effects of CB2R ligands on activated microglia,
cytoskeleton staining was performed to evaluate microglia morphological changes
associated with treatment. Lastly, molecular pathway studies were performed to
determine if in fact functional activity and/or ligand bias resulted in differences or
similarities in downstream signaling cascades.
Materials and Methods
Reagents
The HEK-CNG+CB2 cell line was purchased from Codex BioSolutions, Inc
(Gaithersburg, MD). Tango™ CNR2-bla was purchased from Invitrogen (Carlsbad, CA).
Immortalized Human Microglia - SV40 was purchased from ABM (Richmond, BC).
Puromycin, DMEM, penicillin/streptomycin, gentamicin, PBS, 0.25% Trypsin/EDTA,
Hank’s Buffer, HEPES, EDTA, Tris base, sucrose, MgCl2, and Poly-d-lysine coated
96-well plates catalog # 356461 were purchased from Fisher Scientific (Waltham, MA).
G418 was purchased from KSE Scientific (Durham, NC). FBS was purchased from
Atlanta Biologicals (Flowery Branch, GA). Ro 20-1724, acetonitrile, DMSO,
polyethylene amine, and fatty acid-free BSA were purchased from Sigma Aldrich (St.
Louis, MO). ACTOne Membrane Potential Dye was purchased from Codex BioSolutions
(Gaithersburg, MD). Forskolin and CP 55,940 were purchased from Tocris (Bristol, UK).
LiveBLAzer™-FRET B/G Loading Kit, Solution D, Recovery™ Cell Culture Freezing
Medium, FreeStyle™ Expression Medium, McCoy's 5A Medium (modified) (1X), fetal
bovine serum (FBS) dialyzed, Non-essential amino acids (NEAA), sodium pyruvate,
HEPES (1 M, pH 7.3), 0.05% Trypsin/EDTA, Zeocin ™, Hygromycin, Geneticin were
purchased from Invitrogen (Carlsbad, CA). Black-wall, clear-bottom, 96-well assay
plates #3603 were purchased from Corning (Corning, NY). Dojindo Molecular
Technologies IncSupplier Diversity Partner Cell Counting Kit-8 (NC9864731) was
purchased from Thermofisher (Waltham, MA). Lipopolysaccharide (LPS) from
Escherichia coli O111: B4 (L2630) was purchased from Sigma Aldrich (St. Louis, MO).
Antibodies CD 68 (ab213363), CD 204 (ab123946) and CD 206 (ab64693) were
purchased from Abcam (Cambridge, UK). The human CD 16 antibody was purchased
from R & D systems. Meso-Scale Discovery (MSD) high bind plates (L15XB), anti-rat
(R32AH-5), and anti-rabbit (R32AB-5) SULFO-TAG antibodies were purchased from
Meso-Scale Discovery (Gaithersburg, MD). Prigrow III Medium (TM003) was purchased
from ABM (Richmond, BC). CREB phospho-S133 kit (64CREPET), advanced ERK
phospho-T202 /Y204 kit (64AERPET), NFkB phospho-S536 kit (64NFBPET), P38
phospho-T180/Y182 kit (64P38PET), Phospho-JNK (Thr183 / Tyr185) (64JNKPEG) and
phospho-c-Jun (Ser63) cellular kit (64JUNPEG) were purchased from Cisbio (Bedford,
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MA). 12 wells BioCoat™ Collagen I Multiwell Plates (08-774-2) and actin cytoskeleton
staining kit (FAK100) were purchased from Thermofisher (Waltham, MA).
Cell Culture
CNR2-bla U2OS cell line was cultured in McCoy's 5A medium with 10%
dialyzed FBS, 1%P/S, 0.1 mM NEAA, 25 mM HEPES, 1 mM sodium pyruvate, 200
μg/ml Zeocin ™, 50 μg/ml Hygromycin, 100 μg/ml Geneticin. CNR2-bla cells were
passaged every 2 to 3 days or when confluence reach 80%. HEK-CNG + CB2 cells were
cultured in DMEM with 10% FBS, 1% P/S, 25 μg/mL G418, and 5 μg/mL puromycin.
HEK-CNG+CB2 cells were passaged every 2–3 days or when confluence reached 80%.
Immortalized SV40 human microglia were maintained in Prigrow III media with 1% P/S
and 10% FBS and were passaged every 2–3 days or when confluence reached 80%. Cell
culture flasks were changed every five passages or after two weeks of use.
ACTOne (G-Protein) Functional Assay
The ACTOne functional assay is used to measure the G-protein signaling as a
function of cAMP production following ligand binding to CB1/2 receptors. In this assay,
forskolin is used to activate adenylyl cyclase and phosphodiesterase (PDE) inhibitor (Ro
20-1724) is added to prevent the endogenous hydrolysis of cAMP by PDE enzymes. The
HEK-CNG + CB2 cells were plated in clear poly-D-lysine coated 96-well plates in
plating media (DMEM, 10% FBS, 1% P/S) at 50,000 cells/100 μL medium and plates
were incubated for 16-18 hours at 37°C / 5% CO2. The next day, 100 μL of ACTOne
membrane potential dye was added to each well and the plates were maintained at room
temperature for 1 h in the dark. 5X of tested compounds were prepared from 1 × 10−6 to 1
× 10−9 with 25 μmol/L Ro 20-1724, and 800 nmol/L forskolin in PBS with 2.5% (v/v)
DMSO. Once test compounds were added, plates were read using a BioTek (Winooski,
VT) plate reader (Ex 540 nm, Em 590 nm) for one hour. The data at 50 mins were
combined and analyzed to determine the compound's pharmacological activity. Six to
nine biological replicates were used for data analysis. The gold standard CP 55,940 was
used as a positive control in each experimental run and plate read is considered
acceptable if CP 55,940 has EC50 from 1 to 10 nM and % of cAMP suppression from 70
to 95.
Tango™ -BLA (β-Arrestins) Functional Assay
CNR2-bla cells were plated in black-wall, clear-bottom, 96-well assay plates in
FreeStyle™ Expression Medium at 50,000 cells/100 μL well and incubated for 16-18
hours at 37°C / 5% CO2. The next day, 10X stock of test compounds were prepared in
FreeStyle™ Expression Medium with 0.5% DMSO. The final concentrations of tested
compounds were 1 x 10-6 to 1 x 10-9. Test compounds were added to test wells, full
agonist control CP 55,940 (at 5 μM) was added to the stimulated wells and assay medium
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with 0.5% DMSO was added in the cell-free and unstimulated wells. The plates were
incubated in humidified 37°C/5% CO2 for 5 hours. After that, a 6X loading solution was
prepared as described in assay protocol and assay plates were removed from the
humidified 37°C/5% CO2 incubator and 20 μL of loading solution was added to each
well. The plates were incubated at room temperature for an additional 2 hours and
maintained in the dark to protect plates from light and evaporation. Plates were read
using Synergy 2 BioTek (Winooski, VT) plate reader (Ex 409/20 nm, Em 460/40 nm, Em
530/30 nm) and fluorescence reading were set to a bottom-read mode with optimal gain
and 5 reads. CP 55,940 served as a positive control for all runs and the acceptable run
was defined by CP 55,940 EC50 between 30-40 nM for CB2R, with % activation range
between 80-100%. Three to nine biological replicates were used for data analysis.
In order to determine antagonist activity, cells were plated at 50,000 cells/100 μL
well and incubated for 16-18 hours at 37°C / 5% CO2. Following day,10X stock of
antagonist compounds were prepared in assay medium with 0.5% DMSO and 10 μL of
antagonists were added to each well and incubated for 30 minutes in humidified 37°C/5%
CO2. 10X stock of EC80 concentration of CP 55,940 was prepared in an expression assay
medium with 0.5% DMSO. After 30 minutes of incubation with the antagonist, 10 μL of
CP 55,940 EC80 were added to each well and incubated in humidified 37°C/5% CO2 for 5
hours. After that, 6X loading solution was added to each well and the plates were
incubated at room temperature for an additional 2 hours and were covered to protect
plates from light and evaporation. Plates were read using Synergy 2 BioTek (Winooski,
VT) plate reader (Ex 409/20 nm, Em 460/40 nm, Em 530/30 nm) and fluorescence
reading were set to a bottom-read mode with optimal gain and 5 reads. At least four
biological replicates were used for data analysis.
Cytotoxicity Assay
SV40 cells were plated at 5000-10,000 cells/well (100 μl/well) on a 96 well plate
and incubated for 24 hours at 37 °C 5% CO2. On the second day, the 10% FBS media
was replaced with 1% FBS media and plates incubated for 24 hours at 37 °C 5% CO2.
Following day, drugs (HU-308, JWH-133, SR144528, and SMM-189) were added at
final concentrations 10-4 to 10-6.5 and plates were incubated for an additional 24 hours at
37 °C 5% CO2. After 24 h of incubation, 10 μL of CCK-8 Reagent was added to each
well and the plate was incubated for at least 2 hours in the incubator followed by
absorbance measurement at 450nm wavelength using BioTek plate reader.
M1 and M2 Human Microglia Cell Surface Markers
SV40 cells were plated on 96-well Meso Scale Discovery high bind plate at a
density of 20,000 cells in 50 μL (10,000 cells in 100 μL) per well and incubated at 37 °C
5% CO2 overnight. The following day, a 10% FBS medium was removed, replaced with
100 μL of 1% FBS medium and the plates were incubated for 18-24 hours at 37 °C 5%
CO2. After 24 h, LPS (final concentration 100 ng/mL) was added to each well and
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stimulated for one hour (except control wells received 1% FBS media). After 1h of LPS
stimulation, drugs (HU-308, JWH-133, SR144528, and SMM-189) were added at 3 μM
and plates were incubated for an additional 24 hours at 37 °C 5% CO2. The expression of
M1 (CD 16, CD 68) and M2 markers (CD 204, and CD 206) was assessed using 30 μL
per well of antibody prepared in PBS at a concentration of 2 μg/mL. After a two-hour
incubation on a shaker plate at 130 rpm, wells were washed using 150 μL PBS, and 30
μL per well of secondary antibody (anti-rat or anti-rabbit) containing sulfo-tag in PBS
was added at a concentration of 2 μg/mL. Plates were then incubated for an additional
two hours, washed three times with 150 μL per well of PBS, and read in 2X
surfactant-free read-buffer using a SECTOR Imager 2400 (Meso Scale Discovery).
Scratch Assay
SV40 cells were plated at 50,000 cells/ml on 12 wells collagen I coated plates and
incubated at 37 °C 5% CO2 overnight. On the second day, Prigrow III 10% FBS media
was replaced with 1% FBS media and the plates were incubated for 18-24 hours at 37 °C
5% CO2. On the third day, a scratch was made using 100 μl pipette tip and wells were
gently washed twice with 1% FBS Prigrow III media to remove detached and floating
cells. Cells were then stimulated with LPS (100 ng/ml) for LPS control and treated wells
for 30 mins (control wells received 1% FBS media only). After LPS stimulation, drugs
(HU-308, JWH-133, SR144528, and SMM-189, all at 3 μM) were prepared in 1% FBS
Prigrow III media containing LPS and added to the treatment group. Plates were
incubated for an additional 24 hours at 37 °C 5% CO2 and images were taken at 0 hours
and 24 hours and the number of cells migrated was analyzed using ImageJ.
ROS Detection
SV40 cells were plated at 10,000 cells/ml on 96 well black wall clear bottom
collagen I coated plate and incubated for 24 hours at 37 °C in 5% CO2. On the second
day, Prigrow III 10% FBS media was replaced with serum-free media and the plates were
incubated for 18-24 hours at 37 °C in 5% CO2. The following day, LPS at 1 μg/ml was
added to the wells (except control received serum-free media) for 30 minutes, followed
by drug addition at 3 μM concentration (HU-308, JWH-133, SR144528, and SMM-189).
The plates were incubated at 37 °C in 5% CO2 for six hours. Then, the media was
removed, dye was added to the cells at 20 μM concentration and incubated for an
additional 30 minutes in the incubator. Plates were washed twice with serum-free media
(phenol red-free) and fluorescence measurements were made using BioTek Synergy 2
(BioTek Instruments, Inc. Winooski, VT) with 485/20 excitation and 528/20 emission
filter and the read was set to bottom read for 45 minutes.
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Cytoskeleton Staining
SV40 cells were plated on 12 wells collagen I coated plate and incubated for
18-24 hours at 37 °C in 5% CO2. The following day, Prigrow III 10% FBS media was
replaced with 1% FBS media and the plates were incubated for 24 hours at 37 °C in 5%
CO2. The third day, cells were stimulated with IL-4 (100 ng/ml), IL-10 (100 ng/ml) and
LPS (1 μg/ml) for 30 minutes followed by addition of drugs (HU-308, JWH-133,
SR144528, and SMM-189) at 3 μM concentration to the treatment wells. Plates were
incubated for an additional 24 h at 37 °C in 5% CO2 and cells were fixed and
permeabilized using 1X permeabilizing solution. Cells were stained using actin
cytoskeleton staining kit (FAK100) according to manufacturer protocol.
TRITC-conjugated Phalloidin was used to detect F-actin and DAPI was used to stain the
nucleus. Fluorescence images were taken using the BZ-X microscope and five fields
were taken per each group.
SV40 Molecular Pathway Study
The signaling pathways were measured to determine the level of phosphorylated
proteins c-Jun, ERK1/2, p-38, JNK, CREB, and NF-κB. The SV40 cells were plated at
50,000 cells/100 μL per well in Prigrow III media containing 10% FBS and plates were
incubated for 18-24 h at 37 °C in 5% CO2. The next day, full growth media was gently
removed and replaced with 100 μl of Prigrow III media containing 1% FBS media and
plates incubated overnight at 37 °C in 5% CO2. On the third day, LPS (100 ng/ml) was
added to LPS control and treated wells for 30 mins to stimulate the cells (negative control
wells received Prigrow III media with 1% FBS only). After 30 minutes, compounds
(HU-308, JWH-133, SR144528, and SMM-189) were prepared in 1% FBS media at 3
μM concentration and were added at three-time points, 60, 180, and 360 minutes. After
completion of the kinetic study, SV40 media was gently removed and cells were lysed
using Cisbio lysis buffer for (30-60) minutes. 16 μL of lysate was transferred into low
volume 96-well HTRF white plates and 2 μL of d2 (acceptor) and 2μL of Eu3+Cryptate
(donor) antibodies provided for the Advanced p-ERK1/2 (Thr202/Tyr204), p-CREB
(Ser133), p-p38 (Thr180/Tyr182), p-NF-κB (Ser536), p-JNK (Thr183/Try185), p-c-Jun
(Ser63) kits were added. The positive control was included in each assay by replacing the
cell lysate with supplemented lysis buffer. The assay was incubated at room temperature
overnight and the HTRF signal was analyzed with BioTek Synergy 2 Multidetection
Microplate Reader (BioTek Instruments, Inc. Winooski, VT) with flash lamp excitation
330/80 nm and emission at 620/10 nm and 665/8 nm.
Data Analysis
For the binding assays, Ki values were determined using Cheng and Prusoff
equation (Cheng & Prusoff). For the ACTOne data, the analysis was done using
nonlinear regression analysis and fluorescent measurements at 50 mins. The data were
normalized using a scaling equation:
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For the agonist study, A= Blank well-containing dye and cells only, B = Forskolin
stimulation, X` = Normalized value, X max = 100 %, X = min 0 %.
For the Tango-BLA assay, the analysis was done using fluorescent measurements.
The background (cell-free wells) was subtracted from both emission channels (460 nm
and 530 nm). Blue/Green Emission Ratio was calculated for each well by dividing the
background-subtracted blue emission values by the background-subtracted green
emission values.
Background-Subtracted Fluorescence (Fl) = Fl Sample – Fl Cell-free control
େ୭୳୫ୟ୰୧୬୫୧ୱୱ୧୭୬ሺସ୬୫ሻ

Emission Ratio (ER) = ୪୳୰୭ୣୱୡ୧୬୫୧ୱୱ୧୭୬ሺହଷ୬୫ሻ
For the Cisbio pathway study, these two equations were used for data analysis.
ୗ୧୬ୟ୪ሺହ୬୫ሻ

HTRF Ratio = ୗ୧୬ୟ୪ሺଶ୬୫ሻ Ͳͳ כǡͲͲͲ, CV % =

ୗ୲ୟ୬ୢୟ୰ୢୈୣ୴୧ୟ୲୧୭୬
ୣୟ୬ୖୟ୲୧୭
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Results and Discussion
Evaluation of CB2R Agonists and Inverse Agonists Functional Efficacy at
G-Proteins Activation and β-Arrestins Recruitment
Soethoudt et al. have previously characterized the efficacy of HU-308, JWH-133,
and SR144528 in activating G-proteins and β-arrestins pathways; however, the functional
assays used are not part of our standard pharmacological screening protocols for CB1R
and CB2R ligands. Since the major objective of this dissertation focuses on the
development of novel CB2R inverse agonists, it was necessary to characterize the
aforementioned ligands in parallel with SMM-189 to allow us to identify similarities and
differences in the functional activity which could be exploited to develop better CB2R
ligands. This is due to the fact that functional assays can generate considerable
discrepancies in EC50 values due to conditions and the reporter systems used, as we have
previously reported for the CB1R (Chaela S Presley, Abidi, & Moore II, 2016). To this
end, I utilized the ACTOne cell-based assay that measures the G-protein signaling as a
function of the cAMP level following ligand binding to CB2R. For β-arrestins
recruitment, the TANGO-bla assay was used that indirectly measures β-arrestins
recruitment at CB2R. For all functional assays, CP 55,940 was utilized as a positive
control since it is a full agonist at both signaling pathways.
Using ACTOne functional assay, the four compounds (HU-308, JWH-133,
SR144528, and SMM-189) were measured for G-protein activation in HEK-CNG + CB2
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cells. The CB2R agonists HU-308 and JWH-133 caused a dose-dependent suppression of
cAMP accumulation in HEK-CNG + CB2 cells yielding pEC50s of 7.5 and 7.7,
respectively (Figure 4-3A, Table 4-1). In our assay system, these compounds were
approximately one log unit lower in potency compared to the cAMP-Nano-TRF used by
Soethoudt et al (pEC50s = 8.53 and 8.38 for HU-308 and JWH-133, respectively).
However, the efficacies at inhibiting cAMP did not diverge as dramatically wherein
HU-308 was -70% and -80% for JWH-133 compared to Soethoudt’s -98% for both
ligands. One of the most striking deviations in potency but not efficacy is that of CP
55,940. In our system, the pEC50 of this compound is 8.105 and efficacy -80 which is not
significantly different from 12 other research groups, using various human assay systems,
with a mean pEC50 of 7.78 (p = 0.068) and efficacy of -73.8% (p = 0.65) as discussed by
(Chaela Sickbert Presley, 2016). However, the pEC50 = 10.33 (efficacy 98%) for CP
55,940 reported by Soethoudt et al. was significantly different (p = < 0.0001) from any
literature values for human assay systems.
The inverse agonist SR144528 and SMM-189 triggered an increase in cAMP
production, with pEC50s of 7.7 and 6.8 and efficacies of 113 and 82, respectively (Table
4-1, Figure 4-3A). In terms of SR144528, the potency and efficacy reported by
Soethoudt et al. (pEC50 = 7.67 and % max = 151) were comparable to our assay system.
The ACTOne was developed to monitor real-time changes in cAMP as a function of
membrane polarization while the cAMP-Nano-TRF assay is an endpoint assay. This
assay is based on cell lysis and subsequent detection of cAMP via the displacement of
this molecule with an antibody containing a fluorescence resonance energy transfer
(FRET) pair.
Another important difference is that we use Ro 20-1724 to prevent cAMP
degradation while 3-isobutyl-1-methylxanthine (IBMX) was used in the
cAMP-Nano-TRF assay. The former is a selective cAMP-specific phosphodiesterase type
IV (PDE4) inhibitor while the latter is a non-specific inhibitor of cAMP and cGMP
phosphodiesterases. The materials section in Ullmer, C. et al. work in the metabotropic
glutamate receptor 7, (Ullmer et al., 2012), who used forskolin to stimulate cAMP
production, yet this addition is not mentioned by Soethoudt et al (Soethoudt et al., 2017).
Additionally, the calibration curve for cAMP spanned 10 to 0.13 nM yet the calculated
EC50 is 46 pM thus it is not clear how this value was determined nor addressed in the
paper. Therefore, the differences in pEC50s highlight the importance of using a single
system to compare activity across different ligands when doing mechanistic studies.
In the β-arrestins recruitment, HU-308 and JWH-133 were agonists with pEC50s
of 6.6 and 6.0, respectively, wherein HU-308 demonstrated higher potency relative to
JWH-133 and comparable efficacy values (Table 4-1, Figure 4-3B). However, the pEC50
values reported by Soethoudt et at. were approximately one log unit higher in potency
with HU-308 and JWH-133 (7.4, and 7.8, respectively) compared to our assay system.
Moreover, in Soethoudt et al. study, JWH-133 exhibited higher potency in recruiting
β-arrestins relative to HU-308 (PathHunter β-arrestin recruitment assay) which was the
opposite of our assay results. In terms of efficacy, HU-308 and JWH-133 exhibited
comparable efficacy to the values reported by Soethoudt et al. study. Additionally, in our
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Figure 4-3. Functional Activity Evaluation of Selective CB2R Ligands at
G-Proteins and β-Arrestins Pathways.
(A) The functional activity of HU-308, JWH-133, SR144528, and SMM-189 in
HEK-CNG + CB2 cells (ACTOne assay). B) The functional activity of HU-308,
JWH-133, SR144528, and SMM-189 in U2OS + CB2 cells (TANGO-bla assay). C)
Antagonist study of SR 144528 and SMM-189 in U2OS + CB2 cells in the presence of
the EC80 of CP55, 940. N = 2-8, error is SD. CP 55,940 is used as a positive control in all
assays.
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Table 4-1.
Pharmacological Evaluation of CB2R Agonists and Inverse Agonists
at G-Proteins and β-Arrestins Pathways Activation.
Functional
Evaluation
at CB2R
CP 55,940

ACTOne Assay CB2R
Potency
Efficacy
(% max ±
(pEC50 ±
SD)
SD)
8.105 ± 0.06
-80 ± 2

Activity
at
G-Protein
Signaling
Agonist

TANGO-bla Assay CB2R
Potency
Efficacy
(ER ±
(pEC50 ±
SD)
SD)
7.446 ± 0.02
3.8 ± 0.06

Activity
at
β-Arrestin
Signaling
Agonist

HU-308

7.497 ± 0.04

-70 ± 2

Agonist

6.594 ± 0.04

2.7 ± 0.08

Agonist

JWH-133

7.688 ± 0.16

-80 ± 9

Agonist

5.995 ± 0.04

2.8 ± 0.14

Agonist

SR144528

7.686 ± 0.08

113 ± 6

Inverse
agonist

5.927 ± 0.17

0.3 ± 0.50

Neutral
antagonist

SMM-189

6.820 ± 0.12

82 ± 10

Inverse
agonist

5.687 ± 0.12

0.3 ± 0.52

Neutral
antagonist

In the ACTOne assay, negative values indicate cAMP suppression. In TANGO-bla
assays, the underline is the potency and efficacy in the presence of CP55, 940 EC80
(antagonist study). N = 2-8, error is the SD.
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assay system, CP 55,940 recruited β-arrestins with pEC50 value of 7.4, however,
Soethoudt et al. reported a significantly different value that is one log higher in potency
(pEC50 = 8.39, p = 0.001) and comparable efficacy (80% activation).
The inverse agonist SR144528 and SMM-189 did not alter the fluorescence ratios
thus indicating a lack of β-arrestins recruitment. The high affinity and potency in binding
and cAMP activation suggested that these compounds acted as neutral antagonists at
CB2R. To further confirm the activity, antagonist studies were conducted using
increasing concentrations of SR144528 and SMM-189 in the presence of CP 55, 940
maintained at the EC80. The experiments revealed that both ligands suppressed CP 55,940
emission ratio (3.8 versus 0.3) confirming neutral antagonism is present at CB2R
β-arrestins pathway (Table 4-1, Figure 4-3C). On contrary, the pEC50 of SR144528 in
PathHunter β-arrestin recruitment was one log unit higher (pEC50 = 7.47) compared to
our Tango-bla system with the same pharmacological profile as a neutral antagonist.
Overall, HU-308 and JWH-133 activated CB2R G-proteins and β-arrestins pathways,
while, CB2R inverse agonists SR144528 and SMM-189 demonstrated inverse agonism at
G-proteins and neutral antagonism at β-arrestins recruitment.
Effects of CB2R Agonists, Inverse Agonists on M1/M2 Human Microglia Cell
Surface Markers
A recent study reported by Soethoudt et al. that CB2R agonists HU-308 and
JWH-133 demonstrated interspecies differences in signaling bias between mice and
humans. In other words, HU-308 and JWH-133 were G-protein biased at mCB2R,
whereas HU-308 was a balanced ligand and JWH-133 showed signaling bias towards
β-arrestins at hCB2R (Soethoudt et al., 2017). This study highlighted an important
species differences in pathway coupling that could potentially contribute to the divergent
biological responses of cannabinoid ligands reported in the literature (Soethoudt et al.,
2017). Additionally, a prior study done by Presley et al. showed that CB2R agonists
HU-308 and JWH-133 suppressed the expression of M1 and M2 surface markers,
whereas CB2R inverse agonists SR144528 and SMM-189 reduced the expression of M1
markers and significantly enhanced the M2 associated markers expression in LPS
stimulated murine cells (C. Presley, A. Abidi, S. Suryawanshi, S. Mustafa, B. Meibohm,
& B. M. Moore, 2015). Thus, if interspecies differences affect the efficacy of CB2R
ligands in regulating microglia activation, it could have a significant impact when
translating experimental models to human efficacy. To investigate the potential
interspecies differences in pathway coupling, the aforementioned ligands were evaluated
for effects on cell surface markers utilizing immortalized human microglia (SV40). I
hypothesized that CB2R inverse agonists could provide more consistent results between
species by avoiding differences in cAMP activation and downstream β-arrestin coupled
pathways. Therefore, the efficacy of CB2R agonists and inverse agonists in regulating
M1/2 microglia markers were measured using on cell polarization assay.
Cytotoxicity assays were performed using increasing concentrations of CB2R
agonists (HU-308, JWH-133), inverse agonists (SR144528, SMM-189) and EC50 of each
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compound were determined (Figure 4-4). Additionally, since CB2R is upregulated in
activated microglia, the EC50s were also measured in the presence of LPS in the event
that increased CB2R expression could increase the cytotoxicity. As presented in Figure
4-4, the activation of microglia by LPS and the concomitant upregulation of CB2R did
not alter the EC50s. Therefore, these results suggest that CB2R ligands are viable targets
for regulating microglia activity since increased expression is not correlated with toxicity.
Based on the cytotoxicity results, a 3 μM concentration of the drugs was selected,
which was below the EC50s, to perform all the microglia experiments. To measure
changes in the microglial phenotype, the M1 (CD 16, CD 68) and M2 (CD 204, CD 206)
surface markers were examined. The SV40 cells were stimulated with LPS (at 100 ng/ml)
for 1 hour followed by treatment with HU-308, JWH-133, SR144528, and SMM-189 at 3
μM for 24 hours. The results revealed (Figure 4-5) that treatment with CB2R agonists
HU-308 and JWH-133 significantly suppressed the expression of M1 markers CD 16 and
CD 68 compared to LPS control (P < 0.0001). Moreover, CB2R agonists reduced the
expression of M2 associated markers CD 204 and CD 206 in comparison to LPS,
although only JWH-133 did so significantly with CD 206 (P < 0.001).
In the case of CB2R inverse agonists, SR144528 and SMM-189 also significantly
decreased the expression of M1 markers CD 16 and CD 68 relative to LPS stimulus (P <
0.0001) and significantly enhanced the expression of CD 204 (P < 0.01) and CD 206 (P <
0.0001, P < 0.001, respectively) compared to LPS. The activity of agonists and inverse
agonists on microglia phenotype, as measured by the expression of surface markers, are
consistent with the report of Presley et al. study (C. Presley, A. Abidi, S. Suryawanshi, S.
Mustafa, B. Meibohm, & B. M. Moore, 2015) indicating that agonists and inverse
agonists polarize murine and human microglia in an identical pattern. Specifically,
agonists HU-308 and JWH-133 suppressed the M1 and M2 markers, whereas inverse
agonists reduced the M1 and enhanced the M2 markers. It is worth noting that the
variation in the M1/2 suppression/activation magnitude between the two studies might
result from differences in ligands concentrations, CB2R expression, or might result from
the interspecies differences in signaling bias between mice and humans.
Effects of CB2R Agonists, Inverse Agonists on Human Microglia Migration
As previously discussed in Chapter 3, Walter et al. reported the presence of CB2R
in microglial lamellipodia and authors also demonstrated the ability of cannabinoid
endogenous agonists 2AG and AEA to trigger microglia migration confirming the
involvement of CB2R in these mediated effects (Walter et al., 2003). Furthermore, it was
proposed that CB2R agonists modulate neuroinflammation by restoring microglia
homeostasis (suppressing M1/2 markers), and also by increasing microglial migration
that might recruit other immune cells, thus providing neuroprotection (Ken Mackie &
Stella, 2006). Conversely, CB2R inverse agonists alleviate neuroinflammation by biasing
microglia towards M2 wound healing state and reducing microglia migration that
together attenuates the inflammatory signal.
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Figure 4-4. SV40 Cytotoxicity Assay (with and without LPS) for A) HU-308, B)
JWH-133, C) SR144528, and D) SMM-189.
N = 3, error is SD.
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Figure 4-5. On Cell Polarization Assays for CB2R Ligands Using Immortalized
Human Microglia.
Panels A and B) HU-308, JWH-133, SR144528 and SMM-189 (at 3 μM) significantly
reduced the expression of M1 markers CD 16 and CD 68 at 24h compared to LPS (100
ng/ml) control (**** P < 0.0001). Panels C and D) The expression of the M2 markers CD
204 and CD 206 were decreased with HU-308 and JWH-133 and significantly increased
with SR144528 and SMM-189 treatment (at 3 μM) in comparison to LPS at 24 h (** P <
0.01, *** P < 0.001, **** P < 0.0001). Asterisks above columns are comparisons to LPS
stimulus. N = 7-10, error is SEM.
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Therefore, the main objective of this study was to investigate the effects of CB2R
agonists (HU-308, JWH-133) and inverse agonists (SR144528, SMM-189) on microglia
migration using scratch assay. To this end, a scratch was made through SV40 microglia
using 100 μl pipette tip followed by 30 mins stimulation with LPS at 100 ng/ml. The cells
were then treated with LPS alone (at 100 ng/ml) or in combination with HU-308,
JWH-133, SR144528, and SMM-189 at 3 μM concentration and plates were incubated
for 24 hours. The scratched area was evaluated at two time points (0 and 24 h) and the
number of migrated cells was counted using ImageJ. As presented in Figure 4-6,
treatment with LPS alone triggered a significant increase in the number of migrating cells
indicating microglia polarization towards the M1 pro-inflammatory phenotype
(Karlstetter et al., 2011). Treatment with CB2R agonists HU-308 and JWH-133
decreased microglia migration in comparison to LPS, however, the decrease was
insignificant (Figure 4-6). Conversely, the application of CB2R inverse agonists
SR144528 and SMM-189 significantly attenuated microglia migration relative to LPS
(Figure 4-6, P < 0.05, P < 0.001, respectively) and the suppression levels were
comparable to the untreated cells. These data strongly support our hypothesis that CB2R
agonists alleviate neuroinflammation by restoring the balance between M1/2 microglia
phenotype and increasing migration relative to untreated cells, whereas, CB2R inverse
agonists polarize microglia to an anti-inflammatory M2 state and suppress cells
migration, thus providing neuroprotection.
Effects of CB2R Agonists, Inverse Agonists on Reactive Oxygen Species (ROS)
Production by Human Microglia
Studies have reported that neuroinflammation is the underlying cause of multiple
neurodegenerative diseases such as AD (McGeer & Rogers, 1992), PD (McGeer,
Yasojima, & McGeer, 2001), HD (Sapp et al., 2001), TBI (Dusart & Schwab, 1994).
During the neuroinflammatory cycle, resting microglia are polarized to an M1 activated
phenotype with the production of pro-inflammatory cytokines, NO, and ROS. As part of
this response, CB2R is upregulated in these M1 activated cells, providing an excellent
opportunity to utilize CB2R ligands as a potential therapeutic approach for these diseases
(Leleu-Chavain et al., 2012). As discussed in Ribeiro et al. study, CB2R agonists and
inverse agonists significantly reduced the ROS production in LPS stimulated murine and
human microglia confirming the neuroprotective role of these ligands in
neuroinflammation (Ribeiro et al., 2013). Therefore, I hypothesized that the attenuation
of ROS generation following a stimulus is one of the neuroprotective mechanisms of
CB2R agonists (HU-308, JWH-133) and inverse agonists (SR144528, SMM-189) in
activated microglia.
To measure the effects of CB2R agonists and inverse agonists on ROS production
in activated microglia, the dichlorofluorescin diacetate (DCFD) detection assay was used.
The SV40 cells were stimulated with LPS (at 1 μg/ml) for 30 minutes, followed by
treatment with HU-308, JWH-133, SR144528, and SMM-189 at 3 μM for six hours. At
the end of the experiment, DCFD dye was added to the wells at 20 μM and fluorescence
measurements were made using BioTek Synergy 2. As presented in Figure 4-7, LPS
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Figure 4-6. Scratch Assay for CB2R Ligands Using Immortalized Human
Microglia (SV40 Cells).
A scratch was made using 100 μl pipette tip followed by two washes with 1% FBS media
to remove detached and floating cells. Then, 1% FBS PriGrow III media was added to the
controls, LPS (100 ng/ml) was added to the stimulated wells for 30 mins followed by
application of HU-308, JWH-133, SR144528 and SMM-189 (3 μM) and the plates were
incubated for 24 hours. Images were taken at 0 and 24 hours and ImageJ was used to
count the number of migrated cells. Asterisks above columns are comparisons to LPS
control (* P < 0.05, ** P < 0.01, *** P < 0.001). N = 7-10, error is SEM.
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Figure 4-7. ROS Detection Assay for CB2R Ligands Using Immortalized Human
Microglia.
Treatment with HU-308, JWH-133, SR144528 and SMM-189 (at 3 μM) significantly
reduced the ROS generation in SV40 treated cells compared to LPS (100 ng/ml).
Asterisks above columns are comparisons to LPS control (** P < 0.01, **** P < 0.0001).
N = 24, error is SEM.
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alone resulted in a remarkable increase in ROS production, while treatment with CB2R
agonists and inverse agonists significantly suppressed ROS production. Application of
HU-308 and SMM-189 caused a significant suppression in ROS generation (P < 0.0001),
and interestingly, SMM-189 treatment reduced ROS below the basal level. Moreover,
JWH-133 and SR144528 treatment resulted in a significant attenuation in ROS
generation (P < 0.01) confirming our prediction that both CB2R agonists and inverse
agonists attenuate ROS generation. This effect could add an additional layer of
neuroprotection in neurodegenerative diseases. These results are consistent with Ribeiro
et al. study (Ribeiro et al., 2013) confirming the anti-inflammatory properties of multiple
CB2R ligands in inflammatory in vitro models.
Morphological Changes of Human Microglia Following CB2R Agonists, Inverse
Agonists Treatment
Resting microglia have the ability to transform to an M1 activated phenotype
following a stimulus or injury. The activated M1 state is mainly characterized by the
induction of pro-inflammatory mediators, expression of M1 inflammatory genes, and
morphological transformation into amoeboid morphology. The transition to the M2
wound healing phenotype responsible for tissue repair and remodeling stage is generally
characterized by a ramified morphology (Chhor et al., 2013). In a previous study done by
C. Presley et al., it was suggested that SMM-189 treatment polarizes M1 microglia into
M2 alternative phenotype after assessment of M1/M2 surface markers, cytokines
production and morphological changes post SMM-189 treatment. Application of
SMM-189 significantly increased the rode like cells in comparison to LPS, supporting the
acquisition of microglia M2 anti-inflammatory state (C. Presley, A. Abidi, S.
Suryawanshi, S. Mustafa, B. Meibohm, & B. M. Moore, 2015).
Therefore, in this study, we sought to investigate the morphological changes of
human microglia after CB2R agonists and inverse agonists treatment using cytoskeleton
staining kit and fluorescence microscopy. The SV40 cells were incubated with media
(negative control), LPS (1 μg/ml, M1 marker), 100 ng/ml of IL-4 (an M2a stimulus), 100
ng/ml of IL-10 (M2c stimulus), HU-308, JWH-133, SR144528, and SMM-189 (at 3 μM)
for 24 hours. At the end of the experiment, cells were fixed, permeabilized and stained
with phalloidin (cytoskeleton) and DAPI (nuclear) according to the manufacturer
protocol. As presented in Figure 4-8B, LPS treatment resulted in a remarkable
transformation of resting microglia into enlarged, rounded cell bodies with fewer
projections, supporting the acquisition of M1 activated phenotype (Abd‐El‐Basset &
Fedoroff, 1995). On the other hand, the application of IL-4 (Figure 4-8C) resulted in a
ramified, rode like morphology with main lamellipodium and multiple elongated small
projections consistent with another study done by Mecha et al. (M Mecha et al., 2015).
Additionally, resting microglia were transformed into slightly rounded cell bodies with
fewer projections when incubated with IL-10 (Figure 4-8D), indicting microglia
polarization into the M2c phenotype (M Mecha et al., 2015). Based on the distinct
morphological changes of microglia after the application of LPS, IL-4, and IL-10, we
investigated whether the morphology of drugs treated cells could be correlated with one
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Figure 4-8. Morphological Assessment of the Effects of A) Control, B) LPS (1
μg/ml), C) IL-4 (100 ng/ml), D) IL-10 (100 ng/ml) in Immortalized Human Microglia
(10 X).
Images acquired after 24 h of treatment. Cells were stained with the nuclear stain DAPI
(blue) and actin filaments visualized with phalloidin (green). White bars in each
photomicrograph represent 50 μm and five fields were taken per group.

129

of the above-described phenotypes (M1, M2a, and M2c). When microglia were treated
with HU-308 and JWH-133 (Figure 4-9A, B), cells demonstrated a mixture of rounded
and rod-like cells with few small processors. Application of SR144528 and SMM-189
(Figure 4-9C, D) resulted in a ramified morphology with a small cell body and several
elongated cell projections, although, SMM-189 treatment demonstrated significantly
higher cell ramification relative to SR144528. It is worth mentioning that all the
treatment groups possess a similar nucleus distribution suggesting that morphological
changes are due to alteration in cell size and shape rather than a change in cell count.
Taken together, the results indicate that CB2R agonists might restore the balance between
M1/2 states while CB2R inverse agonists bias microglia towards M2 alternative
phenotype, which in both cases can lead to neuroprotection.
Effects of CB2R Agonists, Inverse Agonists on Phosphorylation of Six Signaling
Proteins in Immortalized Human Microglia
Several cannabinoid ligands have demonstrated promising anti-inflammatory
properties in microglia (Leleu-Chavain et al., 2012); however, the underlying
mechanisms by which cannabinoids attenuated neuroinflammation are not fully clarified.
Therefore, we sought to determine the effects of CB2R agonists and inverse agonists on
phosphorylation of signaling proteins that are involved in microglia activation and CB2R
signaling pathways including p-NF-κB, p-ERK1/2, p-CREB, p-p38, p-cJun, and p-JNK.
To determine the effects of CB2R agonists and inverse agonists on
phosphorylated proteins, SV40 cells were stimulated with LPS (100 ng/ml) for 30
minutes followed by treatment with HU-308, JWH-133, SR144528, and SMM-189 (3
μM) at three different time points 60, 180, and 360 minutes. To end the experiment, cells
were lysed with the manufacture lysis buffer and the protein phosphorylation levels were
measured for the positive, negative controls, LPS and LPS plus drugs treated wells. Study
results showed that application of HU-308 significantly reduced the level of pERK1/2
(Figure 2-10A) only at 60 mins (P < 0.05) and JWH-133 demonstrated insignificant
increase at 360 minutes, whereas, SR144528 and SMM-189 significantly suppressed
pERK1/2 below the basal levels at 180 (P < 0.05, P < 0.01 for SR144528 and SMM-189,
respectively) and at 360 (P < 0.0001) minutes for SMM-189 only. The addition of
HU-308, JWH-133, and SR144528 (Figure 2-10B) resulted in an early insignificant rise
in p-CREB; however, SMM-189 significantly suppressed the levels of p-CREB at 60 (P
< 0.05) minutes. After 60 minutes, JWH-133 and SR144528 demonstrated a
time-dependent suppression in p-CREB that reached significance at 180 (P < 0.01) and
360 (P < 0.01) minutes. Moreover, application of HU-308 (P < 0.000), JWH-133 (P <
0.01), and SMM-189 (P < 0.000) resulted in a significant reduction of p-NF-κB at 60
minutes (Figure 2-10C). Additionally, a significant decrease was observed with
SMM-189 only at 180 (P < 0.05) minutes. At 360 minutes, treatment with HU-308 (P <
0.001), JWH-133 and SMM-189 (P < 0.01) caused a reduction in p-NF-κB that reached
significant level. Moreover, an initial decrease in p-p38 was observed with SMM-189 at
60 (P < 0.05) minutes followed by a time-dependent rise with the four compounds that
didn’t reach significance at 180 and 360 minutes in comparison to LPS (Figure 2-11D).
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Figure 4-9. Morphological Assessment of the Effects of A) HU-308, B) JWH-133,
C) SR144528, D) SMM-189 in Immortalized Human Microglia (10 X).
Images acquired after 24 h of treatment. Cells were stained with the nuclear stain DAPI
(blue) and actin filaments visualized with phalloidin (green). White bars in each
photomicrograph represent 50 μm and five fields were taken per group.
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Figure 4-10. Several Signaling Proteins Modulation upon HU-308, JWH-133,
SR144528 and SMM-189 Treatments in LPS Stimulated SV40 Cells.
Cells were treated with drugs (at 3 μM) and the protein phosphorylation levels of (A)
p-ERK1/2, (B) p-CREB, (C) p-NFκB were determined at 60, 180 and 360 minutes.
Asterisks above columns are comparisons relative to LPS (100 ng/ml) stimulus (* P <
0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001). N= 6 and error is SEM.
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Figure 4-11. Effects of HU-308, JWH-133, SR144528 and SMM-189 Treatment on
Several Signaling Molecules in LPS Stimulated SV40 Cells.
Cells were treated with drugs (at 3 μM) and the protein phosphorylation levels of (D)
p-p38, (E) p-c-Jun, (F) p-JNK were determined at 60, 180 and 360 minutes. Asterisks
above columns are comparisons relative to LPS (100 ng/ml) control (* P < 0.05, ** P <
0.01, *** P < 0.001). N= 6 and error is SEM.

133

In the case of c-Jun, HU-308, JWH-133, and SR144528 demonstrated an
insignificant rise (Figure 2-11E) in p-c-Jun except for SMM-189 that reached significant
levels at 360 (P < 0.05) minutes. An insignificant increase in p-JNK was seen at 60
minutes (Figure 2-11F) followed by a rise that reached significance with HU-308 (P <
0.01) and SMM-189 at 180 (P < 0.05) and at 360 minutes (P < 0.001, P < 0.05, for HU308 and SMM-189, respectively) relative to LPS alone. Overall, the results revealed that
CB2R agonists and inverse agonists resulted in a distinct modulation of signaling
molecules at the tested concentration, supporting our hypothesis that each class of ligands
has a unique mechanism to alleviate neuroinflammation.
Conclusion
The objective of this chapter was to pharmacologically evaluate two well-known
cannabinoids agonists (HU-308, JWH-133) and inverse agonists (SR144528, SMM-189)
at G-proteins and β-arrestins signaling and assess the in vitro efficacy of the four ligands
in regulating microglia responses post LPS stimulation. Based on the functional
evaluation, HU-308 and JWH-133 demonstrated full agonist activity with a comparable
potency and efficacy at the G-proteins pathway, whereas, HU-308 showed a higher
potency (pEC50 = 6.6) in recruiting β-arrestins with similar efficacy in comparison to
JWH-133. Conversely, SR144528 and SMM-189 exhibit an inverse agonist functional
profile with the exception of SR144528 showed a higher potency (7.7 versus 6.8) and
efficacy (113 versus 82) at G-proteins signaling compared to SMM-189. At β-arrestins
recruitment, both SR144528 and SMM-189 were neutral antagonists and this was
confirmed using a competition study against EC80 of CP 55,940. In terms of functional
selectivity, HU-308 and JWH-133 activated G-proteins and β-arrestins, while, SR144528
and SMM-189 exhibit a less complicated signaling pathway compared to the agonists.
In a continuation of an earlier study using murine microglia, the effects of CB2R
agonists and inverse agonists on the polarization of LPS stimulated human microglia
were examined. The purpose of this investigation was to evaluate whether HU-308,
JWH-133, SR144528, and SMM-189 would produce a similar or distinct biological
responses using human species and compare the results to previous work in murine
microglia (C. Presley, A. Abidi, S. Suryawanshi, S. Mustafa, B. Meibohm, & B. M.
Moore, 2015). This was particularly important considering that Soethoudt et al. recently
reported interspecies differences in HU-308 and JWH-133 signaling bias between mice
and humans (Soethoudt et al., 2017). These experiments were designed to get new
insights on data translation between species and how agonists and inverse agonists would
modulate M1/2 surface markers using LPS stimulated human microglia. The results of
the current study showed that the application of CB2R agonists HU-308 and JWH-133
significantly suppressed the expression of CD 16 and CD 68 (M1 markers) and the M2
associated markers CD 204 and CD 206 relative to LPS. Conversely, the addition of
SR144528 and SMM-189 resulted in a significant reduction in the expression of M1
related markers CD 16 and CD 68, and stimulation of the M2 markers CD 204 and CD
206 that reached significant levels in comparison to LPS. The above-described data
suggests that both CB2R agonists and inverse agonists demonstrated efficacy in
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providing neuroprotection; however, agonists modulated neuroinflammation in a distinct
way relative to inverse agonists. In other words, application of CB2R agonists (HU-308
and JWH-133) restore the balance between the M1 and M2 microglia phenotypes,
whereas, addition of CB2R inverse agonists (SR144528, and SMM-189) bias the
microglia towards M2 wound healing states which was seen and reported in vitro and in
vivo (Bu et al., 2016a; Guley et al., 2019; Liu et al., 2017; Reiner et al., 2015a).
As previously discussed in Chapter 3, Walter et al. reported the presence of CB2R
in the leading edges of microglia and demonstrated the ability of several agonists to
modulate microglia migration (Franklin & Stella, 2003; Walter et al., 2003). Therefore,
the goal of this study was to determine if the agonists and inverse agonists would have
distinct biological responses to microglia migration. In LPS activated human microglia,
HU-308 and JWH-133 induced a small but insignificant decrease in microglia migration
relative to LPS; however, the two treatments caused a higher cell migration compared to
untreated control. The application of SR144528 and SMM-189 resulted in a significant
reduction in microglial migration in comparison to LPS, and the number of migrated cells
post CB2R inverse agonists treatment was comparable to the untreated cells. As we know
from prior studies that CB2R is involved in mediating microglial migration; however, the
lack of knowledge on how CB2R agonists and inverse agonists modulate microglial
migration requires further investigations. It was hypothesized by Walter et al. that CB2R
activation induced microglia migration which proposed to recruit additional immune
cells, thus reducing neuroinflammation (Walter et al., 2003). Herein, I hypothesized that
CB2R inverse agonists treatment results in a reduction of microglia migration that
decreases the recruitment of other immune cells and subsequently alleviates
neuroinflammation. These findings enhance our understanding of the critical immune
role of CB2R in neuroinflammation and provide new insights on utilizing agonists and
inverse agonists as novel anti-inflammatory agents in neurodegenerative diseases.
The above results demonstrated the beneficial anti-inflammatory effects of CB2R
agonists and inverse agonists in LPS activated human microglia. It was logical to ask
whether CB2R ligands have the ability to modulate ROS production that has been
strongly linked to a self-propelling cycle that sustains M1 microglia activation (Lijia,
Zhao, Wang, Wu, & Yang, 2012). Our results have shown that both CB2R agonists and
inverse agonists significantly suppressed ROS production in comparison to LPS;
however, the intensity of ROS suppression by the ligands is different. A possible
explanation of these results might be the differences in ligands functional selectivity
towards certain signaling pathway, and/or other off-target effects that might be activated
at the used concentration. This finding, while preliminary, suggests that one of the
neuroprotection mechanisms of CB2R ligands is that suppression of ROS production in
the activated M1 microglia, consistent with the results of Ribeiro et al. who demonstrated
attenuation in ROS generation using CB2R agonists and inverse agonists in LPS
stimulated murine and human microglia (Ribeiro et al., 2013).
It is known that resting microglia change their phenotype after stimulation with
LPS into an enlarged, rounded cell with short and fewer processors, consistent with the
acquisition of M1 pro-inflammatory phenotype (Wilms et al., 1997). Conversely, IL-4
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polarizes microglia towards M2a alternative phenotype that is associated with tissue
repair, regeneration and reduced inflammation (Walker & Lue, 2015). Moreover, IL-10,
an anti-inflammatory cytokine, induces microglia polarization into acquired deactivated
M2c phenotype that is linked to the induction of several growth factors such as TGF-β
with neuroprotection (for excellent reviews, see (Franco & Fernandez-Suarez, 2015;
Walker & Lue, 2015)). A recent study was done by Mecha et al. who demonstrated that
endogenous cannabinoid ligands 2AG and AEA induced rat microglia polarization
towards M2a alternative phenotype (M Mecha et al., 2015). Therefore, this study was
designed to evaluate the morphological changes after LPS treatment in the presence and
absence of HU-308, JWH-133, SR144528, and SMM-189 with the aim to assess whether
drugs treatment would induce specific morphological changes that could be linked to a
state of microglial polarization. The results revealed that the application of HU-308 and
JWH-133 caused a similar microglia morphology characterized by round and rod-shaped
cells with short processors. The agonists presented morphology is distinct from M1 and
M2 phenotypes; however, it was very similar to the untreated cells. The addition of
SR144528 and SMM-189 caused a remarkable induction in cell ramification that was
closely related in morphology to the IL-4 treated cells, suggesting microglia polarization
towards the M2a phenotype. Based on the discussed results, I proposed that CB2R
agonists provide neuroprotection by restoring the balance between M1/2 microglia
phenotypes, while, CB2R inverse agonists induce cells polarization to an alternatively
activated state, thus alleviating neuroinflammation (Figure 4-12). A further study with
more focus on M2a, M2b, and M2c released cytokines is therefore suggested.
The present studies provided additional confirmation that CB2R is a novel target
for treating multiple neuroinflammatory conditions (Ashton & Glass, 2007) and supports
the notion that both CB2R agonists and inverse agonists provide neuroprotection in
inflammatory in vitro murine and human models (Ribeiro et al., 2013). Moreover, the
results of the molecular pathway study revealed a distinct modulation of signaling
proteins between agonists and inverse agonists that was clearly apparent with p-ERK1/2 in
which HU-308 and JWH-133 demonstrated different responses at later time point.
Specifically, JWH-133 resulted in the induction of cell migration relative to untreated
control that can be correlated to the increase in p-ERK1/2 at 360 minutes based on the
reports that ERK1/2 is an important regulator of cells motility and migration (Klemke et
al., 1997). HU-308 demonstrated weaker responses in the induction of cell migration and
ERK1/2 phosphorylation in comparison to JWH-133. These data are consistent with a
recent study done by Taylor et al. who reported the induction of murine macrophages
chemotaxis and p-ERK1/2 post HU-308 and JWH-133 treatments (Taylor et al., 2015). In
contrast, SR144528 and SMM-189 caused a significant and time-dependent reduction in
p-ERK1/2 that was correlated with the decreased microglia migration, confirming Ribeiro
et al. study that showed SR144528 significantly suppressed p-ERK1/2 in LPS activated
BV2 cells (Ribeiro et al., 2013). In general, CB2R ligands caused an initial and late
increase in p-CREB, p-p38, p-c-Jun, and p-JNK and significant suppression of p-NF-κB
that together might alleviate neuroinflammation and provide neuroprotection. In future
investigations, it might be possible to evaluate proteins signaling at higher concentration
using the predetermined EC50 for each ligand, examine other signaling molecules
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involved in induction of microglia polarization such as STAT-1, STAT-3, STAT-6 and
measure the pro and anti-inflammatory cytokines production following drugs treatment.

Figure 4-12. Anti-inflammatory Effects of CB2R Agonists and Inverse Agonists in
LPS Activated Microglia.
In LPS stimulated cells, resting microglia are polarized to an M1 activated phenotype
with increased production of pro-inflammatory markers and ROS production. The
application of CB2R agonists restores the homeostasis between the M1/2 microglia
phenotypes with attenuation in ROS and pro-inflammatory signaling proteins.
Conversely, the addition of CB2R inverse agonists bias microglia towards the M2 wound
healing state with a significant suppression in ROS and pro-inflammatory signaling
molecules. Taken together, both CB2R agonists and inverse agonists modulate
neuroinflammation in a distinct way that leads to neuroprotection.
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CHAPTER 5.

CONCLUSION

Background
In neuroinflammation, the expression of CB2R is highly upregulated in microglia
in several neurodegenerative diseases such as AD (Cristina Benito et al., 2003; Solas et
al., 2013), PD (Price et al., 2009a), and HD (Palazuelos et al., 2009a). Thus, selective
upregulation of CB2R provides a great opportunity to utilize CB2R ligands as a new
therapeutic approach for treating neurodegenerative disorders. Indeed, significant effort
has been placed on developing novel CB2R agonists - many of which are or have been
evaluated clinically (Fox & Bevan, 2005; Leleu-Chavain et al., 2012). Conspicuously
absent are development programs outside the academic environment investigating CB2R
inverse agonists to treat neuroinflammation. It is clear from our in vitro and in vivo
studies on microglia and murine traumatic brain injury, respectively, that CB2R inverse
agonist offers an alternative approach to agonists which have as yet not performed well in
clinical trials. Therefore, the main focus of this dissertation was 1) to identify the
molecular interactions of CB2R ligands leading to functional switching resulting from
modifications to the SMM-189 scaffold; 2) measure the pharmacological activity of a
library of new analogs of SMM-189; and 3) conduct comparative mapping of the
biological actions of CB2R ligands, as a function of receptor functional activity, on
microglia function. The overreaching goal of my research was to refine and develop our
hypothesis that CB2R inverse agonists offer superior efficacy in regulating microglia
function compare to agonists of the receptor. Ultimately, it is hoped, that the outcome
from this research could be, in part, a catalyst to invigorate research efforts to develop
CB2R inverse agonists as a novel anti-inflammatory therapy for CNS related disorders.
This is an important set of questions to be investigated since I hypothesize that selective
CB2R inverse agonists could effectively alleviate neuroinflammation without the
complication of competing for downstream signal pathway activation due to ligand bias
of CB2R agonist.
Summary of Research Findings
To date, a limited number of CB2R inverse agonists have been studied in terms of
ligand interactions with the receptor. Central to our hypothesis is the presumption that
CB2R inverse agonists offer superior efficacy in regulating neuroinflammation compared
to CB2R agonists. To refine the knowledge of the molecular interaction of our CB2R
inverse agonist, molecular modeling studies were performed on analogs of our lead
compound SMM-189. Specifically, Chapter 2 investigated the structure-activity
relationship (SAR) at C1` position of biaryl aryl menthone scaffold by measuring the
affinity and functional activity at hCB1/2 receptors using ACTOne and TANGO-bla
reporter assays. The chemical structure of our lead compound SMM-189 contains a
ketone, suggesting sp2 carbon attached to an electron-withdrawing group (EWG) is
favorable. If this hypothesis was true then modification of the C1` to an sp3 carbon or
removing the EWG on the sp2 carbon should affect the potency, efficacy, and functional

138

activity of our lead compound SMM-189. Thus, to test the validity of my hypothesis, I
measured the pharmacological properties of a group of C1` modified analogs of
SMM-189 for activity on cAMP stimulation. The studies testing the hypothesis bore out
that in fact, sp2 carbon is necessary to maintain CB2R inverse agonist activity. The
studies also indicated that steric bulk exceeding 1 atom on the C1` sp2 carbon is not
tolerated in the ligand-binding pocket of the inactive conformation of CB2R.
Specifically, converting the ketone to an ethylene group (sp2-sp2 carbons with 2
hydrogens and no EWG) preserved inverse agonist activity - albeit potency and efficacy
declined. The oxime functional group retained the sp2 carbon and EWG along with an
increase in size, i.e. 2 atoms represented by a hydroxyl group, but this analog switched to
a neutral antagonist with concomitant loss of potency and efficacy. Replacing ketone
with a menthol group (sp3 carbon with an EWG) yielded a neutral antagonist for CB2R
with reduced potency at the receptor. An inversion in functional activity was observed
when the C1` position was modified to a gem-dimethyl (sp3 carbon with 2 methyl groups)
which significantly enhanced the pharmacological profile towards CB1/2 receptors as
well as switching the functional activity to a full agonist of both receptors. Interestingly,
removal of the 2 methyl groups at the C1` provided the methylene analog of SMM-189
(sp3 carbon with 2 hydrogens) causing yet another switch in functional activity from a
full agonist to a neutral antagonist which significantly improved affinity and selectivity
towards CB2R in comparison to SMM-189. Thus, from the results of these experiments,
the initial hypothesis was proven to be true with the caveat that – in addition to the
requirement of an EWG attachment to the C1`sp2 carbon – only a single atom can be
attached to the C1` if inverse agonist activity is to be retained.
Additional studies were conducted to determine the ligands mediated β-arrestins
recruitment at the CB1 and CB2 receptors. Our lead compound SMM-189 did not affect
emission ratio, and by extension β-arrestins recruitment, suggesting SMM-189 is a
neutral antagonist at the β-arrestins pathway. This was further confirmed by a
dose-response study of SMM-189 against EC80 of CP 55,940 confirming neutral
antagonism is present at CB2R β-arrestins signaling. Moreover, the ethylene substitution
at the C1` demonstrated a similar pharmacological profile as SMM-189 in which neutral
antagonism is detected at CB2R β-arrestins pathway. The other C1` modified analogs
(oxime, menthol, and methylene) demonstrated neutral antagonism at CB2R β-arrestins
signaling. Surprisingly, the gem dimethyl compounds showed an agonist activity with
high potency and moderate efficacy at CB2R β-arrestins pathway, whereas, the
compounds exhibited weak agonist activity in recruiting β-arrestins at CB1R.
It is not uncommon that relatively small functional group modification in
compounds affect potency and efficacy; however, it is uncommon that a small
modification at a single position results in molecules exhibiting a spectrum of functional
activities for a G-protein coupled receptor, i.e. inverse agonist to neutral antagonist to full
agonist. Specifically, in the antagonist studies, all the SMM-189 analogs exhibited
orthosteric antagonism against CP 55,940 indicating the binding pocket in CB2R was the
same. This observation and the functional switching pharmacological profiles, discussed
above, were far too intriguing for me not to try to understand the molecular basis for this
unique effect on CB2R functional activity. Therefore, molecular modeling techniques
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were employed to determine if the hybridization of the C1` carbon, as well as
substitution, had a directing effect on the interactions of the biaryl (rings A and B) or aryl
(ring C) with the toggle switch residues in CB2R. The molecular docking studies
revealed that ring C in BMM-V-43 structure (contains an ethylene group) established
multiple aromatic π-π stacking interactions with Trp 258 residue in TM6, suggesting
these interactions maintain CB2R in the inactive state, thus inverse agonism of
BMM-V-43 is observed at G-protein signaling of CB2R. On contrary, BMM-V-21 and
BMM-V-23 (gem dimethyl analogs) demonstrated agonist activity at both CB2R
signaling pathways and molecular modeling results showed that both compounds didn’t
constrain Trp 258 residue, allowing upward movement of helix VI and CB2R activation.
While, neutral antagonists (19, 27 and 29) demonstrated weaker or no interactions with
the toggle switch residue Trp 258, suggesting this class of ligands (neutral antagonists)
might interact equally with both active and inactive CB2R conformations that led to the
neutral antagonism at CB2R.
The identification of the functional group requirements at the C1` was but one
piece of critical information on the SAR of the SMM-189 scaffold of CB2R inverse
agonist. We had previously examined functional group effects of C ring modifications in
SMM-189 as well as the requirement for the resorcinol B ring; however, the effects on
potency and efficacy in A ring modifications of SMM-189 remained unexplored. To
expand the SAR, I measured the effects of various A ring modification of twenty analogs
of SMM-189, synthesized in our lab, on the affinity and pharmacological activity in the
biaryl/aryl menthone scaffold. Within this series of compounds, I discovered that
compound 45, containing a trifluoromethyl phenyl A ring and a thiophenyl C ring
improved affinity and selectivity towards CB2R (Ki = 154 nM, SR = 64.9). Additionally,
compound 45 behaved as a highly potent CB2R inverse agonist with modest efficacy
(pEC50 = 7.4, % max = 57) in the ACTOne functional assay lacking activity at CB1R.
Compound 45 was a neutral antagonist in β-arrestins signaling, without effect on
β-arresting recruitment for CB1R, indicating functional selectivity of compound 45
towards the CB2R and modification of G-protein pathway activation.
The results from my previous molecular modeling studies were then used to
determine if in fact the SAR proposed above was valid in the new SMM-189 analogs.
Molecular docking of compound 45 into modified CB2R crystal structure showed that the
thiophenyl C ring blocked the toggle switch residue Trp 258 by forming π-π stacking
interactions that maintained CB2R in the inactive state, thus this interaction resulted in 45
inverse agonist activity at CB2R as measured by cAMP activation.
The high potency and selectivity of compound 45 provided an exciting
opportunity to expand on the mechanisms of the anti-inflammatory effects of this
compound class in activated microglia. With regard to SMM-189, studies on these effects
were largely limited to the measurement of changes in phenotype yet lacked mechanistic
details in the effects on downstream signaling activity. How this class of compounds
regulated downstream signaling was unknown and as such I expanded on previous
studies to collect data on this current deficient in our knowledge. First I determine if
compound 45 regulated the phenotype of murine and human microglia stimulated with
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LPS similarly to SMM-189. The results showed that compound 45 significantly
suppressed the expression of M1 pro-inflammatory markers and enhanced the expression
of M2 associated markers in both murine and human cells. Moreover, the addition of
compound 45 resulted in a ramified cell morphology with multiple body projections,
supporting our hypothesis that 45 polarizes microglia towards M2 anti-inflammatory
state, disrupts the neuroinflammatory cycle, thus alleviates neuroinflammation. This
effect paralleled earlier results using SMM-189 to regulate activated microglia suggesting
a common pathway(s) are involved in this class of CB2R inverse agonist.
The correlation of compound 45 with SMM-189 provided the basis for a more
extensive project to go beyond basic markers and probe the effects on this class of CB2R
inverse agonist on microglia function. To this end, compound 45 was tested for effects on
activated microglia in migration and ROS assays. These studies revealed that 45
significantly suppressed the microglia migration and ROS production, supporting the
acquisition of M2 alternative phenotype. How CB2R inverse agonists regulate microglia
downstream signaling is largely unknown; therefore, I measured the effects of compound
45 on signaling pathways known to be activated in LPS stimulated microglia as well as
potential pathways that CB2R could affect microglia polarization toward an alternative
M2 activation state. These studies revealed that 45 suppressed p-ERK1/2 and p-NF-κB
levels, which were consistent with Ribeiro et al. study (Ribeiro et al., 2013), and
enhanced p-p38, p-CREB, p-c-Jun, and p-JNK in comparison to LPS. The activation of
these pathways, previously unexplored, suggest that inverse agonist may have unique
regulatory mechanisms relative to CB2R agonist. Furthermore, I hypothesize that
compound 45 binds to the inactive state of CB2R, sequesters Gαi which subsequently
activates PKA, possibly via unmasking constitutively activity of other G-protein coupled
receptors, enhancing p-p38, p-CREB, p-cJun, p-JNK and block p-ERK1/2, p-NF-κB;
together leads to neuroprotection (Figure 5-1). It is worth mentioning that several factors
could potentially influence the overall results such as ligands functional selectivity, cell
type, CB2R expression, and experimental research methodology. Notwithstanding, I
propose that CB2R inverse agonists offer an alternative approach to treating
neuroinflammation without the complicating factors of ligand bias and alternative
pathway activation.
In further support of the benefits of CB2R inverse agonist over agonist, a
comparative study of “gold standard” CB2R agonists and inverse agonist was conducted
and compared to SMM-189 – which has demonstrated efficacy in the murine model of
traumatic brain injury. Under the same experimental conditions, the pharmacological
activity of HU-308, JWH-133, SR144528, and SMM-189 on downstream CB2R
signaling pathways and immune responses were investigated using LPS activated human
microglia. In terms of functional activity, HU-308 and JWH-133 are agonists at G-protein
activation (pEC50s of 7.5 and 7.7) and β-arrestins (pEC50s of 6.6 and 6.0, respectively)
recruitment, while, SR144528 and SMM-189 exhibit inverse agonism at G-proteins
(pEC50s of 7.7 and 6.8 for SR144528 and SMM-189, respectively) and neutral
antagonism at β-arrestins signaling, confirming less signaling complexity relative to the
agonists. Using on cell polarization assays, I found that HU-308 and JWH-133
suppressed both M1 and M2 microglia markers relative to LPS, while, SR144528 and
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Figure 5-1. Proposed Neuroprotective Mechanism of Compound 45 in LPS
Activated Human Microglia.
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SMM-189 reduced M1 and enhanced M2 related markers in LPS activated human
microglia. These results were consistent with Presley et al. study in murine cells (C.
Presley, A. Abidi, S. Suryawanshi, S. Mustafa, B. Meibohm, & B. M. Moore, 2015).
Additional testing was performed to measure the morphological effects using
cytoskeleton staining of drug-treated microglia. Treatment with HU-308 and JWH-133
caused morphological changes that were comparable to untreated cells, while application
of SR144528 and SMM-189 induced cell ramification, indicating microglia polarization
to M2 state. Therefore, I proposed that HU-308 and JWH-133 alleviate
neuroinflammation by restoring the homeostasis between M1/2 phenotypes, while,
SR144528 and SMM-189 polarize microglia towards the M2 anti-inflammatory,
pro-wound healing state.
Evaluation of the four ligands in migration and ROS assays revealed that CB2R
agonists modulated microglial migration in a distinct way relative to CB2R inverse
agonists. In the scratch assay, HU-308 and JWH-133 slightly decreased migration in
comparison to LPS and resulted in an insignificant increase in microglia migration
relative to untreated cells similar to their effects in macrophages (Taylor et al., 2015).
Conversely, CB2R inverse agonist SR144528 and SMM-189 resulted in a significant
reduction in microglia migration relative to the LPS stimulus. In the ROS assay, all the
four ligands significantly suppressed the production of ROS, indicating results
consistency with Ribeiro et al. study (Ribeiro et al., 2013) and confirming
neuroprotective roles of CB2R ligands in LPS stimulated microglia. Although the results
were consistent with other reports, how the effects translated into regulation of
downstream signaling remained an open question. Therefore, a molecular pathway study
was performed for the four ligands in SV40 cells. Interestingly, CB2R agonists (HU-308,
JWH-133, Figure 5-2) and inverse agonists (SR144528, SMM-189, Figure 5-2) caused a
distinct modulation of signaling proteins that was clearly apparent with p-ERK1/2 at 360
minutes. HU-308 treatment caused a slight induction in ERK1/2 phosphorylation relative
to JWH-133 that showed increased induction in p-ERK1/2 and microglia migration
compared to the untreated cells. These results were consistent with a study done by
Taylor et al. who reported stimulation of murine macrophages chemotaxis and p-ERK1/2
after HU-308 and JWH-133 treatments (Taylor et al., 2015). On contrary, CB2R inverse
agonists SR144528 and SMM-189 caused a significant and time-dependent decrease in
p-ERK1/2 that was linked to the suppression in microglia migration, confirming Ribeiro et
al. study who reported a significant suppression of p-ERK1/2 after SR144528 treatment in
LPS activated BV2 cells (Ribeiro et al., 2013). An intriguing result was the regulation of
p-cJun and p-JNK using SMM-189 compared to SR144528. This may suggest that within
the CB2R class of inverse agonists that: 1) off-target effects need to be considered in the
overall in vitro response, or 2) there may also be a form of ligand bias for inverse agonist
that has yet to be characterized.
Taken together, the discussed studies provided valuable insights into the
anti-inflammatory effects of CB2R ligands in stimulated human microglia. The
mechanisms underlying the immunoregulatory effects of CB2R ligands revealed a more
complex signaling pathway and the overall results make significant contributions to the
cannabinoids fields by confirming the notion that CB2R agonists and inverse agonists.

143

Figure 5-2. Proposed CB2R Agonist and Inverse Agonist Signal Transduction
Pathways in Human Microglia.
Agonist binds to CB2R, activate Gαi subunit that inhibits AC and decreases cAMP level
and PKA activity. The dissociated βγ dimer activates PKC and PI3K, which, in turn,
activates several MAPKs. On contrary, CB2R inverse agonist binds to the inactive state
of CB2R, sequester Gαi causing an increase in cAMP and PKA activity that leads to
phosphorylation of several MAPKs.
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could serve as a novel therapeutic approach to treat human neuroinflammatory
conditions.
Therapeutic Utility of Inverse Agonists in Human CNS Disorders
It is generally known that GPCRs are capable of producing basal level activity in
the absence of a ligand and the magnitude of this type of activity is determined by the
receptor structure (flexibility), density (cell-dependent), availability of signaling
molecules and receptor coupling to downstream effectors. The discovery of the
constitutive activity led to the identification of the inverse agonist class that behaves as an
inverse agonist in constitutively active systems and neutral antagonists in the absence of
basal level activity. In fact, most of the antagonist drugs that have been discovered are
inverse agonists such as anti-histamine drugs. Therefore, the behavior of a ligand can
differ significantly depending on the system that was utilized in the ligand
characterization. In other words, an inverse agonist can act as a neutral antagonist in
systems with a low level of basal activity or in different cell types. Thus, the therapeutic
utility of inverse agonist class can be applied in diseases that have a high level of
constitutive activity or in cases that high expression of target receptor is observed.
Additionally, an inverse agonist can regulate specific disease state by one of several
proposed mechanisms (Figure 5-3). One possible mechanism is that inverse agonist can
sequester Gαi proteins that leads to the depletion of Gαi proteins of other receptor systems
expressed in the cell. Another possible mechanism is that the depletion of Gαi can
enhance the basal level activity of other receptors coupled to Gαs, thus enhancing the
cAMP production and PKA activity. Lastly, the application of inverse agonists can also
stimulate the receptor expression (enhance recycling), thus increasing the efficacy of the
endogenous agonist ligands (Berg & Clarke, 2018).
Research Limitations
In this dissertation, a number of important pharmacological and experimental
limitations need to be considered.
Pharmacological Limitations
First, our compounds were functionally evaluated at G-proteins and β-arrestins
signaling only, and we lack the knowledge of the pharmacological activity at other CB2R
signaling pathways such as GIRK pathway (Soethoudt et al., 2017) that have been
reported to be activated by CB2R ligands. Second, the selectivity ratio (SR) of our
compounds was determined based on the affinity and pharmacological testing in CB1R
cell lines; however, the off-target effects of our compounds at other known and orphan
GPCRs remain to be determined. For instance, vanilloid receptor 1(TRPV1), GPR55 and
GPR18, were reported to be highly expressed in microglia and play a critical role in
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Figure 5-3. Therapeutic Mechanisms of CB2R Inverse Agonist Class in Human
Neurodegenerative Diseases.
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inflammation (McHugh, Page, Dunn, & Bradshaw, 2012; McHugh, Roskowski, Xie, &
Bradshaw, 2014; Pietr et al., 2009; Schilling & Eder, 2009). Third, the efficacy of
compound 45 as anti-inflammatory agent was evaluated in vitro only and as we know that
the in vitro microenvironment lacks the interactions with other immune cells and neurons
which could greatly influence the overall results (Schmid et al., 2009). Lastly, microglia
can be easily classified as M1 and M2 states in cell culture; however, these cells exhibit
more complex indistinguishable phenotypes in vivo that pose a challenge to reflect the in
vitro outcomes (Ransohoff, 2016).
Experimental Limitations
The current studies have examined the anti-inflammatory responses of CB2R
ligands in murine and immortalized human cells; however, the results of these studies
need to be confirmed using primary human or induced pluripotent stem cells (iPSC)
derived microglia. Additionally, LPS was used as an M1 simulant which can be distinct
from beta-amyloid (Aβ) or alpha-synuclein (αS) that are naturally present in
neurodegenerative disorders. Furthermore, our experimental approach was designed to
mimic the neuroinflammatory condition by incubating stimulus first for a period of time
followed by drug treatment; however, this approach is completely different from the
reported methodology in cannabinoid literature, i.e. pre-incubation of cells with ligand
prior to activation. Additional investigations are required to validate the proposed
anti-inflammatory mechanisms for the CB2R ligands in stimulated human microglia
using specific pathway inhibitors. Finally, in reviewing cannabinoid literature, we lack
the presence of previous studies investigating the efficacy of CB2R inverse agonists as
anti-inflammatory agents, and this lack might complicate the drawing of accurate
conclusions.
Future Directions
Future studies are recommended to investigate several research questions that
address some of the pharmacological, and experimental limitations present in this
dissertation. First, it is important to examine the off-target effects of the biaryl/aryl
menthone scaffold in CEREP panel or SAFETY SCREEN 44 that evaluate compound
effects on 44 selected targets including other GPCRs, transporters, ion channels, nuclear
receptors, kinases, and other non-kinase enzymes. CEREP panel is designed to measure
common off-target activities that may cause unwanted human adverse effects. For
example, in Soethoudt et al. study, HU-308 affects four targets in this assay, JWH-133
was the most selective ligand with no off-targets, and SR144528 hits only two; all
compounds were tested at 10 μM concentration (Soethoudt et al., 2017). Moreover, it
would be interesting to evaluate additional signaling proteins that might involve in CB2R
immunoregulation effects in microglia such as STAT-1, STAT-3, and STAT-6 signaling.
For instance, a study done by Kozela et al. demonstrated that pre-treatment with THC at
10 μM significantly suppressed the expression of pro-inflammatory STAT-1 protein in
LPS activated BV2 cells (Kozela et al., 2010). Additionally, another study reported by
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Ehrhart et al. showed that treatment with JWH-015 at 10 μM significantly decreased the
phosphorylation of STAT-1 proteins in primary mouse microglial cells (Ehrhart et al.,
2005). Another possible area of future study would be to determine the efficacy of CB2R
ligands in primary human or induced pluripotent stem cells (iPSC) derived microglia that
closely resemble human microglia in their in vivo environment. The iPSC-derived
microglia provide an excellent experimental approach to hopefully avoid genetic
variation in isolated human microglia and obtain a clearer picture of the basic pathways
affected by CB2R agonists and inverse agonists (Abud et al., 2017). A further study
might assess the microglia-mediated neuroprotective effects of CB2R ligands using the in
vitro co-culture of neurons and microglia - an assay to better model microglia-neurons
interactions that are important in neuroinflammation (Luongo, Palazzo, Novellis, &
Maione, 2010). More work is needed to explore the CB2R dependent and independent
immune responses of the ligands using microglia isolated from CB2R knockdown mice.
Furthermore, additional testing of the pro and anti-inflammatory cytokines that can
distinguish between the M2 microglia phenotypes (M2a, M2b, and M2c) is suggested.
For instance, M1 microglia is associated with the release of pro-inflammatory mediators
such as IL-6, TNF-α, IFN-γ, while, M2a microglia is identified by the release of the
anti-inflammatory IL-4, IL-13, and M2c microglia is recognized by the production of
IL-10, TGF-β (Zhang, Zhang, & You, 2018). Other possible future studies using
amyloid-beta (Aβ) or α-synuclein (αS) aggregates as a stimulus could provide new
insights into the neuroprotective effects of CB2R ligands under conditions that are
closely similar to neurodegenerative diseases. Finally, it is important to assess the in vivo
efficacy of CB2R ligands in several neurodegenerative animal models to determine
which disorder could greatly benefit from CB2R selective drugs. In sum, a major
challenge in the field is to successfully translate the promising preclinical immune results
of CB2R ligands into clinical scenarios that effectively treat human neurodegenerative
disorders.
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